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Preface 3
The 1998 ‘Annual report on the state of the drugs
problem in the European Union’ is central to the
continued advancement of a concerted knowledge
base on which to build a strategic approach to drug
policy within and beyond the Member States that
constitute the European Union. The EMCDDA both
instigates and reflects improvements in communi-
cation and shared awareness of the extent of drug
problems and the suitability of specific markers as
epidemiological indicators within and between 
nations.
As stated in the declaration on demand reduction
adopted by the United Nations in June 1998 ‘de-
mand reduction programmes should be based on a
regular assessment of the nature and magnitude of
drug use and abuse and drug-related problems in
the population. This is imperative for the identifica-
tion of any emerging trends. Assessments should
be undertaken by States in a comprehensive, sys-
tematic and periodic manner, drawing on results of
relevant studies, allowing for geographical consid-
erations and using similar definitions, indicators
and procedures to assess the drug situation. De-
mand reduction strategies should be built on
knowledge acquired from research as well as les-
sons derived from past programmes. These strate-
gies should take into account the scientific ad-
vances in the field, in accordance with the existing
treaty obligations, subject to national legislation
and the comprehensive multidisciplinary outline of
future activities in drug abuse control’. It is exactly
this approach that is reflected in the work of the
EMCDDA in general, and the content of its annual
report in particular.
Each annual report contributes to a developing un-
derstanding of both the need for monitoring and
the recognition that effective policy is contingent
on a satisfactory and accessible information base.
The EMCDDA is increasingly recognised as an in-
valuable source of information, whose autonomy
and political independence guarantee that its an-
nual reports are viewed as key documents for un-
derstanding the major features of drug problems
and the legal, political and social responses to them
initiated within the European Union. However, each
report also represents a reconfiguration of the cen-
tral themes that address policy and practice-related
concerns and this is most obviously manifested in
Chapter 3 of the 1998 report.
This chapter examines the drug situation in the 10
central and east European countries (CEECs) which
are part of the PHARE project for accession coun-
tries to the EU. As with the 15 Member States, the
goal of the EMCDDA’s project remains twofold — to
report on those existing indicators that provide the
most accurate picture of drug problems and re-
sponses in each nation, while encouraging partici-
pants to improve the quality, reliability, comparabil-
ity and accuracy of the information they gather. Al-
though the EMCDDA is aware of resource restric-
tions, gradual improvements in multi-method 
collection and dissemination remain central to 
the objective of improving communication and
cooperation.
In Chapter 1, a new distinction is made between
current trends and directions (based on a combina-
tion of informal and less systematic sources) and
key epidemiological indicators (structured around
agreed definitions where these are available). Thus,
the current trends section allows the incorporation
of qualitative measures and informed opinions on
recent events, where the pay-off is timeliness rather
than precision. In contrast, in the key indicators sec-
tion, drug trends are slightly less up-to-date, but are
more likely to fulfil scientific criteria of reliability
and validity. The overall objective is to employ a va-
riety of methodologies in establishing a wide-rang-
ing series of images of drug activity and response,
rather than to be over-reliant on snapshots whose
clarity is compromised by their processing time.
However, the EMCDDA’s aim of improving the over-
all quality of data available is evidenced in the
structure of the chapter on demand reduction,
where emphasis is given to those projects which
have been adequately evaluated. Particularly in the
area of primary prevention there is a paucity of sci-
entific evidence, not only in Europe but also inter-
nationally, and so the aim has been to present not
only those projects that appear important and in-
dicative, but also those that make some attempt at
satisfactory evaluation. Thus, while there is thor-
ough consideration of new projects that may shed
Preface
Annual report on the state of the drugs problem in the European Union4
light on the direction, for example, of drug educa-
tion, the EMCDDA approach is to encourage inno-
vation married to systematic and scientific method.
The later chapters emphasise, in particular, the fi-
nancial structures in place. Chapter 7 examines the
data available on public spending in response to
drug problems, with examples given from the limit-
ed data sources available. Chapter 5 outlines the
changes that have occurred in EU spending in the
past year and, in particular, the shifts in the break-
down of spending between money spent within
the Union and that spent internationally. Chapter 6
provides an up-to-date account of more general
global activity and the recent work of the main in-
ternational bodies to combat the drugs problem.
While there is still much work to be done, the suc-
cesses of the last year clearly vindicate the work
of the EMCDDA. The overall role of the Centre has
expanded as a centre of excellence for addiction
information, but the Centre has also become in-
creasingly active in improving the knowledge
base for policy-makers, practitioners and re-
searchers alike. The annual report, as an integral
component of EU activity, not only reflects with
increasing accuracy and clarity the drug situation
in the EU countries, but it increasingly provides
an invaluable basis for initiating systematic re-
search and evaluation carried out comparatively
by the EU and beyond.
We are, however, aware that the EU can be no more
insular than the Member States from which it is
constituted, and the EMCDDA will continue to pro-
mote collaborative endeavour between these
Member States, bodies and organisations whose
work is more international. The EMCDDA is increas-
ingly at the core of the relationship between key
European informants through the national and in-
ternational networks of its focal points and the 
EMCDDA’s Reitox network.
Yet our work is essentially educational, progressive
and proactive — we must promote the role of in-
formation collection, management and dissemina-
tion as the critical base for all policy decision-mak-
ing and it is here that the annual report reflects the
success of the efforts made by both the EMCDDA
and the national focal points. With each annual re-
port, we are conscious of increased impact and
readership and of improvements in comparability
and quality. This is a slow and gradual progress, but
with the continued commitment and goodwill of
contributors, both the quality and impact of the
document will gain further ground.
I hope you find this report both interesting and
useful to you in your work, and that it encour-
ages you to support what we at the EMCDDA are
trying to do. Our success requires your coopera-
tion and we are aware that without the support
and feedback of readers we will be foiled in our
task of striving for clarity and quality. We are
committed to the task of improving awareness
and information and I hope you are stimulated
by our endeavours
Georges Estievenart
Executive Director
EMCDDA
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Information on emerging trends, although drawing
on key indicators, relies on more qualitative assess-
ments, local as well as national, that may lack com-
parability or validity, with rapidity achieved at the
expense of scientific precision. Although less time-
ly, epidemiological indicators may be more reliable
and comparable, and are essential for scientific
comparisons and to explain observed trends.
Although the EMCDDA is improving the availability,
quality and comparability of key indicators, and the
timeliness of emerging trends data, much remains
to be done.
As present coverage of different kinds of informa-
tion is incomplete, the degree of comparability is
variable making direct comparisons misleading.
Even where data quality and comparability are
good, the diversity of local cultures, and of different
approaches to, and definitions of, drug concepts
must be considered.
11
Trends, prevalence and patterns of use
This chapter is divided between
emerging trends and key
epidemiological indicators of drug
use and supply. The aim of the
chapter is to help policy-makers
develop appropriate responses in a
timely fashion.
Chapter1
Emerging trends in drug use and drug problems
Cannabis: Stable after increases in the early 1990s,
especially in higher prevalence countries, some rise in
others.
Some rise in populations entering treatment, but this
may in part reflect recording practices and other
factors.
Amphetamines: Continuing to rise, likely to be more
significant in future than Ecstasy.
Ecstasy: No longer rising in those Member States
where it appeared earlier and prevalence is higher, but
still rising in others. Some diffusion to other
populations.
Other synthetic drugs: New products reported in some
Member States, but not replacing amphetamines and
Ecstasy.
Cocaine: Modest but steady rise in use, although
prevalence is still low.
Crack remains localised, but some spread in selected
areas.
Heroin: Increases among some synthetic drug users
and other young populations reported by some
Member States.
Problematic patterns of use: Diffusion to small towns
and rural areas reported in some countries.
Deaths: Generally stable or decreasing, although with
some exceptions.
Infectious diseases: Rates of new AIDS cases strongly
declining as a result of new treatments which delay
disease progression. AIDS changing into an indicator
of treatment uptake rather than of HIV infection.
Prevalence of HIV infection stable or declining in most
countries, but continued transmission in young and
new injectors.
Prevalence of hepatitis C infections remains extremely
high.
* )
For further information on methods and sources,
the reader is referred to previous annual reports
and to the recently published report on informa-
tion sources.
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Cannabis
Although the most common illicit drug in EU coun-
tries, there are considerable differences in patterns
of use over time and between countries.
Following significant increases in use in many
Member States in the late 1980s or early 1990s,
prevalence has now stabilised in some countries,
though it continues to increase in others. Seizures
of cannabis increased fourfold from 1985 to 1994,
but have stabilised since.
This is not the first time that cannabis use has in-
creased, stabilised and in some cases declined.
Cannabis first emerged as a significant phenome-
non at the end of the 1960s and early 1970s, when
sharp increases in use were observed, mainly in
north European countries. Prevalence seems to
have stabilised or decreased in the late 1970s and
1980s before increasing again late in the 1980s.
Of the total adult population, 5 to 30 % have ever
tried cannabis and 1 to 9 % in the past 12 months,
depending on the country. The proportions are
higher among younger adults with 10 to 40 % hav-
ing ever used and up to 20 % in the last year. In
most countries, rates are higher in urban areas.
Amongst current or recent users, use is more com-
monly occasional or intermittent. Cannabis is not
often the primary drug in health and social care in-
dicators, though a minority of heavy users seek
help. In most countries, cannabis accounts for be-
tween 2 and 10 % of treatment admissions, al-
though in a few it is between 13 and 16 %.
Amphetamines, Ecstasy and LSD —
synthetic drugs
A major issue for young people’s drug use is the
emergence, since the late 1980s, of ‘dance drugs’,
dominated by Ecstasy, though also including am-
phetamines and LSD. These drugs became popular
within a broader evolution of youth culture over
the last 10 years, and, in particular, were associated
with clubs, raves and house parties. The main
groups involved have been socially integrated ado-
lescents and young adults in the 15 to 25 age
range. Initially, users did not tend to mix Ecstasy
with other substances, but subsequent reports indi-
cated a diffusion of Ecstasy use across social groups
and an increased use of Ecstasy in addition to, or in
combination with, alcohol, cannabis, ampheta-
mines, benzodiazepines, LSD, or cocaine.
These developments are described in the 1997 an-
nual report and in ‘New trends in synthetic drugs in
the European Union’ (EMCDDA Insight series).
Recent indications suggest that, in some countries
at least, Ecstasy use may have ceased increasing,
and has been tried by 0.5 to 3.0 % of the total adult
population, a proportion that is higher among old-
er adolescents and young adults (up to 9 % in 16 to
29-year-old populations). Recent use is less com-
mon than experimentation.
Overview
Suggested explanation: National variations in
the proportion of cannabis users seeking treat-
ment could reflect the extent of heavy cannabis
use, the range of services available, or factors
such as court requirements for drug offenders.
Cannabis may be one component of a wider
range of personal, social and legal problems, in-
cluding alcohol and other drugs.
Suggested explanation: The impression that
house culture, in which Ecstasy played a sym-
bolic as well as psycho-pharmacological role, is
diverging is supported by predominantly anec-
dotal information from diverse sources — spe-
cialised youth media, local researchers and front-
line agencies. Ecstasy has become just another
drug on the market and is decreasingly a unify-
ing cultural symbol.
These sources note increasing availability and use
of amphetamines (tried by between 1 and 9 % of all
adults, but by up to 16 % of young adults) and 
!!
*
)
)
cocaine, while alcohol remains prominent in youth
culture. Although historically more common in
northern Europe, amphetamines are now found
across the EU. While usually consumed orally or by
snorting, amphetamine injecting is reported in
some countries.
Indicators of supply and availability reinforce the
impression that amphetamines and cocaine may
be the growth area in the stimulant-type drug mar-
ket, rather than Ecstasy. These indicators suggest
that although seizures of synthetic drugs have in-
creased substantially since the late 1980s current
trends are now diverging. Market indicators of LSD
declined following a peak in 1993-94.
In 1997, market indicators for Ecstasy showed signs
of stabilising in countries that first experienced an
increase in the late 1980s, whereas they are still in-
creasing in countries where Ecstasy emerged more
recently and where the extent of use is lower. In
contrast, market indicators of amphetamines show
a continuing rise across the EU.
Among treatment populations, these substances
are not usually the primary problem. Ampheta-
mines are the main drug in a minority of the treat-
ed population, although amphetamine problems
are more common in parts of northern Europe.
Ecstasy and LSD are very unusual, though small 
increases are being reported for Ecstasy.
Fatalities from amphetamines and Ecstasy are rela-
tively rare and are often associated with the con-
text of use — continuous dancing in hot, crowded
conditions. In many countries, there are no record-
ed cases of fatalities, though some may be missed.
Recorded health problems are also low, given the
number of people who have taken amphetamines
or Ecstasy, although they may be under-recorded.
More problems arise if use becomes chronic, in-
volves high doses or is in combination with other
drugs.
Temporary depression and short-term deficits of
memory and concentration have been reported fol-
lowing Ecstasy use. Evidence on the long-term neu-
rotoxicity of Ecstasy remains unclear in humans,
although indicated in animal studies.
Cocaine
Law enforcement indicators, especially the quanti-
ties of cocaine seized, increased sharply in 1996 and
1997 after a pause in the rapid increase observed
from the mid-1980s. Prices show little sign of 
increase, and the long-term trend has been a 
substantial fall in retail price.
Indicators of the demand for cocaine do not show
such a marked rise. A small proportion of adults, 1
to 3 %, have tried cocaine, with recent experience
usually reported at less than 1 %, although rates are
higher amongst younger adults. Use of cocaine
among school-age children is also low, 1 % or less in
many countries, although 3 to 4 % in some Member
States.
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Suggested explanation: The discrepancy be-
tween supply and demand indicators for cocaine
may occur because, although supply has in-
creased substantially, perhaps as a result of
changes in the global market, demand has grown
more slowly. The long-term fall in price is consis-
tent with this. It is also possible that law enforce-
ment agencies have been intercepting an in-
creasing proportion of cocaine imported into the
EU, but that since supply exceeds demand, this
has had little impact on price or availability.
The most plausible interpretation of cocaine indica-
tors suggests modest but steady increases in the
use and availability of cocaine in many Member
States. Prevalence of use is higher than for heroin,
but remains relatively low in comparison with am-
phetamines or Ecstasy (and of course cannabis).
Cocaine use tends to occur in recreational contexts,
tends to be sniffed (snorted) and is taken on an oc-
casional basis. A minority use cocaine much more
frequently and experience problems.
Cocaine is rarely mentioned as the main drug in treat-
ment clients; in most cases less than 5 %, although in
a few countries it is 10 to 15 %. However, it is com-
monly reported as being used in conjunction with
heroin.The smoking of crack cocaine has been identi-
fied for several years among heroin users and margin-
alised groups in some Member States, but is limited.
Heroin and other opiates
Despite increasing attention to ‘new’ problem
drugs, heroin continues to be a major threat to
public health and safety. In most Member States
heroin addiction represents a substantial and dis-
proportionate burden in terms of treatment,
health-care costs, deaths and drug-related crime.
In general, trends in both the supply of heroin and
in levels of use and dependence are relatively 
!
stable (under 1 % of the general population, up to
2 % in younger age groups, although it may be
higher in some ‘at risk’ areas). However, prevalence
is increasing in some Member States, and several
countries report heroin smoking by new groups of
young people, both from socially integrated popu-
lations and from minority groups.
Member States use different definitions and meth-
ods for estimating problem drug use and addiction,
but generalised indicators suggest that between
0.2 and 0.3 % of the total population in the EU are
addicted to heroin. In most treatment centres, her-
oin is the main drug (Finland and Sweden are excep-
tions). Whilst differences between countries exist,
those within countries can be considerably greater.
In many countries, heroin dependence is concen-
trated among marginalised subgroups in urban 
areas, although diffusion to rural areas seems to be
taking place in some countries. Problems linked to
increased social exclusion of marginal groups, in-
cluding addicts, are reported in some countries.
Opiates are present in most acute drug-related
deaths, although other substances are often also
present. The proportion of heroin users who inject
has been decreasing in most EU countries, with
smoking the most common route in some Member
States.
Other significant substances
The misuse of solvents and other volatile inhalants
is primarily a phenomenon found among younger
adolescents. In schoolchildren aged 15 to 16 years,
they are usually the second most common sub-
stance after cannabis, though in some countries
with a low prevalence of cannabis, use of solvents is
more common than that of cannabis.
An increase in the non-medical use of medicines is
noted in several countries, often in combination
with alcohol. Benzodiazepines are commonly re-
ported as a secondary drug amongst people enter-
ing treatment, and are also often detected in acute
deaths of opiate addicts. Systematic information is
limited at EU level.
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New areas of development
A priority for the EMCDDA and national focal points is
to improve the timeliness and relevance of information,
to make information more useful to policy-makers, by:
1. extending coverage beyond institutional sources
and research studies to include more informal or
unconventional sources;
2. improving existing indicators, and giving more
attention to analysing and exploiting the data these
indicators provide;
3. developing more innovative methods of data
collection, analysis and forecasting to better
identify, monitor and understand changing patterns
of drug use.
Geographical diffusion
Although uneven, there is a geographical diffusion of
drug use from cities to towns and rural areas, which
has implications for needs assessment, service
provision and training. Differences in patterns of
diffusion may also improve our understanding of the
distribution of drug behaviours at European, local and
regional levels.
Youth culture and drugs
The emergence of Ecstasy illustrates clearly the need
for analysis of drug trends to occur in the context of
wider social and economic trends, in particular those
that relate to youth culture. Similarly, the role of young
people in the consumer market for recreational
products, including drugs, must be considered.
Social exclusion, drug use, drug problems
Social exclusion, marginalisation, minorities and
migration are often intertwined with drug trafficking, drug
use and drug-related problems, though the relationship is
neither simple nor unidirectional. Developing effective
strategies to respond to drug problems requires a broader
and more thorough analysis.
Drug-related crime and public safety
Little information is provided on this in national reports,
yet a 1996 EMCDDA pilot project indicated that
considerable local information exists, although it may be
hard to find. If questions about drug-related crime or
public safety measures are to be addressed, then the
availability and quality of information must be improved.
Drug markets, availability and supply
The main focus of the Centre’s work in epidemiology
has been on the demand for drugs. This will remain a
central theme, but it will be necessary to pay more
attention to supply and to drug markets, which is
where demand and supply meet.
*
)
Drugs and health
One of the strongest associations between illicit
drug use and health problems is found among 
injectors. Although rare in the general population,
injecting rates range from 10 to 15 % to 80 %
among opiate addicts entering treatment. Injecting
drug users (mainly heroin addicts) are many times
more likely to die than non-injectors, and are at
much higher risk of infectious diseases such as AIDS
and hepatitis.
The proportion of injectors among treated heroin
users is decreasing in almost all countries, particu-
larly among clients coming to treatment for the
first time. Injecting rates vary considerably be-
tween countries. Heroin is the most common drug
involved, although amphetamines are injected in
parts of northern Europe. Opiate injectors often in-
ject other substances like cocaine, while some re-
ports mention new injection substances, like ana-
bolic steroids
In the European Union, most cases of death from
acute intoxication involve opiates, although other
substances such as alcohol and benzodiazepines
are also frequently found. After increases in the
1980s and early 1990s, the number of acute drug-
related deaths are generally stable or decreasing, al-
though the increase continues in some countries.
In almost all countries, the prevalence of HIV infec-
tion in drug injectors is declining or stable. Model-
ling studies, however, show that new generations of
injecting drug users continue to be infected mean-
ing that HIV has become endemic. Young and new
injectors often show more risk behaviour than
more experienced drug users.
The incidence of new AIDS cases is falling sharply
as a result of new treatments that delay disease
progression. As a consequence, AIDS reporting is
becoming more an indicator of treatment uptake
and less an indicator of HIV infection. Early ex-
treme optimism about the effectiveness of new
treatments for AIDS has recently been tempered.
Hepatitis in drug injectors, in particular hepatitis C,
remains a serious problem with potentially large
implications for health services. The extremely high
prevalences of hepatitis C in most countries indi-
cate ongoing risk behaviour among injectors, much
of which is probably unnoticed — sharing spoons,
cottons and other ‘works’.
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This section provides a comparative account of
drug use and consequences in Member States, by
examining indicators of prevalence, health conse-
quences, the criminal justice system, and illicit drug
markets, several of which are key indicators in the
Centre’s work programme in epidemiology. The
Centre is seeking to establish common EU stan-
dards governing the comparability and quality of
data collection, analysis and reporting. At present
these key indicators concern prevalence (popula-
tion surveys, prevalence estimates of problem drug
use) and health consequences (demand for treat-
ment, drug-related deaths and drug-related infec-
tious diseases).
Establishing common standards is a slow process.
Many of the factors responsible for the lack of com-
parability and variable data quality are being clari-
fied through analyses of definitions, methods, cov-
erage of information sources and procedures for
data handling. However, it will take time for these to
be implemented and for this to become apparent
in the comparability of indicators. As a result, more
attention is given in this annual report to the analy-
sis of indicators of the illicit drug market.
General population surveys
Population surveys, assessing the extent and pat-
terns of drug use, generally provide information on
whether a person has ever tried a drug (lifetime
prevalence) or has taken it recently (last 12 months
or last 30 days), along with sociodemographic char-
acteristics and attitudes towards drugs. This
methodology is useful for substances whose use is
relatively extensive, but is more limited for more
marginalised forms of drug use which require large
samples and which may exclude those without a
stable address or telephone number.
Indicators of prevalence, consequences and patterns of use
*
)
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During the last four years, eight EU countries have
conducted national, or near national, population
surveys measuring drug use (Belgium (Flanders),
Denmark, Finland, France, Germany, Spain, Sweden
and the United Kingdom). Several of them con-
ducted new surveys in 1997 (Germany and Spain)
or are conducting them in 1998 (Sweden and the
UK) or 1999 (France and Denmark). In addition,
other countries are conducting national surveys 
in 1998 (Greece, Ireland and the Netherlands),
although they had previously conducted local 
surveys.
Several countries have set up a series of similar sur-
veys (Finland, Germany, Spain, Sweden and the UK)
which will enable evaluations of trends at national
level. These become increasingly valuable as more
surveys are repeated in each country.
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Table 1: Lifetime prevalence of drug use in recent nationwide surveys among the general 
population in some EU countries
(a) Hard drugs.   (b) Cocaine or crack.  (c) Designer drugs.  (d) Amphetamines + Ecstasy.
Note: In some countries (Finland and the United Kingdom) the age range for young adults is more restricted than in other countries.
This may tend to produce higher prevalence figures among young adults in these countries.
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Method All adults (%)
Belgium (Flanders) 1995 Phone 1 142 18-65 5.5 0.5 0.9 0.5 18-39 9.5 1.0 1.7 1.1
Denmark (1) 1994 Inter. 2 521 16-44 37.0 5.0(a)
(2) 1994 Mail 1 390 18-69 31.3 2.0 4.0 16-44 43.0
Ger (former West) 1995 Mail 6 292 18-59 13.9 2.2 2.8 1.6 18-39 21.0 3.7 4.1 2.8
(former East) 1995 Mail 1 541 18-59 3.6 0.2 0.7 0.7 18-39 6.4 0.3 1.3 1.3
Spain  (1) 1995 Interv. 9 984 15-70 13.0 3.3(b) 2.3 1.8(c) 15-39 21.9 5.7(b) 3.8 3.1(c)
(2) 1997 Interv. 12 445 15-65 21.7 3.2 2.5 2.5
France 1995 Phone 1 993 18-69 16.0 1.2 0.7(d) 18-39 25.7 1.8 1.4(d)
Finland  (1) 1992 Mail 4 892 18-74 4.8 0.6(a) 18-34 10.1 1.1(a)
(2) 1996 Mail 4 429 16-74 7.3 0.7 16-29 15.0
Sweden (1) 1994 Interv. 933 15-69 7.0 0.0 1.0 0.0 15-34 9.0 0.0 3.0 0.0
(2) 1996 Interv. 1 500 15-69 9.0 1.0 2.0 0.0 15-34 12.0 1.0 3.0 1.0
U. Kingdom (1) 1994 Interv. 9 646 16-59 21.0 2.0 8.0 2.0 16-29 34.0 3.0 14.0 6.0
(2) 1996 Interv. 10 940 16-59 22.0 3.0 9.0 3.0 16-29 36.0 4.0 16.0 9.0
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Figure 1: Cannabis use in the adult population
Although prevalence differences between coun-
tries exist, international comparisons should be
made with caution, as differences may result from
methodological factors such as data collection
methods and the sampling frame used, or the con-
text. Countries may use different age ranges to re-
port results, when even slight age differences may
markedly shift prevalence rates. Also, factors such as
the country’s proportion of rural and urban popula-
tions may influence the overall prevalence figure.
Most drug experimentation in the EU has been with
cannabis. Lifetime experience of cannabis in the
population ranges from 5 to 7 % in Belgium (Flan-
ders) and Finland to 20 to 30 % in Denmark, Spain
and the UK. Young adults report higher rates rang-
ing from 10 % in Belgium (Flanders) to 35 to 40 % in
Denmark and the UK. In general, prevalence of use
in big cities is higher than in the whole country.
The figures for lifetime experience of illegal sub-
stances other than cannabis should be considered
with caution, as their low prevalence makes them
more susceptible to random variations, and social
reactions may decrease willingness to report use.
Amphetamines are generally the second most
prevalent substance, with 1 to 4 % having experi-
mented with them. The UK figure is significantly
higher than other countries (9 %). Cocaine has been
tried by 1 to 3 % of the population, and by 1 to 6 %
of young adults. Ecstasy has been tried by 0.5 to
3 % of the general population, while Ecstasy use is
concentrated among young adults (1 to 9 %), with
prevalence higher among people in their 20s.
That recent use (last 12 months) is much less com-
mon than lifetime experience may indicate that, for
most people, drug use is an occasional experience,
and that in only a limited proportion of cases does
drug use become continuous.
Recent cannabis use (last 12 months) is reported by
1 to 9 % of the adult population, depending on the
country; Finland, Sweden and eastern Germany
present the lowest rates, and Spain and the UK the
highest. As with lifetime experience, recent use is
higher among young adults; in most countries be-
tween 3 and 10 %,although reaching 20 % in the UK.
Prevalence of recent use of substances other than
cannabis is very low. Among the adult population,
use in the last 12 months has rarely exceeded 1 %,
and among young adults has generally been below
2 %. Higher levels are reported for cocaine and Ec-
stasy in Spain, and for amphetamines and Ecstasy in
the UK.
Consistent trend information is limited, as few EU
countries have serial surveys using the same meth-
ods or follow-ups. However, cannabis use has in-
creased in most EU countries in the last three to
four years, although in countries with medium or
high use (Denmark, Germany and the UK) the in-
crease has been small. Trend information on other
substances is even more limited at population level;
a small increase in cocaine, and clear but moderate
increases in amphetamines and Ecstasy. However,
trends based on the whole population may be not
accurate for amphetamines and Ecstasy, as they are
mainly used by people in their early 20s.
School surveys
School survey (generally of 12 to 18-year-olds)
methodology is similar to general population sur-
veys, although in this case the information is usu-
ally collected in the classroom with anonymous
self-administered questionnaires. In schoolchildren
lifetime experience is generally recent, so lifetime
and last 12 months’ prevalence do not have the big
differences found in adults. All EU countries have
conducted national school surveys in the last five
years except in Germany, where a regular youth (12
to 25-year) survey is conducted. In 1995, an interna-
tional study (ESPAD) was carried out in 25 European
countries (EU and non-EU) by the Swedish Council
for Information on Alcohol and other Drugs (CAD)
and the Pompidou Group.
As with adults, there are differences in school popu-
lations in drug-use patterns between countries. Re-
ported prevalence may be influenced by the same
factors as general population surveys (method-
ology, sampling and context). The exact age of the
students is also important as, in this age range, one
or two years of difference may double prevalence
rates. Opportunities for drug use are influenced by
social factors, and experiences frequent at 16 years
in one country, may occur at 18 in another. For in-
stance, in Finland, the 1995 national school survey
reported a lifetime prevalence of 5 % for cannabis
among 15 to 16-year-olds, but in the same year, 17
to 18-year-olds in Helsinki reported a 30 % lifetime
prevalence rate for cannabis.
The proportion of 15 to 16-year-olds who report
cannabis use ranges from 3 to 5 % to 40 %, de-
pending on the country. Finland and Portugal re-
port the lowest rates, Ireland and the UK the high-
est. However, some countries with low cannabis
prevalence report higher levels of solvent or am-
phetamine use.
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In most countries, solvents are the second most
common substance used among 15 to 16-year-
olds, ranging from about 3 % (Belgium (Flanders),
Luxembourg and Spain) to 20 % (UK). In some
countries solvents are more prevalent than
cannabis (Greece and Sweden). Amphetamines
have been used by 1 to 13 % of 15 to 16-year-olds,
Ecstasy by 1 to 9 % and LSD and hallucinogens by
1 % to more than 10 %. Ireland, the Netherlands
and the UK report relatively higher figures for am-
phetamines, hallucinogens and Ecstasy. The lowest
prevalence figures are for cocaine, with a range of
1 to 4 %, and heroin, with 1 % or less in most coun-
tries, although 2 % in Denmark, Ireland, Italy and
the UK.
Trend information on recent years is available in
Belgium (Flanders), Denmark, Ireland, the Nether-
lands, Sweden and the UK. In most of these coun-
tries lifetime experience with cannabis shows a
clear increase. Lifetime experience with ampheta-
mines and Ecstasy also increased, although at lower
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Table 2: Last 12 months’ prevalence of drug use in recent nationwide surveys among the general
population in some EU countries
(a) Hard drugs.   (b) Cocaine or crack.   (c) Designer drugs.   (d) All illegal drugs. (e) Amphetamines + Ecstasy.
Note: In some countries (Finland and the United Kingdom) the age range for young adults is more restricted than in other countries.
This may tend to produce higher prevalence figures among young adults in these countries.
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Method All adults (%)
Belgium (Flanders) 1995 Phone 1 142 18-65 18-39 2.7(d) 0.5** 0.7(d) 0.5(d)
Denmark (1) 1994 Interv. 2 521 16-44 7.0(d) 0.5(a)
(2) 1994 Mail 1 390 18-69 3.3(d) 16-44 6.0(d)
Ger (former West) 1995 Mail 6 292 18-59 5.0(d) 0.9** 0.8(d) 0.9(c) 18-39 8.8(d) 1.6** 1.5(d) 1.6(d)
(former East) 1995 Mail 1 541 18-59 1.9(d) 0.2** 0.2(d) 0.6(c) 18-39 3.5(d) 0.3** 0.4(d) 1.2(d)
Spain (1) 1995 Interv. 9 984 15-70 6.6(d) 1.7(b) 1.0(d) 1.2(c) 15-39 11.6(d) 3.2(b) 1.7(d) 2.2(c)
(2) 1997 Interv. 12 445 15-65 7.5(d) 1.5** 0.9(d) 1.0(c)
France 1995 Phone 1 993 18-69 4.7(d) 0.2** 0.3(e) 18-39 8.9(d) 0.3** 0.6(e)
Finland (1) 1992 Mail 4 892 18-74 1.2(d) 18-34 3.0(d)
(2) 1996 Mail 4 429 16-74 1.9(d) 16-34 5.2(d)
Sweden (1) 1994 Interv. 933 15-69 0(d) 15-34 1.0(d)
(2) 1996 Interv. 1 500 15-69 1(d) 15-34 1.0(d)
U.  Kingdom (1) 1994 Interv. 10 000 16-59 8.0(d)  < 0.5** 2.0(d) 1.0(c) 16-29 20.0(d) 1.0** 7.0(d) 3.0(d)
(2) 1996 Interv. 10 940 16-59 9.0(d) < 0.5** 3.0(d) 1.0(c) 16-29 21.0(d) 1.0** 8.0(d) 4.0(d)
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Figure 2: Use of amphetamines, cocaine and Ecstasy
in the adult population (ever used)
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Figure 3: Drug use among 15 to 16-year-old
school students (ever used)
Table 3: Lifetime prevalence of use of different illegal drugs among 15 to 16-year-old students 
in recent nationwide school surveys in some EU countries
(a) Spain:  (= plus other synthetic drugs). (b) France: (= amphetamines, Ecstasy and stimulants). (c) Austria: (= hard drugs). (d) Sweden:
(= cocaine and crack) — Ireland, Italy and United Kingdom: LSD (=‘LSD and other hallucinogens’).
In some countries, crack use has been reported independently of cocaine: Ireland, 3 %; Italy, 2 %; United Kingdom, 3 %.
In Germany a youth survey (12 to 25-year-olds) has been conducted every three to four years since 1970 instead of the school survey.
In the 1994 survey the total sample was 4 000 (12-25 years): lifetime prevalence for any illegal drug among 14 to 17-year-olds was 12 %
(former West Germany) and 4 % (former East Germany). Source: Bundeszentrale für gesundheitliche Aufklärung, Die Drogenaffinittät
Jugendlicher in der Bundesrepublik Deutschland. Wiederholungsbefragung 1993/1994: Köln.
Notes:  (1) Due to the differences in reporting of results, in some cases it was necessary to make some reasonable estimates (results
are presented in bold).
(2) In all the surveys the method for data collection was written questionnaires.
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Belgium (Flanders) 1996 4 771 18.9 3.6 6.0** 2.5 1.1(c) 1.0
Denmark 1995 2 571 18.0 6.0 1.9(b) 0.5** 0.4 0.5(c) 2.0
Greece 1993 10 543 4.8 3.0 6.3 4.0(b) 1.1 0.9(c) 0.6
Spain 1994 21 094 22.1 19.4 3.2 3.5(b) 2.9(a) 4.5 1.7(c) 0.5
France 1993 12 391 15.3 11.9 5.5 2.5(b) 1.5 1.1(c) 0.8
Ireland 1995 1 849 37.0 37.0 3.0(b) 9.0** 13.0 2.0(c) 2.0
Italy  1995 1 641 21.0 19.0 8.0 3.0(b) 4.0** 5.0 3.0(c) 2.0
Luxembourg 1995 1 341 15.0 6.0 2.6 10.6(b) 0.9** 0.9 0.9(c) 0.0
Netherlands 1996 10 455 31.7 31.1 7.8(b) 8.1** 4.3(c) 1.3
Austria 1994 2 250 9.9 9.5 2.0(c)
Portugal 1995 4 767 4.7 3.8 0.2 1.0(c) 0.9
Finland 1995 2 300 5.5 5.2 4.4 0.5(b) 0.2** 0.3 0.2(c) 0.1
Sweden 1997 5 683 7.6 6.8 8.7 0.9(b) 0.8** 0.5 0.5(d) 0.5
U.  Kingdom 1995 7 722 42.0 41.0 20.0 13.0(b) 8.0** 14.0 3.0(c) 2.0
levels. On the other hand, cocaine experience
shows only a small increase. As in adult surveys,
generalisation of trend information drawn from
school surveys has some limits; some trends may
not be well represented in the age group covered
(mainly the 15 to 16-year-olds).
Estimates of problem drug use
Problem drug use, injecting or use associated with
criminal behaviour, is rare in the adult population
and practically absent at school ages. Therefore, it is
not possible to obtain reliable prevalence figures
through general population or school surveys. To
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Table 4: National prevalence estimates of problem drug use in EU countries
(a) C-RC = capture-recapture, IDUs = injecting drug users, GPs = general practitioners.
(b) Opiate addicts (IDUs as well as smokers), amphetamine addicts, cocaine addicts and patients undergoing methadone treatment.
(c) Almost all are opiate misusers (using at least 100 times /year) or injecting drug users.
(d) This estimate assumes opiate addicts show up in the health or social system at least once in their career; those who do not are
excluded.
(e) Almost all are opiate misusers or injecting drug users.
(f) Injected at least once in last year, or daily/almost daily use of any illegal drug (including cannabis and Ecstasy). Of these, 19 % had
opiates as primary drug, 34 % had used opiates at some time and 93 % injected in the last year (mostly amphetamines).
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Denmark (1) 1996 mortality data multiplier 'heavy drug 12 500 2.4 4.2
abusers'(b)
Germany (2) 1995 arrests, treatment, multiplier, other IDUs or frequent 100 000-150 000 1.2-1.8 2.2-3.3
deaths,  surveys;  GPs methods hard drug users(c)
France (3) 1993 treatment surveys demographic heroin addicts 160 000 2.8 5.0
(November census) model  (mostly IDUs)(d)
Italy (4,5,6) 1992 treatment, police, C-RC, opiate addicts 190 000-313 000 3.3-5.5 5.9-9.7
prison, deaths, AIDS, multiplier (mostly IDUs)
cohort studies
Luxembourg (7) 1997 treatment, multi-indicator, 'high-risk drug 1 900-2 300 4.6-5.5 8.0-9.7
drug offences, register consumers'(e)
prison demographic
model,  police
multiplier  
Netherlands 1993  treatment, police, experts multiplier, opiate addicts 25 000-28 000 1.6-1.8 2.7-3.1
(8,9) municipalities  extrapolation (including IDUs)
Austria (10) 1993 ambulance calls, deaths, 'consistency 'illegal opiate 10 000-15 000 1.3-1.9 2.2-3.3
other overdoses, drug checks', case- consumers'
register finding
Finland (11) 1995 hospital treatments, C-RC, amphetamine 5 300-10 500 1.0-2.1 1.8-3.6
penal actions, multiplier  and opiate users
traffic offences
Sweden (12) 1992 social services, treatment, case-finding, 'severe drug 14 000-20 000 1.6-2.3 3.0-4.3
correctional system  C-RC  abusers' (f)
Rate/1 000
)
estimate prevalence, one must employ multiplier
techniques or advanced statistical models like
three-sample capture-recapture.
These estimates were first developed, and are more
easily applied, at local level. An updated overview is
presented of local prevalence estimates. Even when
techniques vary and definitions are not always
compatible, it suggests that important differences
exist between cities and towns in Europe, estimates
in ages 15 to 54 varying from 1.8 per 1 000 for one
small Dutch town to between 22 and 39 per 1 000
for a small Scottish town. Less dramatic but still im-
portant differences are observed between major
cities. However, differences within a country may be
just as pronounced, as illustrated by the Nether-
lands (from 1.8 up to 10.1 to 11.5 per 1 000 aged 15
to 54) and UK (from 5.3 up to 22 to 39 per 1 000
aged 15 to 54). In 1997, a study commissioned by
the EMCDDA produced estimates for opiate use in
six cities using similar methods and definitions. Esti-
mated prevalence in ages 15 to 54 ranged from be-
tween 4.2 and 8.1 per 1 000 in Helsinki (Finland) 
to between 12.7 and 29 per 1 000 in Setúbal 
(Portugal). This suggests that the wide range 
of prevalence found in other studies cannot be 
attributed to methodological differences only.
Prevalence estimates at national level are more
problematic, as within-country heterogeneity and
lack of data are more pertinent, and so should
again only be used as a crude indication of preva-
lence. Updated national estimates are presented for
the nine countries that could provide an estimate
and give methodological details. Methods and defi-
nitions vary significantly, from ‘opiate addicts’ or
‘heroin addicts’ in some countries to a wider defini-
tion of ‘heavy/severe drug abusers’ or ‘high-risk
drug consumers’ in others. In Sweden even frequent
users of cannabis and Ecstasy are counted, al-
though more than 90 % are amphetamine injec-
tors. Even though these methodological differences
make the picture more diffuse, it is clear that differ-
ences in prevalence between countries cannot be
very large. Estimates for all countries in ages 15 to
54 vary by about a factor of 2 to 3, for example from
1.8 to 3.6 per 1 000 in Finland to 5.9 to 9.7 per 1 000
in Italy and 8.0 to 9.7 in Luxembourg.
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Figure 4: National prevalence estimates 
of problem drug use 
)
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Table 5: Local prevalence estimates of problem drug use in EU countries 
(a) C-RC = capture-recapture, IDUs = injecting drug users, GPs = general practitioners.
(b) Almost all are opiate misusers or injecting drug users.
(c) Dutch 3 564 foreign; 2 205;  total 5 769. The estimate of foreigners and thus the total could be too high, as these form an open population.
(d) Amphetamine users: 1 590-3 780: opiate users: 490-1 390.
(e) Injected at least once in last year, or daily/almost daily use of any illegal drug (including cannabis and Ecstasy). 
(f) Includes cannabis and Ecstasy users in contact with social services. Of these 44 % were opiate users and 95 % injected in the last
year (mostly amphetamines).
(g) Includes IDUs, arrest data may be confined to problem users of opiates and amphetamines. 
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D Berlin (1) 1995/96 GPs C-RC, monitor GPs IDUs 6 500-8 000 3.2-3.9
Bremen (2) 1996/97 medical/social, justice case-finding  illegal drug users in 4 347 11.9
contact with services
E Barcelona (3) 1993 emergencies, 3-sample C-RC opiate addicts 10 594-16 132 7.2-11.0
treatment, prison
Madrid (4) 1992 deaths, treatment, 3-sample C-RC heroin addicts 41 000 14.1
AIDS regist., prison and multipliers
Navarra region 1990 health and justice case-finding heroin users 1 231 4.2
                                    (5) systems in treatment
F Toulouse (6) 1995 repressive, medical/social, case-finding, opiate users 1 700-2 600 4.3-6.5
low-threshold 3-sample C-RC in difficulty
I Lazio region (7) 1992 publ. treatment, 3-sample C-RC opiate addicts 24 060 8.0
therapeut. comm., police
Rome (8) 1996 surveillance system, 3-sample C-RC drug abusers 12 742-16 167 7.9-10.1
hospital, emergencies (mostly opiate users)
L Luxembourg 1997 treatment, drug offences, multi-indicator register, 'high-risk drug 760 16.2
  City (9) prison demographic model, consumers'(b)
police multiplier
NL Alkmaar (10) 1991 field study case-finding, opiate users 98 1.8
nomination, snowball
Amsterdam (11) 1996 treatment regist., 2-sample C-RC opiate addicts 3 564-5 769(c) 7.8-12.7
methadone in police cells
Rotterdam (12) 1994 low-threshold truncated Poisson problematic 3 497-3 990 10.1-11.5
methadone treatment opiate users
Utrecht (13) 1993 police, methadone, C-RC, nomination, opiate users 950 6.3
field study network analysis
A Vienna (14) 1993 hospital, ambulance, 4-sample C-RC opiate addicts 4 332-11 668 4.6-12.4
police, deaths  
P Setúbal (15) 1996 health centre, specialised 3-sample C-RC opiate users with 620-1 423 12.7-29.0
centre (2 semesters) health problems
FIN Helsinki (16) 1995 hospital drug treatments, 3-sample C-RC amphetamine 2 280-4 450(d) 4.2-8.1
 police, traffic offences  and opiate users
S Malmö 1992 needle exch., treatment, case-finding,  C-RC severe drug abusers(e) 1 100-1 300 8.8-10.4
                (17, 18) social serv., detention
Stockholm (19) 1996 treatment, social services case-finding drug users in contact 1 633 3.9
with services (f)
UK Dundee (20) 1990/94 treatment, police, HIV test 4-sample C-RC misusers of 1 974-3 458 22.3-39.0
opiates/benzod.
Glasgow (21) 1990 treatment, police, 4-sample C-RC IDUs 7 491-9 721 11.9-15.4
 HIV test, needle exch.
Liverpool (22) 1991 treatment, police, 3-sample C-RC users of 2 344 9.8
infectious diseases unit opiates/cocaine
South and 1993 police, GPs, needle exch., 4-sample C-RC opiate, amphetamine 682-4 153 2.7-16.3
East Cheshire comm. drug teams  or cocaine misusers
region (23)
Wales 1994 treatment, police, C-RC serious drug users(g) 8 357 5.3
region (24) needle exch., probation
Rate/1 000
Demand for treatment
Information on treatment admissions provides use-
ful information on characteristics and patterns of
drug use (injection, multiple drug use, etc.) among
problematic users and may be a useful indirect in-
dicator of trends in problematic drug use and as a
basis for other prevalence estimation methods.
However, changes in treatment modalities or re-
porting procedures must be taken into account.
Finally, this information is valuable from a public
health perspective to assess needs, to identify pat-
terns of service uptake and to plan and evaluate
services.
Almost all EU countries provide information on
drug treatment, but sources and methods vary ac-
cording to the types of treatment centres which
provide reports.This may explain some of the cross-
national differences reported in substances and
other characteristics. New services (e.g. substitution,
low threshold) may attract new users, increase the
number of treatment admissions, or change trends
and profiles (e.g. age, sex, route of administration).
With these limitations in mind, some common fea-
tures can be identified among clients entering
treatment in EU countries.
The majority of clients (70 to 95 %) require treat-
ment for opiate (mainly heroin) use. Finland and
Sweden are the exception, with only 34.8 and
39 % of cases presenting for opiates, although in
both countries treatment information is based on
hospital discharges only and so biases the popu-
lation. In some countries, methadone is increas-
ingly mentioned as the primary drug, but this may
be a result of data collection methods; for exam-
ple, clients already enrolled in a methadone pro-
gramme are admitted to another clinic and then
recorded as a ‘methadone case’.
Cocaine is usually reported as a main drug by less
than 5 % of treatment admissions. In Belgium
(Flanders) (9 %), Luxembourg (11 %) and the
Netherlands (14,5 %) the proportion is higher. Co-
caine is frequently reported as a secondary drug by
heroin users.
Cannabis is generally reported as a main drug by
about 10 % or less of treatment admissions. In
Finland, Germany, Greece, Ireland and the Nether-
lands the proportion is higher and some coun-
tries have recently recorded increases. This 
requires more detailed examination, as other 
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factors should be considered, such as the type of
reporting centres, the sources of referral, and oth-
er characteristics of the client. For instance, in
Spain, a significant proportion of cannabis cases
reported opiates (heroin 19.8 %) or cocaine
(30.9 %) as ‘secondary drugs’ and in the Nether-
lands 40 % of them reported alcohol, cocaine or
Ecstasy as the secondary drug.
Amphetamines, Ecstasy and hallucinogens are pri-
mary drugs for generally less than 1 to 2 % of treat-
ment cases. However, amphetamines are reported
more in Finland (39.5 %), Belgium (Flanders)
(24.4 %), Sweden (20 %) and the UK (9 %).
Prevalence of injecting among treatment admis-
sions varies between countries, although differ-
ences also exist within countries. The substances
most commonly injected are opiates, ranging from
10 to 15 % (Belgium (Flanders) and the Nether-
lands) to more than 80 % (Luxembourg and
Greece). In the Scandinavian countries and the UK,
amphetamines are often injected. In some coun-
tries, an important proportion of clients admitted
for cocaine inject it, but this is not the common pat-
tern of cocaine use in the EU.
In recent years the proportion of cases for opiates
has decreased, while cases of cocaine and cannabis
have increased, although at low levels. The propor-
tion of injectors in the treated population is de-
creasing in almost all countries. These trends are
more pronounced among clients seeking treat-
ment for the first time, suggesting real changes in
patterns of use among problem drug users.
Gender and age distribution of treatment admis-
sions are relatively similar across the EU. Most are
male (70 to 90 %), a figure which has remained sta-
ble in recent years. Treatment clients are generally
in their 20s or 30s, with a mean age ranging from
23.7 years (Ireland) to 33.0 years (Sweden). In recent
years a moderate increase in clients’ mean age has
been noted.
Suggested explanation: It has been suggested
that this indicates an ageing cohort of problem
drug users, with few new cases. If this were true,
the mean age of clients should increase by al-
most one year annually, but the observed in-
crease is smaller, and does not occur in all EU
countries.
*
!
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Table 6: Some characteristics of persons treated for drug problems in different EU countries
Belgium (Brussels): amphetamines (= stimulants including amphetamines). Germany: ‘IV route of ad. main drug’ (%) and (‘% IV route of
adm.’)  (= currently injecting the drug). Portugal: IV route of ad. main drug (%) (= currently injecting any drug).
In Germany, Italy and Luxembourg the ‘% IV route of adm.’ refers to heroin.
In several countries ‘Amphetamines’ also include Ecstasy: Belgium (Flanders) 3.7 %; Belgium (Wallonia) 1.6 %; Greece 0.2 %; 
Italy 0.4 %; Netherlands 1.6 %; Spain 0.4 %.
Others: Belgium — Brussels (include alcohol).
Belgium — Wallonia  (include alcohol).
France (solvents, hypnotics-sedative).
Sweden (multiple abuse).
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Belgium (Brussels) (1) 1996 22 25 70/30 73.6 (9) 2.8 (9) 1 02.1 16.3
Belgium (Flanders) 1996 52 09 84/16 54.8 09.2 24.4 1.3 07.4
Belgium (Wallonia) 1996 29.6 33.5 24.2 72/28 18.3 57 (32) 02.2 (23) 2.1 0.2 09.1 26.2
Denmark (2) 1997 32.5 20 40 73/27 27 84.6 (53) 00.7 2 10.5 00.6
Germany (3) 1997 27.8 37 21 77/23 36.3 72 (47) 07(36) 1 2 13 02
Greece (4) 1997 29.3 26.7 21.7 86/14 69.1 83.7 (82) 00.4 (50) 0.0 0.2 11.6 01.1
Spain (5) 1996 29.2 26.7 16.3 84/16 32.5 89.7 (36) 05.6 (8) 1(1) 03.0 00.6
France (6) 1995 28.9 24 17 73/27 81.6 02.1 0.8 0.4 08.1 06.7
Ireland (7) 1996 23.7 65 07 72/28 42.6 79 00.5 0.4 0.4 12 07.7
Italy (8) 1997 30 21.2 21.9 86/14 86.7 (75) 02.3 (26) 0.7 (7) 0.4 06.7 03.2
Luxembourg (9) 1997 28.5 27 15 81/19 79 79 (87) 11 (82) 1 04 04
Netherlands (10) 1997 30.4 25.1 25 80/20 10.3 66 (14) 16.3 (3) 4.6 (6) 0.2 11.2 02
Austria
Portugal (11) 1996 27 37.6 09.7 81/19 45 93.3 (49) 01.5 (57) 03 00
Finland (12) 1996 32 30 66/33 34.8 00.6 39.5 8.6 16.5
Sweden (13) 1996 33 17 42 72/28 39 < 1 20 < 1 07 33
U. Kingdom (14) 1996/97 43 15 75/25 37 76 (43) 03 (5) 8 (42) 0 06 07
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Figure 6: Main drug for which clients demanded
treatment in different EU countries
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Figure 6.1: Proportion of clients treated for opiate
problems using the IV route (1996/97)
In Germany, Italy and Luxembourg data refer to heroin. In
Ireland data refer to main drug.
Deaths and mortality
Deaths related to the use of drugs are a cause of social
concern, and their number is often simplistically used
as a marker of a country’s drug situation. However,
statistics on drug-related deaths depend not only on
the prevalence and patterns of use, but also on the
methods and definitions used to record cases.
In the EU,statistics refer mainly to acute deaths short-
ly after the use of drugs, called ‘acute intoxication’ or
‘overdoses’. Direct comparisons between countries
cannot be made but, if recording methods are main-
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tained consistently, drug-related deaths can be a use-
ful indicator of trends for severe forms of drug use.Im-
proving data quality and comparability is difficult, as
countries rely on different types of registries, and use
different recording and reporting procedures. The
EMCDDA has been analysing national recording pro-
cedures, and standards for reporting have been de-
veloped. The feasibility of implementing these stan-
dards will be tested in all EU countries. Information
has been exchanged with Eurostat and the World
Health Organisation (WHO), whose representatives
participated in the EMCDDA working group.
Table 7: Number of acute drug-related deaths recorded in EU countries, 1985-97
(da) data available but not comparable with other years.
(1) It is considered different from the total population only when the cases of death are obtained from a clearly defined subgroup of
the population.
(2) Cases from the former West Germany. Former East Germany: 1996 (13 cases), 1997 (15 cases).
(3) Population and cases refer to six large cities.
(4) Population aged 15-49.
(5) In this table, cases included are only those whose underlying cause of death was the ICD-9 codes 292, 304, 305.2-9, E850.0, E854.1
or E854.2. In 1996 ICD-10 was implemented; but although data are available there is not yet an agreement on the codes to be selected.
(6) For comparability reasons only overdoses were taken from all national data on drug-related deaths.
Important note (for all countries):
Data from different countries are not directly comparable, as there are some differences in case definition and methods of data col-
lection (see Table 8 of the 1997 EMCDDA annual report).
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Belgium 12 20 17 37 49 96 90 75 80 46 48 10.1
Denmark 150 109 140 135 123 115 188 208 210 271 274 266 274 05.2
Germany (2) 324 348 442 670 991 1 491 2 125 2 099 1 738 1 624 1 565 1 699 1 486 81.8
Greece 10 28 56 62 72 66 79 79 78 146 176 222 222 10.4
Spain  143 163 234 337 455 455 579 556 442 388 394 429 14.5(3)
France 172 185 228 236 318 350 411 499 454 564 465 393 228 58.2
Ireland 22 8 7 15 8 11 14 17 20 19 31 40 01.8 (4)
Italy 242 292 543 809 974 1 161 1 383 1 217 888 867 1 195 1 566 1 153 57.1
Luxembourg 1 3 5 4 8 9 17 17 14 29 20 16 9 00.23(4)
Netherlands (5) 40 42 23 33 30 43 49 43 38 50 33 15.4
Austria  (6) da da da da 20 36 70 121 130 140 160 179 132 07.9
Portugal 18 22 33 52 82 143 155 100 142 145 169 09.8
Finland 3 11 14 17 26 15 17 13 19 05.1
Sweden 150 138 141 125 113 143 147 175 181 205 194 250 08.8
U. Kingdom da da da 1 212 1 191 1 284 1 402 1 450 1 399 1 651 1 805 58
*
Other types of deaths (infectious diseases, acci-
dents, suicides) should be included in evaluations
of the overall impact of drug use in society,
although information sources and methods for
recording cases are different than those for acute
intoxications.
Some groups of drug users are at increased risk of
death. Opiate injectors have a mortality which is 20
to 30 times higher than non-drug users of the same
age from overdoses, infectious diseases (AIDS and
others), accidents and suicides. If opiates are not in-
jected, or combinations of substances are avoided,
the risk is lower. Users of other substances, that do
not inject, have a much lower risk of death, espe-
cially from acute intoxication. Other potential 
mortality risks, such as substance-related traffic 
accidents, should be evaluated.
In the EU, opiates are found in most cases of deaths
from acute intoxication, although other substances
are often present. Alcohol and benzodiazepines are
frequently found and may be risk factors for fatality
in cases of opiate intoxication. Acute deaths relating
solely to cocaine or amphetamines are unusual.
Deaths related to Ecstasy or similar substances,
although widely publicised, are few in number. This
may change if chronic intense use develops, or if use
in combination with other substances increases.
Some general trends in drug-related deaths can
be outlined, although the effects of changes in
recording procedures cannot be ruled out. In
most EU countries, acute drug-related deaths in-
creased markedly during the late 1980s and early
1990s. Since then, trends have diverged, although
with a general trend towards stabilisation or de-
crease. In several countries, the highest were from
1990-92, with a downward trend since, albeit ac-
companied by transitory rises. In other countries
there has been an upward trend until recently
(1994-96), followed by a decrease, whereas in
some countries the upward trend still continues.
Finally, in a few countries (Finland and the
Netherlands) there has been no clear trend in re-
cent years, with the number of reported deaths
having been relatively stable.
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Absolute numbers of acute drug-related deaths cannot be directly compared between countries due to differences in definitions and
methods of data collection.
Note that here trends but not numbers are presented.
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Figure 7: Trends in the number of drug-related deaths in EU countries, 1991-96
Three years’ moving averages indexed (1991 = 100) 
Suggested explanations: The underlying 
causes of these trends are difficult to identify
and interpretations should be made with cau-
tion. Changes in trends in drug-related deaths
may be related to stabilisation in problematic
drug-use prevalence, to changes in the patterns
of use (e.g. decrease of injection), to the effects
of interventions, or changes in registration prac-
tices. !
Infectious diseases
There are large differences in prevalence rates for
HIV infection among injectors between countries,
ranging from 0 % (Finland) to 30 % (Spain). Large
differences also exist within countries, between re-
gions and cities. There is no simple explanation for
this. In some countries, the cities with high preva-
lence (Edinburgh and Amsterdam) were among
those first affected by the epidemic, so awareness
and prevention responses were too late to prevent
the strong rise. In others, risk behaviour may have
been so extensive that an epidemic was unavoid-
able (Spain and Italy), irrespective of awareness and
prevention measures.
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Table 8: Prevalence of HIV infection among injecting drug users in EU countries
Information based on local data is given between parentheses.
(a) In all problem drug users, % in injecting drug users (IDUs) not known but almost certainly higher.
Data based on self-reports may be unreliable.
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Belgium (Wallonia) (1) 1996 first treatments, self-reports 294 1.4(a) n.a.
Belgium (Flanders) (2)  1993 Antwerp: study treatment/streets 217 (5) n.a.
Denmark (3) 1995  estimate from HIV notification 4 n.a.
Germany (4) 1996 drug users in treatment, self-reports 2 074 3.9(a) stable
Greece (5) 1997 treatment, screening/self-reports 708 0.5-2.0 stable
Spain (6) 1996 survey treatment centres 871 30 decrease
France (7) 1995 survey treatment centres, self-reports 6 429 16-20 decrease
Ireland (2) 1993 Dublin: study treatment/streets 185 (8) n.a.
Italy (8) 1997 treatment in public services 73 784 16 / 1-28 decrease
Luxembourg (9) 1997 treatment reporting system, self-reports 280 2-4 stable
Netherlands (10) 1996/97 repeated treatment/street studies 1 333 2-26 stable
Austria (11) 1997 opiate overdose deaths 132 1.5 (stable)
Portugal (12) 1996 survey treatment centres, self-reports 379 14 stable
Finland (13) 1997 Helsinki: needle exchange, self-reports 131 (0) (stable)
Sweden (14) 1997 study nine prisons 196 3 stable
United Kingdom 1996 unlinked anonymous 3 373 0.6 decrease
(England+Wales) (15)
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HIV backcalculation models show that new 
generations of injecting drug users continue to be 
infected, though at lower levels than in the 1980s 
(EU Concerted Action BMH1-CT94-1723, RIVM, NL)
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Table 9: AIDS incidence related to injecting drug use (IDU) in countries of the European Union 
(by 31 March 1998)
(Annual incidence rates per million population and cumulative % of AIDS cases related to IDU)
Notes: (1) Figures for the years 1995, 1996 and 1997 are adjusted for reporting delays.
(2) In some countries there may be small differences between incidence rates provided by the European Centre and national figures 
due to reporting delays.
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Annual incidence rates per million population
Belgium 0.0 0.1 0.5 0.7 1.0 1.2 2.2 2.2 2.1 2.0 1.3 1.0 0.6 6.5
Denmark 0.0 0.2 0.6 1.2 1.6 3.1 3.1 3.5 4.1 4.6 5.4 3.3 1.8 7.9
Germany 0.2 0.6 1.6 2.3 2.9 2.9 2.9 3.3 3.4 3.6 3.1 2.6 1.7 14.2
Greece 0.0 0.1 0.1 0.2 0.5 0.6 1.2 0.6 0.8 0.5 0.4 0.9 1.2 4.0
Spain 2.4 7.1 17.0 38.8 52.0 64.7 73.2 78.6 85.5 119.0 110.3 103.1 74.7 65.4
France 0.8 2.7 6.0 11.1 15.6 18.5 20.8 22.8 25.2 23.1 22.0 16.1 7.2 23.8
Ireland 0.6 0.3 2.8 3.1 6.8 8.3 9.4 10.3 10.8 6.8 6.0 7.1 1.6 43.0
Italy 1.7 4.8 12.0 21.3 29.0 36.1 43.3 48.2 52.6 58.8 58.4 50.3 31.6 62.4
Luxembourg 0.0 2.7 0.0 2.7 8.0 0.0 2.6 7.7 12.7 5.0 0.0 4.9 4.8 15.7
Netherlands 0.1 0.4 1.1 2.3 2.3 2.7 2.9 3.7 3.9 3.9 4.8 3.0 2.8 10.9
Austria 0.8 0.4 3.6 4.3 5.6 5.8 7.0 7.2 7.4 5.2 4.7 3.1 2.3 25.5
Portugal 0.1 0.3 0.7 1.0 3.0 4.2 7.3 13.0 23.6 32.6 39.3 48.0 50.5 43.5
Finland 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.6 0.2 0.2 0.2 0.4 0.2 3.7
Sweden 0.0 0.0 0.1 0.6 0.5 1.3 2.3 2.5 3.8 3.0 2.7 2.5 1.0 11.5
U. Kingdom 0.0 0.1 0.3 0.5 1.1 1.4 1.5 1.4 2.6 2.3 2.5 2.1 1.4 6.5
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Figure 9: AIDS incidence related to injecting drug
use in countries of the EU
Trends, prevalence and patterns of use 29
0
10
20
30
40
50
60
70
80
90
100
%
 in
fe
ct
ed
 (
ev
er
)
A
50
-5
6
72
-7
9
DK
21
50
F
53
-7
0
D
48
63
EL
3-
12
50
-9
4
IRL
84
I
40
67
L
22 19
NL
59
-6
3
74
-8
4
P
74
E
59
83
S
55
92
UK
22
48
-7
7
34
53
FIN
Hep B
Hep C
n.
a.
n.
a.
n.
a.
Figure 10: Hepatitis B and C infection among 
injecting drug users in the EU
Table 10: Prevalence of antibodies against hepatitis B and C among injecting drug users 
in EU countries
Information based on local data is given between parentheses. Self-reports on hepatitis infection may be unreliable.
n.a.: data not available.
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Hepatitis B
Denmark (1) 1995 estimate 21 1995 estimate 50
Germany (2) 1996 Dortmund: treatment (48) 1996 Dortmund: treatment (63)
Greece (3) 1997 methadone/drug-free treatment 3-12 1997 methadone/drug-free treatment 50-94
Spain (4) 1996 treatment 59 1996 treatment 83
France (5) n.a. 1995 survey treatment centres, 53-70
self-reports
Ireland (6) n.a. 1995 Dublin: treatment (84)
Italy (7) 1997 treatment 40 1997 treatment 67
Luxembourg (8) 1997 treatment, self-reports 22 1997 treatment, self-reports 19
Netherlands (9) 1994/96 Rotterdam/Heerlen/Maastricht: (59-63) 1994/96 Rotterdam/Heerlen/ (74-84)
treatment Maastricht: treatment
Austria (10) 1996 Vienna: hospital, (50-56) 1996 Vienna: hospital, (72-79)
low-threshold treatment low-threshold treatment
Portugal (11) n.a. treatment, self-reports 74
Finland (12) 1997 Helsinki: needle exchange, (34) 1997 Helsinki: needle exchange, (53)
 self-reports  self-reports
Sweden 1997 study nine prisons, saliva (13) 55 1994 Stockholm: (92)
study prison/treatment (14)
United Kingdom 1996 unlinked anonymous, 22 1994 survey treatment centres (16) 48-77
 England + Wales (15)
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As an infected person can remain in a drug-using
population for more than 10 years, the prevalence
of HIV infection mainly depends on population dyn-
amic factors like deaths (e.g. AIDS-related deaths or
overdose) and migration. Therefore, once high
prevalence has developed it may take many years
to diminish.
Prevalence rates of HIV among injectors are stable
or declining in most EU countries. This is the result
of different factors, like spontaneous behaviour
change among injecting drug users aware of AIDS,
behaviour change as a result of harm reduction
measures like needle exchanges and methadone
programmes, and because many of those engaging
in the greatest risk behaviour have already been in-
fected and died.
Modelling studies, based on estimates of HIV inci-
dence from reported AIDS cases, show that new
generations of users continue to be infected. This,
however, is masked by the overall decline in inci-
dence rates after the explosive first phase of the
epidemic, occurring in most countries in the second
half of the 1980s. The HIV epidemic has now en-
tered the endemic phase in most west European
countries meaning that new infections balance
deaths and migration.
Incidence rates for AIDS show large differences be-
tween countries.The proportion of AIDS cases related
to injecting also differs between countries. Although
some of this may be explained by differences in in-
jecting rates, these are not sufficient to explain the
large differences found between countries.Therefore,
risk behaviours among injecting drug users must
have significantly differed between countries around
the time of introduction of HIV. AIDS monitoring is
becoming less useful as an indicator of the extent of
HIV infection due to new and highly effective AIDS
treatments. Declines now seen in AIDS incidence
mainly result from the delay of the onset of AIDS in
HIV-infected persons.Therefore, AIDS is becoming an
indicator of treatment uptake rather than of HIV in-
fection. Centralised reporting of known HIV cases is
under consideration in Europe to complement the
existing AIDS reporting.
Prevalence of hepatitis B infection differs markedly
between countries; from 3 to 12 % (Greece) up to
about 60 % (Spain, the Netherlands). Hepatitis C in-
fection in general shows higher and more similar
rates, to over 90 %, even in countries with low rates
of hepatitis B and HIV infection (Greece). High rates
of hepatitis infection may imply that risky injecting
practices are ongoing but at rates insufficient for
HIV. Rates of hepatitis B infection are probably lower
than hepatitis C because most infected people do
not become chronic carriers and can only infect oth-
ers for a limited period. In contrast, hepatitis C be-
comes chronic in most cases and can lead to long-
term liver disease like cirrhosis and liver cancer.
It is estimated that around 500 000 injecting drug
users are infected with hepatitis C in the EU.These in-
fections may lead to significant disease burden and
health-care costs, possibly comparable to HIV, and
may include persons who have stopped using drugs
for a long time. It is therefore important to develop a
detailed understanding of which measures are most
effective in preventing transmission. As those most
at risk of developing long-term liver problems may
be those infected by both hepatitis B and C, the vac-
cine for hepatitis B may be one cost-effective
method of preventing disease. Treatment for hepati-
tis C is rapidly improving, which may have important
implications for drugs and health-care services.
Police arrests and prison data
The only data systematically available on police in-
terventions refer to offences against drug laws (traf-
ficking, possession, etc.). These reflect the legisla-
tion of each Member State, the administrative pro-
cedures for recording, and police resources and pri-
orities. It is not possible to compare data directly, so
emphasis is given to time trends.
Since 1985, there have been moderate increases
(less than twofold) in Denmark, Luxembourg, Swe-
den and Italy, but in Belgium, Finland, Greece, Portu-
gal, Spain and the UK increases have been more
than fourfold. In recent years these increases have
accelerated in many countries, though in Denmark,
Ireland, Italy, Sweden and the United Kingdom they
have stabilised or decreased.
Not all countries provide data that distinguish use-
related from traffic-related offences. In those that
do, use-related offences predominate, ranging from
60 % in Portugal and Germany, to over 85 % in Aus-
tria, Sweden and the UK. In most countries, the pro-
portion of use-related offences is either increasing
or stable. In most, cannabis is the predominant
drug, although changes vary between countries.
Only in Italy and Portugal is heroin the main drug,
in the Netherlands ‘hard drugs’, and in Sweden 
amphetamines.
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Few Member States have reliable information on
drug users in prison, and the type of data varies
widely, from people imprisoned for drug offences,
to drug users identified on entry to prison, to levels
of use revealed by surveys or tests in prison. Drug
users constitute a significant proportion of the
prison population in many countries, from 25 to
70 % or more. It is not always clear whether these
estimates refer to users or to problematic users,
though when specified, the proportions of prob-
lematic users is typically 20 to 50 %.
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Table 11: Drug-related arrests in EU countries: trend over the last three years (1)
(1) Trend: over the three last years available.
(2) – : <-7 %; 0 : +/- 7 %; + : between + 7 % and + 40 %; + + : > +40 %.
(a) Data refer to 1996. (b) Data refer to 1995.
I. Among all drugs mentioned (alone or not). II. Possession and small-scale trafficking (the law just differs between
small and large quantities). III. Use/trafficking excluded. IV. Use and possession together. V. All illicit drugs except
hashish and marijuana. VI. Criminal offences related to import/export, sale delivery, transportation, production,
possession, etc.
n.a.: data not available.
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Belgium ++ cannabis: 65% n.a. use IV: 72% n.a.
Denmark – n.a. n.a. n.a. n.a.
Germany + cannabis: 43%(a) 0 use: 64% 0
Greece + n.a. n.a. n.a. n.a.
Spain ++ cannabis: 56% + trafficking only
France + cannabis: 79% + use: 79%III +
Ireland – cannabis: 63%(a) 0 use: 75%(a) –
Italy 0 heroin: 45% – sale: 80% +
Luxembourg + opiates n.a. n.a. n.a.
NetherlandsVI ++ ‘hard drugs’V: 81%(a) + trafficking only
Austria + cannabis: 63%I(a) + useII: 86%(a) +
Portugal ++ heroin: 58%(a) – use: 54%III(a) +
Finland ++ cannabis: 47% – use: 76% +
Sweden 0 amphetamines: 51%(b) + use: 91%(a) 0
United Kingdom + cannabis: 77%(a) 0 use: 88%(a) 0
In 1
997
Tre
nd
In 1
997
Tre
nd
Proportion of main type
of offence
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Table 12: Arrests for drug law offences in EU countries, 1987-97
Cou
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Belgium P U/T 6 393 7 000 6 093 7 051 10 720 18 179 19 482 19 467 18 376 36 872
Denmark P U/T 7 862 7 031 7 566 8 915 9 535 10 290 12 421 9 536 9 008 8 678 8 234
Germany O U/T 74 894 84 998 94 000 103 629 117 046 123 903 122 240 132 389 158 477 187 022 205 099
Greece P U/T 2 257 2 471 2 660 3 081 3 197 2 966 2 636 3 340 4 400 6 420 6 040
Spain P T 25 545 27 911 27 407 24 812 28 581 27 713 30 161 31 703 44 318 65 707 78 847
France A U/T 31 105 31 213 33 510 34 213 45 063 54 468 51 657 59 697 69 432 77 640 89 285
Ireland C U/T 1 196 1 333 1 344 2 071 3 088 3 494 3 833 4 443 4 164 3 278
Italy P U/T 19 373 23 320 20 582 18 343 22 966 27 617 23 525 25 957 21 913 22 171 22 705
Luxembourg A U/T 89 138 102 151 130 172 91 152 128 149 154
Netherlands(a) O T 5 420 4 820 4 700 5 900 4 430 3 380 3 010 4 040 3 470 6 593
Austria O U/T 4 778 4 963 4 474 4 829 5 392 7 805 10 915 12 632 13 093 16 196 17 868
Portugal O U/T 2 192 1 845 2 534 3 586 4 667 6 280 5 197 4 708 6 380 9 054 9 333
Finland P U/T 1 203 1 024 741 1 346 1 969 2 399 3 063 3 175 3 944 6 059 7 015
Sweden P U/T 6 533 6 697 6 625 7 676 8 123 7 974 7 394 8 604 9 573 8 810
United Kingdom P U/T 26 278 30 515 38 415 44 922 47 616 48 927 68 480 85 691 93 631 95 010
Total 182 850 212 861 232 808 248 093 267 444 309 326 342 601 361 469 402 194 455 907
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Figure 12: Arrests for drug law offences in EU countries, 1991-96
Three years’ moving averages indexed (1991 = 100)
Definitions
Belgium: persons concerned in cases of illicit drugs registered by the police; Denmark: charges for violations of drug  laws; Germany: drug offences (directly
supply-related crimes not included); Greece: arrests (caught by the police); Spain: arrests related to illicit drug trafficking; France: arrests for violation of drug
laws; Ireland: charges for drug offences; Italy: arrests; Luxembourg: arrests for violation of the 1973 drug law; Netherlands: offences against the Opium Act;
Austria: reports for violations of the Narcotic Drugs Act; Portugal: presumed offences against the drug law; Finland: suspects of narcotics offences; Sweden:
suspects of offences against the Narcotic Drugs Act or the Goods Smuggling Act; United Kingdom: persons found guilty of drug law offences.
Study unit: P: persons; O: offences; A: arrests; C: charges.
U/T: use/traffick; T: traffick.
(a) Criminal offences related to import/export, sale delivery, transportation, production, possession, etc.
Drug market indicators — seizures, 
price, purity
The quantities of drugs seized by law enforce-
ment agencies are indirect indicators of the supply
and availability of drugs. However, seizures reflect a
range of factors other than the quantities of drugs
imported and distributed, including law enforce-
ment resources, priorities and strategies, as well as
the vulnerability of traffickers to enforcement ef-
forts. Only a proportion is seized, but there is no
factual basis for the assumption that seizures rep-
resent 10 % of the total supply. This proportion will
vary over time, between countries and between
drugs. In addition, one exceptionally large seizure
can seriously distort the figures for a given year or
country. In general, consistent changes are a surer
guide to trends than year-by-year fluctuations.
Variations in seizures between Member States do
not always reflect differences in availability or con-
sumption in these countries. This applies particular-
ly to countries which, for reasons of geography or
history, are the first destination for importation (of
cannabis, heroin and cocaine) or are producers (of
synthetic drugs). Thus it is valuable to take into ac-
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Table 13: Number of drug seizures: trend over the last three years (1)
(1) Trend: over the three last years available.
(2) – – : <-40 %; – : <-7 %; 0 : +/- 7 %; + : between + 7 % and +40 %; ++ : >+40 % and + - : fluctuation.
(a) Data refer to 1996. (b) Data refer to 1995.
I. Too small figure to estimate a trend. II. Hashish only. III. Ecstasy and LSD together.
n.a.: data not available.
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Cannabis
Belgium (b) 5 714II + – 1 046 + 3 158 0 1 002III ++ 281I + 102(a) –
Denmark 4 886II – 723 + 2 509 – 110III ++ 15I ++ 1 324(a) +
Germany 29 826II + 5 482 + 9 509 0 2 368III 0 727I – 3 571(a) +
Greece n.a.II n.a. n.a. n.a. n.a. n.a. n.a.III n.a. n.a.I n.a. n.a.(a) n.a.
Spain 44 227II ++ 12 275 ++ 15 399 + 2 474III + n.a.I n.a. 2 474(a) + –
France 34 266II ++ 1 471 + 3 924 – 628III 0 171I + 163(a) ++
Ireland (a) 3 449II + – 93 ++ 664 ++ 405III ++ 42I – – 217(a) + –
Italy 11 423II + 3 163 + 6 851 – 847III + – 173I – 53(a) +
Luxembourg 190II + – 54 + 237 0 12III – 3I n.a. 3I(a n.a.
Netherlands n.a.II n.a. n.a. n.a. n.a. n.a. n.a.III n.a. n.a.I n.a. n.a.(a) n.a.
Austria 4 973II + 65 ++ 861 – 253III ++ 113I ++ 221(a) ++
Portugal 1 566II ++ 1 234 ++ 3 458 + 34III ++ n.a.I n.a. n.a.(a) n.a.
Finland 1 686II + 16 0 153 ++ 74III ++ 14I 0 1  339(a) ++
Sweden 4 545II + 116 ++ 833 0 203III ++ 86I ++ 4 639(a) 0
U. Kingdom (a) 91 432II 0 4 093 + 9 819 ++ 6 173III ++ 1 133I – – 18 207(a) ++
Cocaine Heroin Ecstasy LSD Amphetamines
*
count the number of seizures of different drugs
which, in many countries, includes a proportion of
small seizures from the retail/consumer level of the
market. This may be a better indirect indicator of
availability than total quantities, which are skewed
by small numbers of large seizures.
Confirmation of this would be assisted by breaking
down seizure data into quantities involved. At pres-
ent, seizure data should be treated with caution
and interpreted alongside other indicators, such as
number of seizures, price and purity, availability at
consumer level and qualitative information from
experts.
1994 and, where 1997 data are available, a rising
trend is still observed, especially in Austria, Finland,
France, Germany, Italy, Portugal, Spain and Sweden.
The data are not reliable enough to make price
comparisons between Member States, though gen-
erally cannabis prices appear to be stable. The
cannabis market is entrenched in most of the EU
and, depending on country, availability is high and
stable, or is increasing.
Heroin
The quantities of heroin seized increased threefold
in the late 1980s and early 1990s, from under
2 tonnes in 1985 to over 6 tonnes in 1991. Since
then, the quantities have fluctuated at a slightly
lower level within a 5 to 6 tonne range, the total for
1997 showing a decrease on previous years. Fluctu-
ating patterns are observed in most Member
States. In 1997, the largest amounts were seized in
Germany, followed by Spain, Italy (down from previ-
ous years) and France (2).
The number of seizures shows a clearer pattern.
Overall, the numbers rose steadily from 1985 to
1992 and have since stabilised. There are clear de-
creases over the past three years in France, Italy and
Austria and marked increases in Ireland, the UK,
Spain, Portugal and Finland. In most Member States,
heroin is the second most commonly seized drug,
and in two it is the most common.
The reported street price of heroin varies consid-
erably within and between EU countries, but da-
ta are too unreliable for comparisons. The gener-
al impression is of price stability after a decrease
in previous years, though a few countries report
decreases in 1997 and Italy reports an increase.
From limited reports, purity ranges from under
25 to over 40 %.
Overall, there are no major indications of change in
the heroin market. Whilst heroin is less widely avail-
able than cannabis, there appear to be few difficul-
ties in obtaining supplies for users in most Member
States, especially in major cities, and there are re-
ports of increased availability in smaller cities and
towns.
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(1) The UK and Ireland did not provide data for 1997.
(2) Data from the UK are missing. The UK accounted for large
quantities seized in previous years.
Future direction: Ideally, the analysis of drug
markets should be based on information on the
structure of drug markets and the actors in-
volved, but this is not available for most coun-
tries. The annual report of the Europol Drugs
Unit (EDU) contains further information, but
work remains to be done, in cooperation with
the EDU, national focal points, and other organi-
sations, to elaborate useful indicators. This re-
quires improvements in the quality of data (e.g.
on price and purity at different levels of the 
market).
For this report, the quantities seized were available
from all Member States (1). Data on the number of
seizures, from all but Greece and the Netherlands,
data on prices and purity, from some (though of un-
certain quality and comparability), and observa-
tions figured in a few national reports. The key
points below should be read within this context.
Cannabis
The total quantity of cannabis seized increased rap-
idly in the early 1990s, from 160 tonnes in 1985, 230
tonnes in 1989 to over 740 tonnes in 1994. Follow-
ing modest decreases in 1995 and 1996, this indica-
tor has been relatively stable for three years at
about four times the level recorded in the mid-
1980s. The largest quantities in 1997 were seized in
Spain.
In 10 of the 13 Member States who provided data,
cannabis accounted for the greatest number of
seizures. Like data on quantities, the number of
seizures shows an increase from the mid-1980s, but
at a slower and steadier rate. In most countries, the
increase in the number of seizures continued after
!
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Table 14: Quantities of cannabis seized in EU countries, 1985-97
kilograms
(a) From 1985 to 1994 only police seizures are included. Since 1995, all seizures are included (police, coastguard and customs).
(b) Cannabis leaves + resin + plants.
(c) Since 1991, a significant number of ‘nederwiet plants’ have been annually seized in addition: 71 945 in 1991, 313 242 in 1992, 
194 413 in 1993, 558 706 in 1994, 549 337 in 1995, 1 272 526 in 1996 and 1 479 821 in 1997. 
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Belgium 10 429 3 791 6 562 13 008 9 844 7 918 6 021 9 504 35 217 59 903 38 104 106 690(b) 48 705(b)
Denmark 510 472 1 243 1 369 729 1 250 1 703 2 152 1 273 10 665 2 414 1 772(b) 467(b)
Germany 11 498 2 675 2 998 11 350 12 073 13 641 12 343 12 166 11 353 25 693 14 245 9 355(b) 11 495(b)
Greece(a) 524 638 136 170 683 726 1 985 3 458 485 6 142 1 162 3 374(b) 19 331(b)
Spain 66 400 47 867 59 210 90 940 64 225 70 076 104 751 121 439 160 169 219 176 197 024 247 321(b) 315 328(b)
France 8 248 13 777 12 613 24 425 17 852 21 754 33 121 42 070 45 784 58 015 42 270 66 861(b) 55 122(b)
Ireland 147 16 102 237 191 119 1 154 516 4 205 1 527 15 616 1 940(b)
Italy 1 437 16 026 13 028 7 149 23 215 7 879 9 722 23 233 12 019 18 931 15 392 11 868(b) 59 765(b)
Luxembourg 55 15 21 190 11 33 24 35 403 317 12 21(b) 35(b)
Netherlands(c) 34 901 47 855 48 617 68 238 42 305 109 762 96 292 94 593 138 222 238 258 332 086 102 957(b) 31 513(b)
Austria 390 300 175 205 192 320 12166 248 546 394 697 517(b) 915(b)
Portugal 1 869 5 502 4 933 354 4 631 9 606 7 753 11 720 52 527 40 425 7 493 5 360(b) 9 693(b)
Finland 15 10 25 24 167 72 107 48 118 69 152 103(b) 210(b)
Sweden 1 414 326 579 423 470 601 639 376 563 457 527 287(b) 660(b)
U. Kingdom 22 165 25 136 16 936 45 476 59 369 30 889 32 204 51 103 53 574 63 021 58 484 101 127(b)
Total 160 002 164 405 167 177 263 557 235 957 274 644 319 985 372 661 516 458 742 993 725 679 659 553(b)
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Figure 14: Quantities of cannabis, heroin, cocaine and amphetamines seized in EU countries, 1990-96 
Cocaine
The quantities of cocaine seized increased from
1 tonne in 1985 to over 16 tonnes in 1990. Follow-
ing four years of stability, the amounts rose sharply
to 29 tonnes in 1994, dropped a third in 1995, but
rose to over 32 tonnes in 1996 and in 1997. Spain re-
mains the country where larger quantities of co-
caine were seized.
The number of seizures showed a more steady in-
crease from 1985 to 1997, without any of the sharp
peaks and troughs seen in the data on quantities,
though the numbers were small in Finland, Sweden
and Ireland. This increase was reflected in almost
every Member State, but was most marked in Spain
and Portugal.
The amounts of cocaine seized have increasingly
exceeded those for heroin since 1987, and in recent
years have been four to six times greater. In con-
trast, the number of seizures have been lower, at
around 40 % of those for heroin.
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Table 15: Quantities of heroin seized in EU countries, 1985-97
kilograms
(a) From 1985 to 1994, only police seizures are included. Since 1995, all seizures are included (police, coastguard and customs).
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Belgium 92 78 141 116 89 291 186 107 76 137 129 133 55
Denmark 5.4 17 13 29 37 27 31 39 28 29 37 61 38
Germany 208 157 320 537 727 847 1 595 1 438 1 095 1 590 933 898 722
Greece(a) 11 22 65 53 34 51 279 165 148 283 173 190 146
Spain 253 407 413 480 713 886 741 672 604 824 546 537 479
France 278 220 213 221 295 405 561 328 386 661 499 617 415
Ireland 1.2 1.9 0.1 0.4 0.4 0.6 0.2 0.8 1.3 4.7 6.4 10.8
Italy 275 329 321 573 648 900 1 541 1 358 651 1 150 954 1 270 472
Luxembourg 6.8 7.8 0.3 15 0.5 0.5 10 6.7 10.8 0.9 13.2 2.9 2.5
Netherlands 364 542 517 510 492 532 406 570 916 246 351 516 194
Austria 115 43 33 51 101 72 103 78 105 80 47 81 102
Portugal 3.5 19 30 33 61 36 62 41 92 89 66 47 57
Finland 0.8 0 0 0.2 0.2 0 0.7 1.9 0.7 1.6 16.1 6.5 2.4
Sweden 6 4 5 9 9 12 11 25 22 21 31 26 12
U. Kingdom 366 223 236 237 351 603 493 547 656 744 1 395 1 070
Total 1 985 2 070 2 308 2 865 3 559 4 663 6 020 5 377 4 791 5 862 5 197 5 467
Suggested explanation: This may reflect a ten-
dency for cocaine to be trafficked in larger quan-
tities than heroin, and a lower vulnerability of co-
caine retail suppliers and consumers to law en-
forcement interventions compared with heroin. !
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Table 16: Quantities of cocaine seized in EU countries, 1985-97
kilograms
(a) From 1985 to 1994, only police seizures are included. Since 1995, all seizures are included (police, coastguard and customs).
(b) 3 321 kg cocaine salts + 8 kg cocaine base.
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Belgium 62.0 116.0 270.0 404.0 89.0 537.0 756 1 222.0 2 892.0 479.0 576.00 838.0 3 329(b)
Denmark 0.5 7.1 26.0 10.0 55.0 28.0 40 21.0 11.0 30.0 110.00 32.0 58(b)
Germany 165.0 186.0 296.0 496.0 1 406.0 2 474.0 964 1 332.0 1 051.0 767.0 1 846.00 1 373.0 1 721(b)
Greece(a) 0.0 2.9 24.0 2.2 2.3 34.0 13 9.0 5.0 176.0 9.00 156.0 17(b*
Spain 303.0 669.0 1 134.0 3 461.0 1 852.0 5 382.0 7 574 4 454.0 5 350.0 4 016.0 6 897.00 13 743.0 18 418(b)*
France 96.0 258.0 754.0 593.0 939.0 1 845.0 831 1 625.0 1 715.0 4 743.0 865.00 1 742.0 844(b)*
Ireland 0.3 0.2 0.0 0.0 3.0 1.0 0 10.0 0.4 0.1 22.00 642.0
Italy 104.0 127.0 321.0 616.0 668.0 805.0 1 300 1 345.0 1 101.0 6 636.0 2 603.00 2 379.0 1 594(b)*
Luxembourg 27.0 6.5 18.0 4.6 21.0 23.0 14 12.0 16.0 16.0 0.53 13.0 9(b)*
Netherlands 124.0 274.0 406.0 517.0 1 425.0 4 288.0 2 492 3 433.0 3 720.0 8 200.0 4 851.00 9 222.0 6 744(b)
Austria 5.3 7.4 27.0 14.0 21.0 41.0 84 58.0 84.0 53.0 55.00 73.0 87(b)
Portugal 70.0 165.0 222.0 302.0 793.0 360.0 1 094 1 860.0 216.0 1 719.0 2 116.00 812.0 3 163(b)
Finland 0.0 0.0 0.0 0.1 11.0 0.0 38 0.1 0.0 0.0 0.10 0.1 0.1*
Sweden 0.8 3.0 1.4 6.5 4.6 8.8 226 61.0 14.0 29.0 3.70 18.0 34(b)
U. Kingdom 85.0 103.0 407.0 323.0 499.0 611.0 1 078 2 248.0 717.0 2 261.0 672.00 1 219.0
Total 1 043.0 1 924.0 3 906.0 6 749.0 7 787.0 16 438.0 16 505 17 690.0 16 893.0 29 124.0 20 626.00 32 262.0
As with heroin, there is considerable variation in the
reported street price of cocaine, but the data are
too unreliable for comparisons. After decreases in
previous years, price is relatively stable in most re-
porting countries. Limited data suggest that retail
purity is generally over 50 %. The overall picture is
of an expanding market with increased availability
in recent years, especially in metropolitan areas.
There are few markets in crack cocaine in the EU
countries apart from those established in areas of
the UK, in the Netherlands and France.
Synthetic drugs: amphetamines, Ecstasy, LSD
The quantities of amphetamines seized increased
slowly in the late 1980s. Although relatively low in
1985, there were rapid increases to more than
3 tonnes in 1996. Most of this is accounted for by
seizures in the UK, though there have been signifi-
cant seizures in the Netherlands, Germany, France
and Sweden.
The quantities of Ecstasy seized increased sharply
up to 1996 with larger amounts in the UK, the
Netherlands and Germany. The quantities of LSD in-
creased from low levels in the 1980s to over 1 million
units in 1993 but have fallen substantially since.
The number of seizures has increased since the late
1980s for amphetamines, Ecstasy and LSD in nearly
all Member States, but with recent differences.
While there has been an upward trend in most
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Table 17: Quantities of amphetamines seized in EU countries, 1985-97
kilograms
(a) From 1985 to 1994, only police seizures are included. Since 1995, all seizures are included (police, coastguard and customs);
958 pills were also seized in 1997.
(b) A small number of items were also seized.
(c) Amphetamine pills were also seized: 2 500 in 1990, 30 705 in 1992, 142 in 1993, 11 025 in 1994 and 850 in 1995.
(d) 39 pills were seized in 1990.
(1) Austria, Belgium, Denmark, France, Germany, Ireland, Italy, Luxembourg, Spain, Sweden, UK.
(2) Austria, Belgium, Denmark, France, Ireland, Italy, Luxembourg, Spain, Sweden, UK.
(3) Austria, Belgium, Denmark, France, Germany, Ireland, Italy, Luxembourg, Spain, Sweden, UK.
Note: For Belgium, Ireland and UK, missing data for 1996 and 1997 have been extrapolated on general trend of other countries.
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Belgium 3.51 2.4 9.0 47.0 4.2 15.0 77.0 96.0 19.0(b) 23.00(b) 68.11 24.08
Denmark 4.01 10.0 52.0 30.0 24.0 26.0 24.0 74.0 12.0(b) 13.00(b) 40.11 27.08 119.05
Germany 28.01 85.0 62.0 91.0 67.0 85.0 88.0 105.0 109.0(b) 120.00(b) 138.11 160.08 234.05
Greece(a) 0.01 0.0 (b).0 (b).0 (b).0 0.0 (b).0 (b).0 0.6(b) 0.01(b) 0.11 0.08 0.05
Spain 1.01 5.8 5.2 9.2 22.4 0.3 4.2 22.8 34.2(b) 31.70(b) 35.0 53.48 119.65
France 0.60 1.6 6.8 4.0 13.0 16.0 20.0 13.0 43.0(b) 80.00(b) 104.11 128.08 194.05
Ireland 0.11 0.0 0.1 0.0 0.1 0.3 0.1 0.1 0.7(b) 0.40(b) 1.51 7.68
Italy 0.21 0.4 2.9 1.0 0.6 0.7 0.7 15.0 0.5(b) 3.40(b) 1.11 2.08 0.45
Luxembourg 0.01 0.0 0.3 0.4 0.0 0.0 0.1 0.3 0.4(b) 0.10(b) 0.03 0.02 0.01
Netherlands(c) 42.01 86.0 125.0 53.0 65.0 47.0 128.0 267.0 293.0(b) 215.00(b) 45.11 324.08
Austria 0.3 0.1 0.1 0.2 0.3 0.4 0.3(b) 0.70(b) 1.61 3.78 7.95
Portugal(d)
Finland 0.41 0.1 1.2 2.1 1.0 1.4 5.3 11.6 18.7(b) 9.10(b) 20.11 22.18 22.25
Sweden 106.01 78.0 157.0 98.0 104.0 108.0 104.0 121.0 142.0(b) 210.00(b) 279.11 127.08 186.05
U. Kingdom 77.01 116.0 152.0 137.0 108.0 304.0 421.0 569.0 975.0(b) 1 305.00(b) 819.11 2 622.08
Total 263.01 384.0 574.0 473.0 409.0 604.0 872.0 1 296.0 1 648.0(b) 2 010  0(b) 1 552.11 3 501.08
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Figure 17: Number of synthetic drug seizures in selected EU countries, 1990-96
countries in the last three years, 1997 data show a
levelling or decrease in the number of seizures of
Ecstasy in Austria, France, Germany, Italy, Luxem-
bourg and Spain. However, there are increases in
Finland, Sweden and Denmark. In most Member
States, LSD seizures have levelled or fallen since
1993-94.
Apart from trends over time, there are differences
between Member States. In Denmark, Finland, Swe-
den, the UK and Spain, amphetamines predomi-
nate. In most other countries it is Ecstasy, while
seizures of LSD are less common. Amphetamines
are more frequently seized in Sweden than any 
other drug, and are the second most commonly
seized drug in Finland and the United Kingdom.
As with other drugs, the data available make
comparisons of price and purity difficult. The gen-
eral recent trend has been a decrease in the price
of both amphetamines and Ecstasy, while purity
varies considerably for both. Various reports from
both countries and cities suggest that, during
1997, the methylenedioxymethamphetamine
(MDMA) content of Ecstasy declined but the am-
phetamine content of pills increased. Other syn-
thetic drugs have been reported from Member
States in recent years, including analogues of 
MDMA sold as Ecstasy (e.g. MDA, MDEA, MBDB) as
well as ketamine and DOB. This may reflect mar-
ket testing by illicit manufacturers, but so far
there is no indication that any of these alterna-
tives are achieving a significant proportion of the
market.
Despite rising concern about Ecstasy in recent
years, it is amphetamines that may increasingly
dominate the market in synthetic drugs in the 
future.
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The trend in amphetamine and multiple drug use,
including alcohol, requires more rapid and sensitive
assessments of changing needs and more flexible
planning that is not based on anachronistic images
of the Ecstasy raves of 1988.
Many problems related to illegal drugs apply to le-
gal substances, not only alcohol, but also medicinal
and industrial products, which reinforces the need
for a more integrated approach.
Recognition of social exclusion as a key dimension
of drug problems implies broadening the frame-
work of analysis and extending the range of part-
ners involved in treatment responses to include 
urban planning or employment.
The output of the Centre depends on the availa-
bility and quality of data from Member States, and
on the resources of focal points and experts from
Member States. Much of the data from Member
States are incomplete, of variable quality and not
comparable. This limits the extent to which the
Centre can fulfil its tasks, at least in the short term.
Improving this depends not only on the Centre, but
on the willingness and ability of Member States to
implement measures to improve the availability,
quality and comparability of data.
Final remark
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Table 1: Belgium (Flanders) CATI, COOV, IHE 1995 • Denmark
(1) Health and morbidity in Denmark 1994 — DIKE — (2) Nordic
alcohol and drug-use survey (CFR) • Germany Representative
survey on the use and abuse of alcohol, medicines, tobacco prod-
ucts and illegal drugs (BUND) • Spain (1) Household survey on
drugs 1995. National plan on drugs • (2) Household survey on
drugs 1997. National plan on drugs • France Barométre Santé
1995, CFES • Finland (1) Drug use and opinions on drugs — Os-
mo Kontula and Kaj Kostela — (2) Drugs in Finland in the 1990s.
Kontula O. • Sweden (1) Swedish Council for Information on Al-
cohol and other Drugs (CAN) 1994 — (2) Swedish Council for In-
formation on Alcohol and other Drugs (CAN) 1996 • United King-
dom (1) The British crime survey 1994 (Home Office) — (2) The
British crime survey 1996 (Home Office)
Table 2: The same as for Table 1
Table 3: Belgium (Flanders) HBSC study 1996 • Denmark
ESPAD study 1995, Svend Sabroe et al. 1996 • Greece A.
Kokkevi, K. Stefanis — University Mental Health Research Insti-
tute Athens 1994 • Spain School survey on drugs 1994. Plan
Nacional Sobre Drogas • France Enquête Santé des Adoles-
cents 1993, Inserm-U169 • Ireland ESPAD study 1995, Morgan
M. • Italy ESPAD study 1995, Mariani F., di Fiandra T.,
Schiallero L., Rico G. • Luxembourg ‘Shüler an Drogen’ —
Matheis J., Prussen P., Renter P. IEES. Luxembourg 1995 •
Netherlands ‘Key data; smoking, drinking, drug use and gam-
bling among pupils aged 10 years or older’ (Trimbos Institute; De
Zwart et al. 1997) • Austria Schuller — Suchtmittelstudie/stu-
dent drug survey by the Ludwing Boltzmann Institute for Addic-
tion Research • Portugal Machado Rodrigues, L. et al.; Estu-
dos em Meio Escolar — 3° ciclo — GPCCD, Lisboa 1996 • Fin-
land ESPAD study 1995. Ahlstrom Salrue et al.; 1996. Finnish
Social Research Institute of Alcohol Studies • Sweden School
survey — Sweden 1997 • United Kingdom ESPAD study 1995,
Miller P., Plant M.
Table 4: (1) Denmark National Focal Point, 1998. (Epidemio-
logical study supported by estimates of the total number of
addicts made by each of the 16 Danish counties) • (2) Ger-
many National Focal Point, 1998. (Bühringer G., Adelsberger F.,
Heinemann A., Kirschner J., Knauß I., Kraus L., Püschel K. and
Simon R. (1997) Schätzverfahren und Schätzungen 1997 zum
Umfang der Drogenproblematik in Deutschland. München:
IFT-Berichte 94) • (3) France National Focal Point, Paris:
OFDT, 1995 • (4) Mariani F., Guaiana R., Di Fiandra T. The
Journal of Drug Issues 1994; 24: 579-595 • (5) Perucci C.A.
Prevalence Seminar EMCDDA/Pompidou Group, Strasbourg
1996 • (6) Rossi C. ‘Measuring the extent of illicit drug use by
means of dynamic models of data production processes’, in:
Methods to integrate epidemiological indicators to address
policy-related questions on drug use. European Monitoring
Centre for Drugs and Drug Addiction (EMCDDA), Lisbon (in
press) • (7) Luxembourg National Focal Point, 1998.  (Origer
A. et al. 1995, in: Report on the national information network
on drugs and drug addiction — RELIS/Lindda 1995. Ministry of
Health, AST, Luxembourg) • (8) Netherlands National Focal
Point (Continuity and change. Rijswijk: Ministry of Health,
Welfare and Sports, 1995) • (9) Bieleman B., Snippe J. and
De Bie E. Groningen: Intraval, 1995. (The authors state ‘a min-
imum of 28 000’) • (10) Austria National Focal Point, 1998
(Österreichisches Bundesinstitut für Gesundheitswesen:
Bericht zur Drogensituation 1996. Wien: Öbig, November
1996.) Confirmed by local C-RC study for Vienna • (11) Finland
National Focal Point, 1998 (Partanen P. Report on the number
of amphetamine and opiate users in the Greater Helsinki area
in 1995. Helsinki: Stakes, Aiheita 40/1997) • (12) Sweden Na-
tional Focal Point, 1998. (Olsson O., Byqvist S. and Gomér G.
(1993) Det tunga  narkotikamisbrukets omfattning i Sverige
1992. CAN Rapport-serie Nr 28.  Stockholm)
Table 5: (1) Kirschner W., Kunert M. Berlin: EFB, 1996 •
(2) Zenker C., Greiser E. Erprobungsvorhaben zur Prävalen-
zschätzung des regionalen illegalen Drogenmißbrauchs und
seiner Folgen. Bremen: Bremer Institut für Präventions-
forschung und Sozialmedizin (BIPS), 1998. • (3) Domingo-Sal-
vany A. Hartnoll R.L., Maguire A., Brugal T., Albertin P., Caylà
J.A., Casabona J., Suelves J.M. ‘Analytical considerations in
the use of capture-recapture to estimate prevalence: case
studies of estimating opiate use in the metropolitan area of
Barcelona’. Am J Epidemiol, 1998; 148: 732-40. • (4) Paredes D.,
del Llano J., et al. Comunidad de Madrid, Plan Regional sobre
Drogas, 1994. (Estimate refers to Madrid metropolitan area) •
(5) Moreno Iribas C., Urtiaga Dominguez M. Gaceta Sanitaria,
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Demand reduction targets individuals, families,
groups and whole communities. Unfortunately
many projects do not properly document their work
which impedes information collection. However, the
EMCDDA focal points are building up national 
information networks. This report provides an in-
dicative picture of new developments in demand re-
duction in the EU during 1997. In order to facilitate
easier access to best practice the special focus of this
chapter is on evaluation practice and evaluated
projects.
Demand reduction and drug policy
Drug use occurs in a cultural context and demand
reduction is part of social policy. As drug taking has
become more widespread, there has been a shift
from a predominantly medical approach to includ-
ing social factors and there are calls for community-
based approaches tackling environmental determi-
nants of drug-taking. Demand reduction may be a
starting point for broader general health policy,
based on cooperation between statutory bodies
and community groups.
Major strategies in drug demand reduction
The health promotion approach dominates pre-
vention, integrating prevention measures (in
schools, youth clubs, workplaces etc.), following
WHO principles on health promotion. The focus is
on healthy lifestyle and life-skills, rather than drug
use, as outlined in the UK strategy ‘Tackling drugs
to build a better Britain’ (1998), with its vision of 
a healthy and confident society, free from drug-
related harm.
The relationship between legal and illegal drugs is ac-
knowledged in an Austrian survey (1) of youths who
had experience with heroin and/or cocaine,two thirds
of whom could be described as problem drinkers.
Increasingly, prevention strategies apply a two-
pronged complementary preventive strategy: a
broad, population-targeted, intervention and life-
skills training approach, and a narrower, specific ac-
tion targeting high-risk groups. The broad strategy
aims to identify and strengthen factors which pro-
mote healthy lifestyles and facilitate the develop-
ment of autonomy, responsibility and critical sense.
High-risk group interventions focus on a framework
offering alternatives to drug use. Specific interven-
tions also provide solutions for youths engaged in
risk behaviours, and may include accessing drug
services. The Netherlands introduced ‘focused 
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Demand reduction
The EMCDDA collects, analyses and
disseminates information on
European Union drug demand
reduction activities. The EMCDDA
definition incorporates activities
within health, social, educational
and criminal justice systems aimed
at preventing drug use, assisting and
treating users, reducing harmful
consequences of use and promoting
(re)integration of (former) users.
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prevention’ for interventions aimed at information
and at changing behaviour.
Local initiatives and face-to-face communications
are essential, accompanied by a holistic approach
coordinating programmes and services at local lev-
el, involving communities in the development and
delivery of local strategies, and focusing action
where it is most needed.
Harm reduction
Harm reduction is an integral part of drug policy in
most countries. A 1997 bill was introduced in Lux-
embourg to revise drug law, outline policy needs
and assess the political feasibility of new approach-
es. It considers the legal frameworks for substitu-
tion and maintenance programmes, and the estab-
lishing of safe and hygienic injecting rooms.
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Pre-school interventions
In Germany and Austria, the model of ‘toy-free
kindergartens’ aims to counteract the targeting of
children as consumers, by promoting children’s
ability to enjoy themselves and enhancing their so-
cial competence. The first evaluation in Bavaria
shows that the capacity to establish and maintain
personal relationships, self-reliance, language skills,
creativity and critical thinking, frustration tolerance
and play skills all improved (2). In Austria, a 1998
evaluation studies whether a toy-free period of
three months influences social and emotional skills.
The Italian Ministry of Education’s ‘Arcobaleno’
(Rainbow) project for nursery schools and kinder-
gartens aims at positive child development, acquisi-
tion of social skills, perception of limits and capaci-
ties, handling aggression and the first elements of
developing personal identity. The main themes
chosen for the Arcobaleno project are interpersonal
relationships, personal hygiene, environmental edu-
cation, nutritional education and image education.
Drug prevention in the family
A supportive family environment is important for
demand reduction, based on a caring relationship
with at least one adult and a support system that
encourages positive values. However, prevention
programmes targeting parents are rare. Some
countries provide parents with brochures and other
support to improve general parenting skills.
The British SCODA’s review ‘Drug-related early inter-
vention: developing services for young people and
families’ provides good practice guidance and ad-
vice to professionals on delivering services that
meet the needs of young people. In Scotland, in-
volving parents and carers in planning and care de-
livery is emphasised.
A six week, 12-hour course in the Gaeltacht area of
Ireland provides drug information and skills using
focus groups with parents to determine location,
timing and content. The course addresses alcohol,
cannabis, LSD, Ecstasy, and amphetamine use.
In Luxembourg, the father’s role in children’s educa-
tion is emphasised, since professional constraints
on fathers may reduce their involvement.
Some parents of today will have used drugs them-
selves even if they no longer do so. The messages
and examples they give their children may be as
damaging as those of parents ignorant about
drugs. On the other hand, parents with some drug
experience may be less likely to panic if they dis-
cover their children using or experimenting.
School programmes
Strategies
School is the main arena for drug prevention with
prevention included in a broader health or health
promotion curriculum, often from primary level, be-
coming more drug specific with older students. In
Ireland a pre-school education programme has
started in 38 disadvantaged areas. The new British
strategy also recognises the need for drug educa-
tion to start early to provide knowledge and skills
to resist drugs.
In all countries, comprehensive prevention pro-
grammes remain an exception, even if promising
models have developed in recent years. Some pro-
grammes target all substances (alcohol, tobacco
and illegal drugs) using a life skills approach. While
Specific intervention areas
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effectiveness has been demonstrated, they have yet
to be widely applied.
Prevention programmes have been introduced for-
mally in the school curriculum of all Member States
except Greece and Portugal. In 1997, the Greek Min-
istry of Education requested that a health educa-
tion course be introduced in the high school cur-
riculum.
The UK strategy ‘Tackling drugs together’, launched
in 1995, called on schools to develop policies to
manage drug-related incidents and drug educa-
tion, which 80% of secondary schools and 28% of
primary schools have now done. A British problem
is the tendency to expel school pupils involved in
drug incidents, thus promoting social exclusion and
increasing the risk of more severe drug problems.
In all countries, teacher training in drug prevention
is offered. The involvement of parents is considered
essential in comprehensive drug prevention.
Evaluated programmes
1. In 1994, a prevention programme, ‘On my own
two feet’, was introduced in schools in Ireland to de-
velop interpersonal skills and knowledge enabling
young people to lead healthy lives without drugs.
The materials are designed for schools but are suit-
able in a variety of settings. An evaluation of this
programme (3), suggests that educational efforts
have a role to play in coping with drug problems.
Building on this, a programme for primary schools
has been piloted.
2. The Dutch secondary schools programme ‘The
healthy school and stimulants’ informs pupils of the
risks of substance use and gambling. The approach
teaches facts, and resistance to peer pressure. In ad-
dition, teachers and parents are taught to recognise
problematic behaviour and set rules. The pro-
gramme is independently evaluated annually, com-
paring programme participants with a control
group. The ‘experimental’ pupils felt more free ‘to
say no’ to substances than the control pupils. Use of
alcohol, tobacco and cannabis was less in the ex-
perimental group than in the control group (4).
alcohol tobacco cannabis
experimental group 58.3 % 25.4 % 9.1 %
control group 66.7 % 29.3 % 13.5 %
3. In Greece a health education programme was
implemented in five secondary schools between
1994 and 1997, by teachers trained to use specific
material. Evaluation was carried out before and af-
ter implementation in target and control schools.
Although most were not significant, changes after
implementation were in the desired direction,
specifically for girls.
4. The Portuguese ‘Viva a escola’ project aimed to
‘provide controlled conditions for experiencing
feelings of pleasure, emotion and risk; to develop
capabilities which allow one to assume the princi-
ples of health promotion on individual and collec-
tive levels; to construct a creative, dynamic and
stimulating school environment; to develop au-
tonomous behaviour, responsibility and critical
sense’. One evaluation (5) demonstrated that the
greatest impact was on violence, that it had a
strong impact on interpersonal relations and the
school atmosphere. Another evaluation (6) showed
that it increased diversification to extra-curricular
activities.
5. Swedish evaluations in 1994 and 1995 showed
school drug prevention to be of little benefit and
concluded that drug education has low status in
schools and prevention should be integrated into a
wider programme of community activities (7).
Peer programmes
As well as traditional approaches, peer education
projects are emerging in several parts of Europe.
In an EU financed project, Europeers, individuals are
selected by classmates and trained to lead debates
on drug issues. The Austrian partner of Europeers
reported that most teachers in Europeers schools
thought that peers showed clear positive changes
(in self-confidence, knowledge about addiction
processes, conflict-mastering, resistance to group-
pressure). All pupils increased knowledge about ad-
diction and there was a more positive atmosphere
in class.
The Danish county of Vejle used the peer approach
in the ‘Stormfulde højder’ (Wuthering Heights) proj-
ect which provided information and created dia-
logue. Activities ranged from debates, schools and
workshops, to rave parties and a media campaign.
Youth leisure time activities
Youth organisations play an important role in pre-
vention in many countries.
1. In Austria, a youth centre was designed with pre-
vention experts giving advice on integration. This
collaboration will continue on a permanent basis in
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the form of theme-oriented groups and crisis inter-
vention.
2. The Danish Inter-Ministerial Children’s Commit-
tee has published an overview on the use of culture
by 12 preventive initiatives working with young
people (8). The use of the concept of culture differs
between projects.The concept is divided into:
• relations between people (socialisation);
• art and culture (theatre, art, music, books, etc.);
• values and norms (organisational culture);
• cultural landscapes (areas with diverse demogra-
phy, history and geography).
3. In Finland, adventure camps reach young people
not accessed by traditional education. Young peo-
ple who suffer from insecurity, loneliness, parental
substance abuse or other problems are targeted.
Meeting places with the possibility of overnight
stay have been set up.
4. Independent evaluation found participation in
the Youth Awareness Programme (YAP) in London
consolidated anti-drugs views, and discouraged ex-
isting users from extending their use (9). YAP works
with young people’s services, visits schools, col-
leges, youth clubs and nightclubs, produces
posters, flyers and leaflets, and trains workers in
counselling, first aid and advice. The Merton YAP
project collaborates with projects in France and
Denmark.
5. Training and networking between youth work-
ers promotes prevention. In Austria, following a
similar activity in 1994, a one-month programme in
1997, ‘Preventive autumn’, gathered over 700 youth
workers at six regional meetings. From the first ini-
tiative ‘Compass — Prevention knowledge ex-
change’ emanated which seeks quality assurance,
assessment of prevention methods, including re-
flection, training and networking.
Dance drug interventions
Information material
A collaboration between organisers of rave parties
and the Danish National Board of Health led to the
production of material for distribution at rave par-
ties. The ‘SafeRave’ campaign, relaunched in June
1997, focused on information. A process evalua-
tion (10) concluded that the strength of the cam-
paign lay in cooperation with the techno environ-
ment. The report stated that the campaign did not
obtain optimum success, but achieved a degree of
motivation to take a stand against drugs among
some of the target group.
Activities at dance events
A youth programme in Hanover, Germany, focuses
on the Ecstasy problem. For young people experi-
menting with drugs, prevention means ‘disseminat-
ing information about responsible, hedonistic and
controlled use of drugs (safer use)’ (11). The project
runs mainly ‘on site’, with a ‘drugs info-mobile’. A fly-
er (‘ravers’ guide’) has been devised, directed specif-
ically at new users of Ecstasy or other drugs. For
parents and teachers a brochure ‘Ecstasy, LSD,
speed’ offers information. One finding was that new
groups could be reached who had no access to
counselling facilities.
In Italy, outreach work in pubs and clubs targets
new users of cannabis and synthetic drugs. In-
formed peer groups, often using charismatic lead-
ers, have obtained significant changes in attitudes
and behaviour. Prevention activities on Ecstasy, LSD
analogues and cannabinoids involve restructuring
leisure time, accurate information, and involving
club proprietors. Checks by traffic police intensified,
along with preventive control activities by disc
jockeys, proprietors and youth organisations.
Drug testing
Since 1992, information on the composition (dose,
ingredients) of synthetic drug preparations has
been generated by the Dutch Drugs Information
Monitoring System (DIMS). DIMS aims to prevent
health damage from overdose or toxicity. Drug
samples are sent in or collected during fieldwork
and tested at affiliated offices or in a specialised
laboratory. Preparations containing dangerous in-
gredients lead to warning campaigns.
The pilot project ‘Check it!’ was initiated in Vienna, in
May 1997 to test the contents of Ecstasy tablets at
rave parties. Fifteen samples can be tested simulta-
neously for drug adulteration. The first tests, organ-
ised at one of the largest rave locations, analysed 70
samples handed in by ravers. Only half of the tablets
sold as Ecstasy were pure MDMA or MDE (12). This
project has a prevention component. During events,
streetworkers offer information and counselling to
ravers. In the tent, samples were handed in, informa-
tion and counselling were provided as well as drink-
ing water, and a zone for relaxing.Vienna is planning
to implement the project at European level.
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Guidelines for dance events
The publication ‘City Hall and House’(13) of the
Dutch Ministry of Health, Welfare and Sports gives
advice on measures for large recreational events:
free drinking water, adequate ventilation, cooling-
off rooms; presence of first aid staff; entrance
checks for drug possession; access for emergency
services. The evaluation of the publication sees it as
clearly written, containing valuable information and
useful in policy-making. However, it is only suitable
for ‘house’ parties.
The London dance safety campaign developed
guidelines on the licensing of dance venues. Meth-
ods included dissemination of accurate informa-
tion in clubs and training for professionals in clubs.
The evaluation found an increase in knowledge
while 33 % said the campaign might affect their fu-
ture actions. Sixty-two per cent of professionals in
clubs reported learning new information from the
training.
In Sweden, the police control rave parties and per-
mission to arrange a rave party is accompanied by
police supervision and control. Unauthorised par-
ties are at risk of being raided by police searching
for Ecstasy and other drugs. Youngsters arrested are
subjected to a urine test for drugs, and, if the result
is positive, parents and social services are informed.
Mass media campaigns
Mass media campaigns have been launched in sev-
eral countries with those evaluated revealing some
impact. In Scandinavia, experts are more sceptical
about national campaigns. Priority is given to com-
munity action and personal communication.
A campaign in the Netherlands, launched in 1997,
targeted young people and dealt with cannabis. It
contained television spots and a leaflet on young
people’s experiences, which was distributed in sec-
ondary schools. Half the young people surveyed
had spoken to others about the campaign, of
whom 94 % had a positive opinion. Supplementary
activities in coffeeshops ensured the target group
was reached. Seventy-nine per cent of coffeeshop
visitors knew about the campaign, while coffee-
shop owners were willing to continue using the
materials.
During 1997 a media campaign launched by the
Irish Department of Health and Children alerted
people to the dangers of drug misuse. The target
audiences for this campaign were 15 to 25-year-
olds experimenting with drugs or at risk of use, and
parents. The campaign initiated a telephone infor-
mation line which is now permanent.
Since 1990, there have been six editions of an in-
formation campaign in Italy. The 1996-97 campaign
was evaluated in relation to the message 
given. While adults (30-55 years) prefer moderate
messages, young people (14-24 years) prefer
stronger, more emotionally charged, images. The
seventh campaign will have ‘new drugs’ as its
theme and will attempt to reach youth in their
gathering places and leisure time.
‘D-Day’, a day of national reflection on drug addic-
tion was held in Portugal in January 1997, to make
society aware of the problem, to stimulate debate,
and to give information about resources. The im-
pact was evaluated by the Lisbon telephone help
line Linha VIDA, which observed an increase in calls
during the campaign.
In Spain, two nationwide campaigns were launched
in 1997: ‘Enjoy sport — avoid drugs’ with the objec-
tive to foster sports activities as a preventive strat-
egy against drugs, and ‘Do you know how to have
fun without drugs?’ with the objective of making
people aware of the risks entailed in drug taking
and emphasising the fact that having fun does not
have to be associated with drugs.
In the UK an unofficial campaign followed the
death of a young woman, Leah Betts, who took an
Ecstasy tablet and drank excessive amounts of
water. Although not the first Ecstasy death in the
UK, it received the most publicity because her
parents allowed photographs of their daughter in
intensive care to be taken. Media coverage was
followed by a poster campaign and a video,
which anecdotal evidence suggests has impacted
on young people.
The Finnish ‘Päihdelinkki’ (Drug Link) information
service provides drug-related information on paper,
by phone, fax and through the Internet. The Inter-
net is increasingly used for dissemination of infor-
mation, including personal advice.
Community programmes
Early drug abuse can be handled in informal social
networks with little intervention, as with Swedish
work on community networking. Recent evalua-
tions of drug education recommended that it be in-
tegrated into a wider programme of activities, in
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which the authorities, voluntary organisations and
others cooperate. The National Institute for Public
Health has funded local community schemes with
strict evaluation.
The UK Home Office spends GBP 6 million per an-
num on community-based prevention. Twelve local
teams have been set up to support community
partners, involving over 70 projects. This focuses on
work with parents; young people outside school;
support for drugs education; peer approaches; rural
communities; criminal justice; training for profes-
sionals; local information campaigns; racially and
culturally diverse groups; and combined approach-
es. The first phase supports neighbourhood practi-
tioners, community networks, training and action
research.
A community-based drug prevention programme
including seven different districts in Luxembourg
was implemented in 1996 and 1997 by the Nation-
al Drug Prevention Centre (14). The one-year evalua-
tion showed that about half the community mem-
bers had heard about the activities, although only
one tenth participated. The project provoked more
communication between youth and parents about
drugs. Only minor changes in consumption were
registered, e.g. a decline in smoking among 26 to
40-year-olds.
The inter-agency drugs project (IADP), based in
Dublin, is made up of three sub-committees — ed-
ucation and prevention; treatment and rehabilita-
tion; and supply control. It acts as a forum for inter-
agency interaction and contributes to the develop-
ment of policy and legislation.
Outreach work
A 1997 EMCDDA study describes four models of
outreach work (15) (‘Concepts, practice and termi-
nology in the field of outreach work’, available from
the EMCDDA):
The youth work model
Some outreach projects contact marginalised
youth and help them access ‘natural’ social net-
works. In Finland some of this work is done in
homes with a ‘Tupperware methodology’. In French
cities street educators have operated since the
1970s, and in Vienna ‘park workers’ work liaise with
groups.
In Denmark, the county of Ribe Youth Centre em-
ploys staff who act as soon as there is a suspicion of
young people experimenting with drugs. The staff
member initiates preventive and information work,
to raise awareness concerning drugs and drug atti-
tudes and to divert the energies of the group to
more rewarding activities.
The ‘catching client’ model
The ‘catching client’ model employs outreach work-
ers to motivate drug users to enter treatment.
‘Catching clients’ can also be seen as looking for
clients not in treatment.
Swedish social services ensure that drug users re-
ceive the assistance and care they need. A ‘waiting
approach’ is not in accordance with the legislation.
NGOs are also involved in outreach work, cooperat-
ing with social services and health care.
The public health model
As part of the public health response to the
HIV/AIDS epidemic in the 1980s, outreach workers
provided clean needles, syringes and condoms, and
information about safer use and safer sex. A prob-
lem for outreach work is the relationship with the
police and so specific arrangements and training
must be organised with the police.
Italian drug services launched street operations in
1997 to provide social and therapeutic support for
users who do not access health services. Most pa-
tients, who never use services, or who abandon
services after relapse, live in conditions of econom-
ic and housing difficulty, are exposed to risk of in-
fectious disease, and are at greatest risk of heroin
overdose and/or collapse from polydrug use.
The self help model
The Dutch Mainline project was started eight years
ago by the drug users’ self-help group Jonkiebond
who publish a magazine with hands-on tips for
drug users. A special project concerns a photo-
novel booklet for women users, about half of whom
are sex workers. Similar initiatives have been report-
ed from other countries engaging drug users in
writing journals or pamphlets. Another type of the
self-help model is initiatives for synthetic drug
users in the dance scene.
Prevention of infectious diseases
Drug users are among the groups most affected by
HIV infection. But other blood-borne infectious dis-
eases, such as hepatitis, also affect drug users. Of 
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recent concern is infection with tuberculosis in this
group.
The UK was one of the first countries with HIV
prevention programmes, and due to these early
responses in service provision and prevention,
there are comparatively low rates of seropreva-
lence among injecting drug users (1 % outside
London, 7 % in London). However, the whole range
of sharing activities needs to be addressed if oth-
er infectious diseases are to be controlled. It has
been estimated that as many as 61 % of injecting
drug users in England test positive for hepatitis
C (16). A 1997 survey assessed sharing in people
not in contact with services, to target prevention
messages better.
In Italy, following the alarming spread of HIV, harm
reduction policies have gradually advanced, leading
to greater methadone maintenance provision, and
to ‘street units’. At national level, harm reduction
was formally accepted at the National Conference
on Drug Addiction (Naples, 1997), as part of the Na-
tional AIDS Commission prevention guidelines.
Data collected in 1997 show a discrepancy in the
activation of general measures, which 94 % of serv-
ices implemented, and specific actions (syringe ex-
change, distribution of condoms), which did not
reach 25 %.
Recently, an AIDS prevention project based on peer
education has been initiated in Greece. The project
aims to reach drug users not easily accessed
through snowballing. Former users are trained to
apply prevention and harm reduction techniques
with contacts in the drug scene (also participating
are Belgium, France, Spain and Italy).
The Health Council of the Netherlands advised the
Dutch Government in 1996 to execute an immuni-
sation programme for hepatitis B, directed at the
total population with specific programmes for
high-risk groups. Vaccinations and registration will
be executed by the Municipal Health Service. The
implementation process will be guided by an eval-
uation. In Austria, a hepatitis vaccination pro-
gramme started in 1995.
For tuberculosis, the Italian National Institute of
Health financed a project to evaluate the feasibility
of chemoprophylaxis in drug addicts.
Syringe exchange programmes exist in most EU
countries, but differ in scale and impact. However,
due to methodological issues, evidence for the ef-
fectiveness of specific programmes is scant (17) and
there is no evidence that exchange schemes have
an impact on hepatitis C transmission (18).
Exchange schemes have been rare so far in Finland,al-
though a pilot health education project for injectors
recently started in Helsinki. Attenders may exchange
their syringes and needles, condoms are available and
clients are informed about the risks of contaminated
paraphernalia and about sexually transmitted dis-
eases. Around 500 addicts used the service in 1997,
but accurate information is limited as exchanges were
anonymous. One hundred and thirty clients were in-
terviewed and the results were used to improve con-
tent and methods.
The Portuguese syringe exchange programme ‘Say
no to a used syringe’ was implemented in 1994
and was evaluated for the first time in 1996 (19).
Two hundred and ninety-six drug addicts with a
recent history of injecting were questioned; 78.7 %
injected more than once per day and most had in-
jected in the last 24 hours. Most users questioned
(80.7 %) reuse the same syringe, but do exchange it
at least once a day. The majority of women share
injecting material and it is among women that HIV
infection is more common. This greater vulnerabi-
lity to developing risk behaviours in women may
necessitate the development of gender-specific
prevention.
German findings also show that women heroin
users are significantly more HIV-infected than men.
In Luxembourg, several local outreach prevention
activities contact prostitutes within their work envi-
ronment for HIV and hepatitis testing.
The Vienna syringe exchange programme has more
than doubled the number of exchanged syringes
since 1993. These measures ensure that drug ad-
dicts are aware of risks, reflected in the decreased
number of new drug-related HIV infections. In 
Amsterdam, syringes distributed decreased from 
745 000 in 1995 to 600 000 in 1996, probably due 
to changes in injecting behaviour.
Low-threshold services
In Germany there is an ongoing debate on the best
way to organise low-threshold services. Instead of set-
ting up distinct units for low-threshold and high-
threshold services, the underlying concept of individ-
ual tailoring suggests that the threshold should be set
on the basis of the situation, motivation and ability of
the client. Accordingly, more German services have
)
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created comprehensive and interlinked services for
addicts which also include ‘low-threshold’measures.
In Luxembourg a bill foresees the establishment of
a legal framework for the creation of shelter and
first aid facilities for drug addicts that provide hy-
gienic conditions, meals and sleeping facilities.
The Netherlands has introduced brief interventions
for teaching users self-control (taking drugs in a
non-problematic way). ‘Gebruik(er)sruimten’ build-
ings or rooms allow users to take drugs under hy-
gienic circumstances, and lessen public nuisance.
The addiction care sector also offers possibilities for
supervised accommodation, for daytime drop-in
and night-time shelter. These facilities bridge the
gap between inpatient and outpatient treatment or
between prison and resettlement.
The number of low-threshold day centres in Finland
has increased offering counselling, hygiene and
catering services and some offer health care. Shel-
ters provide temporary accommodation, assess
clients’ needs and may instigate more permanent
treatment processes.
The United Kingdom has few low-threshold servic-
es other than syringe exchange and counselling
services. For physical problems, users often use ac-
cident and emergency (A&E) departments. The
NTORS treatment study found that half the cohort
had attended an A&E department in the previous
two years.
Substitution and maintenance programmes
Legislation
On 1 January 1996 Danish legislation made
methadone treatment a county council remit. One
objective of the change is to ensure that
methadone prescription is coordinated with other
treatment, that the circumstances of the user are
scrutinised before prescribing and alternative treat-
ment is offered.
Practical changes in the prescription of narcotics and
painkillers and for substitution treatment came into
effect in February 1998 in Germany. The revision was
caused by an increase in ‘grey’ substitution and
deaths caused by codeine. It controls the use of
codeine more closely and attempts to reduce the
availability of substitution substances on the black
market.
Until 1997, methadone programmes had only been
tolerated by the Luxembourg Government, but a
1997 bill still to be voted by Parliament establishes
a legal framework for substitution and mainte-
nance programmes.
On 8 July 1997, the Ministry of Social Affairs and
Health in Finland issued regulations on pharmaceu-
tical treatment of opiate addicts based on medical
treatment, psychosocial therapy and follow-up care.
The Ministry’s decision was provoked by substitute
prescribing by private physicians. The authorities
were critical of which medicines were administered
and of the quality of psychosocial treatment.
Substitution treatment
Throughout Europe methadone treatment is in-
creasing. In Germany, treatment data suggest that
whilst heroin is mentioned slightly less frequently
among the main diagnoses, treatment centres are
increasingly seeing users of methadone and
codeine. Codeine substitution was formally far less
regulated than methadone.
The Danish National Narcotic Council reported
problems linked to methadone treatment — differ-
ences in councils’ administration of methadone are
too great, rules for appeals are unclear, and that
there is a lack of consistency in control measures
and sanctions in methadone treatment. The gov-
ernment has recommended that common appeal
regulations be adopted.
The Italian services report a number of dysfunctional
methadone patients injecting heroin even at high
methadone dosages; who continue to use benzodi-
azepines,stimulants,other drugs along with increased
alcohol intake. They will have to be studied better, be
subject to more complex processes and must not sim-
ply be excluded or given higher dosages.
LAAM is prescribed in 12 treatment centres in Por-
tugal. In Denmark, a one-year project of 200 clients
on LAAM will be launched in 1998. Problems en-
countered transferring from methadone to LAAM
will be recorded along with satisfaction, withdrawal
problems, side effects and retention. In Italy, LAAM
is proposed as an alternative to methadone, and
may foster social integration of addicts.
Admission criteria
Some countries have strict admission criteria for
substitution treatment whereas others use addic-
tion as the only criterion.
In Greece, admission criteria include being an IV hero-
in addict of more than 22 years of age, having at least
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two years’ drug use and having unsuccessfully tried
other treatment. The Swedish and Finnish criteria are
similar: four years of IV opiate use, failed drug-free
treatment, no use of other drugs, lower age limit of 20
years.
By the end of 1997, the Luxembourg methadone
programme published revised admission criteria:
• age > 18 years,
• resident of Luxembourg,
• confirmed dependency (DSM IV, urine test),
• unsuccessful detoxicification attempts,
• priority for pregnant women and HIV positive
addicts.
Buprenorphine (Subutex) has been available in
France since February 1996 as an alternative substi-
tution treatment. In contrast to methadone, the
prescription of which has to be initiated in spe-
cialised centres under certain conditions, buprenor-
phine can be prescribed by general practitioners
with no specific admission criteria.
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Table 1: Estimated numbers in substitution treatment (generally methadone)
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Belgium  6 617
Denmark  2 400
Germany 60 000 40 000 methadone / 20 000 codeine
Greece     400
Spain 51 000
France 46 700 - 56 700 41 000 - 51 000 buprenorphine / 5 700 methadone
Ireland   3 000
Italy 40 864
Luxembourg     158
Netherlands 11 676
Austria 2 966
Portugal  2 324 2 007 methadone / 317 LAAM
Finland     200
Sweden      600
United Kingdom 28 776 Notified addicts receiving substitution treatment in 1996
Total More than 265 664
Evaluation
Substitution treatment is the best evaluated field
of demand reduction with generally positive re-
sults: increases in employment, improvement in
emotional status, physical appearance, health, fam-
ily and social relations, finances and vocational
skills, while there are reductions in criminality, in
pending trials, debts, and heroin use. Generally, HIV
positive patients comply with monitoring and
treatment.
A Swedish evaluation study of 655 patients found
that half did not interrupt their treatment. The ma-
jority of 205 methadone clients improved their situ-
ation concerning housing, work/studies, social rela-
tionships, health, family relationships and alcohol
and drug use; 38 % had improved in six of the seven
areas. Hospitalisation and criminality decreased sig-
nificantly (20).
A recent study in Rotterdam (21) showed that 90 %
of methadone clients also use cocaine and heroin
and 70 % use alcohol. In a southern region of the
country, the figures were 55 % and 40 % (average
methadone-dose is 50 mg). There is no correlation
between dose and other substances used. It is not
clear whether methadone regulates the use of 
other substances.
In Luxembourg a new evaluation software is being
developed in collaboration with the national focal
point. It is an information system for collecting,
analysing and storing patient information in a
complete dossier at patient level, with automatic
generation of statistics, and can be used for qual-
ity control.
An evaluation of the Dutch experiment with palfium
illustrates that this is an alternative in the short term
but not in the long term as few users experience pal-
fium as attractive, as its effects are shorter-lasting
and more stimulating than heroin. Between March
1995 and October 1996,53 heroin addicts started on
palfium. Sixty per cent judged the treatment as pos-
itive and considered palfium a surrogate for heroin.
Only a small group stopped using heroin. It was no
problem for clients to return to methadone.
In 1997, a randomised controlled double-blind trial
comparing buprenorphine with methadone was
conducted in Italy. The outcomes considered are re-
tention in treatment, use of street heroin and differ-
ent psychosocial health parameters. Another ran-
domised controlled, not blind, study compares oral
methadone with LAAM.
Medical prescription of heroin
All 15 EU Member States are signatories to the 1961
Single Convention on Narcotic Drugs which limits
the ‘quasi-medical’ use of opium, while heroin used
in medical prescriptions must be approved by the
International Narcotics Control Board of the United
Nations. In the EU, only the Netherlands has so far re-
quested and been granted permission to use heroin.
For years, prescribing injectable heroin to addicts
has been a unique feature of the ‘British system’.
Since the late 1960s, treatment of addicts in the UK
has shifted to specialised clinics resulting in a shift
from heroin via injectable methadone to oral
methadone. The number of drug users prescribed
heroin is currently less than 100 in the UK and only
a handful of clinicians prescribe heroin to drug
users.
The Dutch Government agreed to an evaluation of
the effectiveness of prescribing heroin in addition
to oral methadone in treatment-resistant heroin
addicts, over a period of 12 months. The positive
and negative effects will be assessed for medical
(somatic and psychiatric) status; social functioning;
and illicit use.
In 1992, a Spanish regulation on maintenance treat-
ment with 14 different substances, such as
methadone, LAAM, buprenorphine, opium, heroin,
etc. entrusted the Autonomous Communities to im-
plement these practices.
In Germany, applications have been made by the
Bundesrat (Federal Chamber of the Länder) to re-
form narcotics legislation to allow a study of treat-
ment with heroin. Modifications of this application
are being discussed in different federal Länder.
Treatment systems
A general tendency in EU Member States is in-
creasing interinstitutional cooperation and net-
work building. The improvement of cooperation
between addiction services and those for general
health care are particularly effective. The intention
is to link drug services into a network of local
services.
A review of services in the Eastern Health Board
Area, including Dublin, Ireland, concluded that
‘there is now a wide range of treatment options
available ranging from drug-free therapeutic com-
munities, drug-free counselling, in-patient detoxifi-
cation to methadone substitution and methadone
maintenance to needle exchange and outreach
services. There is also a strong voluntary and com-
munity organisation voice to complement and sup-
port the statutory sector input’ (22).
In 1997 the UK Department of Health published
‘Purchasing effective treatment and care for drug mis-
users’, which recommended:
• greater involvement of primary care profession-
als, such as general practitioners and community
pharmacists, in the care of stable drug users;
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• the need to develop accessible and appropriate
services for young drug users;
• the need to improve care for users within the
criminal justice system; and
• the need to support well-managed methadone
programmes and associated counselling pro-
grammes.
The first In-patient Motivation Centre (IMC),
opened in Amsterdam in 1990. IMCs try to reach
drug users who do not have sufficient motivation
to achieve abstinence and to help them structure
their lives, to learn social and labour skills, and to
prepare for a regular treatment setting. An evalua-
tion showed that 70 % of clients went to regular 
in-patient treatment after three months in the IMC.
This success led a national working group to ad-
vise the Minister for Health to set up 10 IMCs
across the country to reduce nuisance and to pre-
pare drug users for in-patient treatment. The IMC
offers a safe and stimulating environment which
provides concrete working and learning goals, ad-
justed to the abilities, cultural identity and psycho-
logical situation of the client.
In Sweden, Italy, and other countries, attention has
focused on co-morbidity in recent years. Swedish
estimates indicate that between 15 and 85 % of
drug users in treatment are suffering from mental
disturbance, depending on treatment location. Aal-
borg University in Denmark in 1996 showed that it
is possible to reach mentally ill abusers with care
and support (23).
Treatment for Ecstasy users is rarely reported. In
some cities in Italy, however, specialised help and
counselling services for ‘new users’ operate: in Pad-
ua for psychiatric aspects, in Rimini and Cesena for
cultural attitudes, and in Parma for studies on neu-
roendocrine effects.
Drug treatment is basically voluntary, but in Swe-
den, as a last resort, young people exposed to risk
through abuse of addictive substances can be re-
moved from the risk situation against their will.
Similarly, adult users can be placed in care against
their will to relieve a life-threatening situation.
There are 34 special institutions for young people
with about 595 places and 15 homes with about
343 adult substance abusers.
Monitoring and evaluation are key issues in treat-
ment as in other areas of demand reduction but
evaluation practice is underdeveloped. Austria,
Denmark and Sweden are currently improving their
treatment monitoring and assessment systems and,
in Finland, research projects on the treatment sys-
tem were launched in 1997.
In 1997, a therapeutic model of treatment-rehab-
ilitation, ‘integrated treatment of drug addicts’,
was evaluated in Portugal (24). In the first week,
abstinence is attempted without any medication.
In the second phase, detoxification takes place at
home. Simultaneously, family therapy, takes place.
In the third phase, individual and couple therapy,
aimed at the parents, follows. The evaluation (25)
studied those who did not join the programme
(N=20), those who did not finish the second
phase (N=20), and those who finished the second
phase (N=20):
More women than men gave up before finishing
the second phase;
People with higher levels of schooling were more
likely to finish the programme;
Failure was associated with unemployment and on-
set of drug use at an early age.
Addicts who did not enter or complete the pro-
gramme maintained less contact with family, part-
ners and close friends. On the other hand, those
who completed the programme had more frequent
contact with their family and social network, and
greater emotional and material support.
The national treatment outcome research study
(NTORS) assesses the effectiveness of community
and residential (inpatient and rehabilitation) pro-
grammes in England. It is the largest study of treat-
ment outcome for drug users ever conducted in Eu-
rope and provides information about the drug-
related, social, psychological and health problems
of treatment entrants and studies the structure and
content of services. One-year follow-ups show sig-
nificant reductions in the quantity and frequency of
drug use, reductions in sharing of injecting equip-
ment (to less than half the pre-admission levels),
improvements in physical and psychological
health, and marked reductions in criminal activity
(estimated to be worth ECU 6 million per year). The
NTORS findings demonstrate the ‘substantial im-
provements made after treatment by people with
serious and long-term drug problems’.
In Denmark, an evaluation of residential treatment
in seven treatment centres, started in 1996 and to
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be completed in 1999, documents organisational
aspects, client characteristics, treatment effects and
treatment processes (26).
The Trimbos Institute has reviewed the published
Dutch and international evidence on effectiveness
and efficiency. The main results of this study are
presented below (27).
Aftercare
After treatment, drug users often find themselves
without adequate housing, employment and edu-
cation. Different aftercare services assist ex-users in
education, work and housing, with a focus on voca-
tional training in many countries.
‘Needles or Pins’ is a cooperative project between
six Member States, including Austria and Spain, to
reintegrate addicts into the labour market and edu-
cational system. Outpatient medical, psychothera-
peutic and social treatment (including substitution
treatment) are the methods used in the project. It is
evaluated with the Europasi questionnaire.
In France, there are 280 places in ‘familles d’accueil’.
Former users stay with a family for four to five
months monitored by drug services. The families
are paid, but basically it is a voluntary service.
In Greece, employment and social rehabilitation ef-
forts are made by offering incentives to private en-
terprises for employing ex-addicts by subsidising
their salaries for two years. In December 1997, a so-
cial rehabilitation centre was opened to provide re-
lapse prevention services, and vocational training
to programme graduates.
In Portugal, social reintegration programmes are in-
cluded in more than 80 % of treatment centres, fre-
quently in collaboration with NGOs, even if the
numbers utilising them are low. One task of Projec-
to VIDA — national programme for the prevention
of Drug Addiction — is to promote reintegration
initiatives through the Reintegrar support pro-
gramme, created in 1997.
Self-help groups
Self-help groups have emerged among drug users,
for example, in Germany, Luxembourg and Den-
mark. Brugerforeningen in Copenhagen is an asso-
ciation of drug users who want to initiate treat-
ment on the users’ own conditions and to involve
drug users in the decision-making process. It or-
ganises conferences, meetings and provides coun-
selling.
‘Alpenrausch’, the first Austrian public periodical
about drugs, first appeared in June 1997 as a public
voice for those concerned. It offers information on
drugs, drug facilities and is produced and sold in
the streets by (former) drug addicts.
General health care
In the UK GPs are currently the main providers of
generic health care to drug users although they are
frequently reluctant to get involved with ‘trouble-
some and chaotic’ drug users. However, as there are
32 000 GPs in the UK, even a minor shift in GP in-
volvement can have a major impact on service provi-
sion.
In 1997 one-day training sessions on drug issues
were held for personnel in all 21 Finnish specialised
health care districts, on the detection of drug use,
dealing with client contact and effective treatment.
In Austria, drug-related training events are organ-
ised in areas of general health care. As part of the
cooperation with Hungary, a joint training pro-
gramme for medical and nursing staff was initiated
in Burgenland.
A project set up in Frankfurt, Germany, is a model
of cooperation between a general hospital and a
drug centre to improve care for drug-related emer-
gencies and to reintegrate addicts into regular care
as early as possible. First results from this project
show that care has improved and ‘new’ addicts
have been reached who previously had no contact
with services. The quality and duration of inpatient
care has improved. Cooperation has developed
and there is more follow-up care of emergency pa-
tients without previous attachment to the treat-
ment centre. Similar models are run in other parts
of Germany as well.
Student nurses have been involved in prevention in
primary schools in the Paris region. The students
gain legitimacy through their youth and through
their status as future health professionals.
Criminal justice system
Prevention activities by the police
The police are often involved in prevention, in
schools and leisure settings. Relationships between
the police, social and youth workers have improved
in many countries.
The criminal police information service of Vienna
has a special department for prevention of addic-
tion with some officers mainly working with young
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Methadone detoxification S One Dutch study
Methadone maintenance treatment E  Only international studies:
• decrease in heroin use and criminal behaviour
• less nuisance and infectious diseases
Other medication I  Further research is needed:
• detoxification with clonidine, naltrexon, naloxon
• maintenance with LAAM
Combination therapy  I Further research is needed
Psychological/social intervention E • Especially behavioural-oriented interventions are effective;
   ambulatory as well as residential
S • Some evidence for short-term behavioural-oriented family therapy:
• reduction of drug use and criminal behaviour
Alternative intervention I Many foreign studies but no clear effect
Self-help I No adequate study 
Therapeutic community E • Reduction of drug use and criminal behaviour
• more coping strategies and better social functioning
Penitentiary/residential treatment I Dutch and foreign studies
Supply of heroin, morphine I One Dutch study
Intervention for employees  and
users in search of employment I Dutch studies
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Table 2: Overview of evidence for effectiveness of interventions 
in the Dutch addiction treatment and care system
* E= enough scientific evidence; S= some evidence; I= insufficient or no evidence.
people having taken a one-year training course to
become ‘youth addiction counsellors’. A prevention
scheme approved by the Vienna Drug Coordinator
was devised for the police.
In many municipalities in Finland, cooperation be-
tween organisations aims to tackle drug abuse at
an early stage. Street control potentiates interven-
tions in the criminal career of drug experimenters
through instruction and treatment. Police projects
also take care of local criminal problems by utilising
police expertise in cooperation with municipal au-
thorities. By targeting resources to common issues,
e.g. juvenile delinquency, it is possible to prevent,
detect and intervene efficiently and early.
In 1997, the Greek Centre for the Promotion of
Health and the Prevention of Drug Abuse trained
20 police officers, sensitising them to drug use.
Police prevention initiatives reinforced patrolling of
schools to hinder dealing within or near schools.
Dealing with drug offenders
All EU countries have alternative sanctions for drug
offenders, especially for first and/or minor offences.
In Greece 1996 legislation introduced more lenient
treatment by treating the offences of dependent
users as misdemeanours and not felonies. Non-
dependent users whose offences are not serious can
be released, provided they attend a treatment centre.
In Ireland, the police juvenile diversion programme
diverts offenders from criminal activity and pro-
vides an alternative to the formal criminal justice
system. The Children Bill, 1996, proposes that elig-
)
)
ible juvenile offenders are dealt with caution rather
than being prosecuted. The programme is operated
by juvenile liaison officers who complete a sub-
stance abuse course. A proposal to establish special
courts for non-violent drug offenders is to be exam-
ined by experts. Provision is made for ‘certain cases
to arrange for the medical or other treatment or for
the care’ of a person dependent on drugs and con-
victed of an offence.
In 1997, provisions were made in the United King-
dom’s Crime and Disorder Bill for Treatment and
Testing Orders. These court orders are designed to
break the links between addiction and offending,
by requiring offenders on non-custodial sentences
to undergo treatment for drug problems and regu-
lar drug testing. Diversion from the criminal justice
system occurs either before court (police caution-
ing, or ‘discontinuance’, with advice on health/wel-
fare), or at court (a range of sentencing options
with health/welfare/control components) for those
unlikely to receive a custodial sentence. Before sen-
tencing, these offenders would be subject to com-
pulsory drug tests, and if positive, they would un-
dertake a four-week addiction assessment. Those
continuing to test positive for heroin or cocaine
would be sentenced to an order, run concurrently
with probation. The treatment could range from
counselling to residential rehabilitation. Testing
would involve regular random tests. A clear test
would lead to a reduction in testing; a positive, to
more frequent tests. After four months,offenders re-
turn to court for review. If they had complied, the
order would be ended, but if they had failed to
comply, a further four months would be imposed.
In Sweden, outreach workers visit drug users upon
arrest. Police report users who need help to social
services and probation officers cooperate with po-
lice and social services. Magistrates may send a
case to social services if the offender is under the
age of 20.
Alternatives to prison
All EU Member States permit suspended sentences
for addicts. The tendency is to extend this practice.
This could include postponement, exemption from
liability, release on probation, dispensation of the
sentence, or suspension of application of the sen-
tence, the most common measure. There are specif-
ic regulations for addicts in Denmark, Germany,
Greece, Spain, Italy, Austria and Portugal. Depend-
ing on the country, suspension may be simple or
with conditions, e.g. the obligation to undergo
treatment. If conditions are violated, the offender
may go to prison. A recent study on alternatives to
prison — ‘Study on alternatives to imprisonment
for drug addicts’ — is available from the EMCDDA.
Under new Austrian law, suspended prison sen-
tences for convicted addicts have been extended to
sentences of up to three years (formerly two) to fa-
cilitate health measures. In addition the model of
‘therapy instead of punishment’ may be applied for
petty offences associated with drug acquisition.The
courts are requested to report on implementation
of the law.
In the Netherlands, imprisoned users can be co-
erced to undergo treatment. Inmates choose be-
tween serving full sentences or substituting treat-
ment for part of the sentence. Convicted drug users
may also avoid imprisonment by accepting early in-
tervention (supervision and treatment). There are
about 20 such projects. The GAVO project in
Utrecht targets long-term drug users who have
committed at least five offences in the previous
year. Upon court approval, these users may choose
between ‘care’ and continued detention. A case
manager defines care needs, usually including inpa-
tient treatment, training and supervised accommo-
dation. If the user violates the agreements, the sen-
tence may be enforced. Six months after entry into
GAVO, 70 % were still ‘clean’. That dropped to 45 % at
one-year follow-up (28). There was a decrease in reg-
istered offences committed by participants of more
than 70 %. The strategies are multidisciplinary, as
police, judicial authorities and addiction treatment
and care centres join forces.
Prison
Drug trafficking in prisons may be more problem-
atic than outside. Non-availability of sterile syringes
results in widespread sharing of needles. Attempts
have been made in recent years to provide syringe
exchange services in German prisons. A study in
Amsterdam showed that, although drug use occurs
in prison, users seldom inject (29).
A pilot project at an Austrian prison consisted of 21
inmates who committed themselves to abstinence
and agreed to have this checked by urine samples.
In return they were granted privileges, such as free-
dom to decorate their cells. Due to high acceptabil-
ity, the number of inmates involved, and the range
of privileges granted, increased. By the end of 1996,
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about half of the 300 inmates were integrated in
the project. An evaluation study (30) found that
three quarters of all drug-free wing inmates in the
study experienced improvement in their conditions
and well-being. The conclusion is that the opportu-
nity to influence prison stay in the drug-free wing
triggered positive effects.
In Portugal there are seven drug-free units, with
two opened in 1997. In Greece, detoxification units
are to be inaugurated in most prisons in 1998.
Apart from treatment these offer training and reha-
bilitation. In Sweden, 40 % of users in prisons partic-
ipate in a drug-related programme, one third of
these outside prison (31).
In Amsterdam, public prosecutors have the option
to place addicts in one prison in which inmates
must participate in treatment. If they resist, their
stay in prison will be devoid of luxury. In general the
results are not too promising(32). There are some
slight positive changes in self-esteem and self-
efficacy. The use of hard drugs decreased but 70 %
of the inmates do not sign a treatment contract.
A three-year project in Finnish prisons began in
1996. Consisting of four subprojects, it concerns the
treatment of alcohol, medicine and drug abuse. In
the first, prisoners undergo a four-week rehabilita-
tion outside the prison to which they return at
night. In the second, a drug worker looks for moti-
vated prisoners to participate in after-care activities
after release. The third starts with a detoxification of
one week, isolated from other inmates, followed by
transfer for after-care to an outpatient prison unit,
then sheltered housing on probation. The fourth
provides a one week rehabilitation and prison staff
are trained to support inmates. Following release
services are developed with sheltered housing
services and for training and job opportunities.
Substitution treatment is provided in prisons in, for
example, Denmark, Germany, Spain, France, Ireland,
Austria and Portugal. In some cases, only prisoners
already in methadone programmes were eligible
for prescription, but other prisoners can now also
receive methadone.
Some French prisons have developed a programme
for the last month of incarceration in which group
dynamic techniques are used to enhance physical
and psychological health and to plan for the future.
The prisoners are also connected with social, health
and drug services. The programme is currently be-
ing evaluated.
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Table 3: Estimated rates of drug users in prisons
De
fin
itio
n
Cou
ntr
y
Rat
e (%
)
‘Drug addicts’ Germany 33.0
Italy 29.0
‘Imprisoned for drug-related offences’ Luxembourg 17.0
Greece 40.0
UK 10.0 -12.0 70 % have used before prison
France 18.6
Drug users/abusers/drug-related problems Spain 40.0
Sweden 30.0 - 40.0 10 % use in prison
Portugal 70.0 - 80.0
i.v. drug use Austria 15.0 - 20.0
Used addictive substances in last 6 months Netherlands 48.0
Not defined Belgium 40.0
Denmark 33.0    8 % i.v. users
Finland 31.0 11 % i.v. users
No data provided Ireland
Rem
ark
s
Gender-specific issues
Gender-specific prevention approaches are report-
ed in Sweden, Germany and Austria. Recently a re-
port on gender-related drug prevention among
youth was published in Germany(33). In 1996 a
‘Book of ideas for girls’ specific addiction preven-
tion’ and in 1997 a ‘Book of ideas for boys’ specific
addiction prevention’ were published.
Facilities that meet the specific needs of women
users have become more common in Europe, al-
though in many countries there is still a need for
services. Important issues are prostitution, sexually
transmitted diseases, pregnancy and motherhood.
An Italian study showed that over half of drug serv-
ices had begun activities directed at women. Pro-
jects focusing on women’s problems, addiction and
AIDS were financed in the past year. There is a
growing interest in ‘AIDS and women’, due to in-
creased prevalence of HIV infection in women ad-
dicts and/or sexual partners of drug addicts.
The SAOL programme is a Dublin project which of-
fers women in recovery or stabilised on methadone
a chance to acquire skills including literacy, numer-
acy and other social skills to give them a better op-
portunity to return to normal living. This two-year
pilot programme aims to move participants from
addiction to self-reliance. The project gives women
the opportunity to explore their potential through
participative learning that incorporates a communi-
ty development approach. The women are encour-
aged to have a sense of ownership and to become
involved in reviews of course design, delivery and
management. An initial needs-assessment allowed
SAOL to develop a framework covering training, ed-
ucation and development.
Children of drug users
Many addicts have children who often find it difficult
to lead a normal childhood. Their everyday life may
lack stability, and material and emotional resources.
Moreover, they are at risk of being stigmatised, disad-
vantaged, and there is the threat of being removed
from their family. Support systems are necessary for
these children and their parents, but few exist.
Last year a Swedish conference about families af-
fected by drug use highlighted 80 support groups
for children of substance abusers (mainly alcohol).
In these groups children play and talk about their
sorrows and needs. It helps them understand that
they are not alone, and identifies their feelings, de-
fence mechanisms and strengths.
Parents of drug users
Especially in southern Europe, but also elsewhere,
parents of drug users are involved in counselling or
family therapy. The involvement of the family is a
characteristic of treatment in Italy, although not al-
ways possible in countries where the relationships
between children and parents are less close. How-
ever, the treatment of co-dependence has led sev-
eral services to provide specific groups for mothers
of patients. Even three-generation-long problems
appear: often the ‘interventions’ of the grand-
parents oblige the services to deal with the whole
family, involving the preceding generation also.
There is an increasing involvement of parents in drug
prevention and community action facilitated by UK
drugs prevention teams. Surveys report that most
people see parents as responsible for dealing with
drug-using children. These findings support involv-
ing parents in contracts to control unruly children.
Ethnic minorities
Drug use among ethnic minorities has risen or be-
come more visible, suggesting a need for targeted
intervention.
In Sweden, the proportion of heroin users with for-
eign background in treatment has grown. Anecdo-
tal evidence suggests that immigrants had been
afraid to seek help as they feared incarceration and
deportation.
The drug population of Luxembourg is heteroge-
neous. More than 50 % of foreign users in Luxem-
bourg are of Portuguese origin. These observations
have led the Luxembourg Focal Point, in coopera-
tion with the Portuguese Focal Point, to commis-
sion a study on populations demanding treatment:
native clients, Portuguese clients living in Luxem-
bourg and a sample of Portuguese addicts treated
in Portugal. The comparison of socio-demographics
revealed important differences as Portuguese drug
addicts treated in Luxembourg are very young
(M=25 years), with lower educational level than the
other populations.
In Spain, efforts have been taken to counter the
drug problems in the gypsy population, taking into
consideration ethnic and cultural factors. The in-
volvement of indigenous mediators is one of the
strong points of the project.
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Background
This chapter is based on national and international
research, expert missions, and national- and city-re-
ports provided by the central and east European
countries for the European Commission, mainly for
the PHARE multi-beneficiary programme for the fight
against drugs, and international organisations (WHO,
UNDCP, Council of Europe). Although in recent years
drug-related information in the region has increased
in both quality and quantity, only a few countries
have developed standardised methodologies for
epidemiological monitoring. Information flow within
countries relies to a large extent on personal con-
tacts between individuals working in different sec-
tors. Data collection and exchange from regional to
national levels is well organised within some subsec-
tors (hospitals, police, customs), but is insufficient
from national to regional and local levels. Non-gov-
ernmental organisations (NGOs) rarely communicate
data on a regular basis to governmental structures.
In parallel with developments in the framework of
the EMCDDA and Reitox, focal points have been des-
ignated in most central and east European countries.
Depending on the country’s priorities in drug mat-
ters, the focal points are based in institutions spe-
cialised more in either supply reduction or demand-
reduction activities. All countries recognise the mul-
tidisciplinary role of the focal point and in some
countries it is located at inter-ministerial level. The
role and function of some focal points is already for-
mally included in the national drugs programme but
most have limited financial and human resources. In
an attempt to raise their profile and effectiveness,
changes are occurring in the location and position of
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Chapter3
The nature and extent of drug use in
central and eastern Europe
Most of the central and east
European countries (CEECs) face
increasing problems associated with
the traffic and transit of illicit drugs
as well as a rise in local drug
consumption. Despite the shared
experiences over the last few
decades the region cannot be seen
as homogeneous. Firstly, the
geographical, historical and cultural
differences between the countries
are at least as great as those
between the EU Member States.
Secondly, in some countries,
important changes began taking
place as early as the 1970s and
1980s, which might have influenced
present drug use patterns.
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the focal points, but more political support is needed
to further develop their role (See map on p. 68).
School surveys — ESPAD
Valuable progress has been made in prevalence es-
timations and descriptions of the pattern of drug
use amongst young people in the CEECs. The Euro-
pean schools survey reports on alcohol and other
drug use (ESPAD) among 15 and 16-year-old stu-
dents (born 1979), was conducted in spring 1995,
including the following CEECs; the Czech Republic,
Estonia, Hungary, Lithuania, Poland, the Slovak Re-
public and Slovenia (15). Bulgaria conducted school
surveys in two main cities in 1995/96; the Slovak Re-
public extended the age range of ESPAD to include
14 to 18-year-olds, and repeated the survey in one
main city in 1996; the Czech Republic conducted a
school survey in 1994 and in 1997, and plans to re-
peat it every three years. (2,8)
Other information sources
Three countries, the Czech Republic, Estonia and the
Slovak Republic, have conducted surveys
(1994/95/96) on drug use in the population.The Slo-
vak Republic plans to repeat its survey every two
years. Slovenia and Poland conducted prevalence es-
timation studies in 1996 and 1993 respectively. (2,8)
Information on arrests, seizures and court data, as
well as information on price and purity, is collected
by almost all of the countries. Law-enforcement
sources often do not distinguish between seizures
of drugs in transit through the country and those
destined for the domestic market. It is not always
clear whether general indications of an increase or
a decrease in seizures is based on the quantity
seized or on the number of seizures. (17)
Because of differences in drug information systems
across the CEECs countries and in the operational
definitions of terms such as drugs, hard drugs,
abusers, etc., it is difficult to compare the preva-
lence of problematic use across countries. As a re-
sult, most prevalence estimates published to date
are based on indirect indicators of drug use, data
of uncertain validity and representativeness, or on
the perceptions of law enforcement, treatment or
prevention professionals. (16)
Historical and current patterns 
of drug use
Traditional patterns of use
During the 1970s and 1980s, drug use within the
CEECs was quite different from that found in western
Europe. Countries such as Poland, Hungary, Slovenia
and the former Czechoslovakia have a longer history
of use of illicit drugs and non-medical use of pharma-
ceutical drugs. Having identified the problem, several
countries developed treatment and research activi-
ties. Others, which had tighter socio-political control
structures such as Romania and Albania,have a much
shorter history of identified drug use. In the region as
a whole, drug use and related problems became a
matter of concern only after the political changes of
the early 1990s. (1,5,8,12,16)
Domestically produced drugs
In the late 1970s, the intravenous use of domesti-
cally produced drugs, such as the amphetamine-
type stimulant Pervitin and hydrocodeine, called
‘Brown’, was reported in the former Czechoslovakia
(mainly in the Czech part). At the same time in
Poland intravenous use of home-produced opiates,
made out of locally grown poppies and called
‘Kompot’ or ‘Polish heroin’, became popular. Later,
use of home-produced opiates appeared in Lithua-
nia, Latvia and Estonia. Consumption of tea made
from dried poppy-heads was common among opi-
ate users in Bulgaria, Hungary and Poland. Local cul-
tivation of cannabis was reported from several
countries, but the extent of use during the 1970s
and 1980s is unclear. (1,5,8,10,12,13,16)
Misuse of legal drugs
The misuse of legally manufactured medicines, like
barbiturates, tranquillisers (often in combination
with alcohol) and opiate-containing medicines be-
came widespread in Hungary, the former Czechoslo-
vakia and Bulgaria during the 1970s and into the
1980s. (1,5,16) In Poland barbiturates and tranquillis-
ers have been used in combination with ‘Polish
heroin’ since the late 1970s. In Albania, Bosnia and
Herzegovina, and the former Yugoslav Republic of
Macedonia (FYROM), the non-medical use of pre-
scription drugs is a more recent phenomenon. (5,12)
Solvent misuse increased during the early 1970s in
Czechoslovakia and during the mid-1970s in Hun-
gary, but declined after 1975 and 1985, respectively.
Solvent use amongst adolescents and ethnic mi-
norities was also reported from Bulgaria, Romania
and the Baltic States. Those involved were mainly
13 to 14 year-olds. (1,5,16)
Imported drugs
In the early 1980s, the use of imported heroin in-
creased in parts of former Yugoslavia, partly due to
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changes in the social attitudes and values of 
young people. (16) In the 1990s, most countries in
the region experienced an increase in heroin 
transit. (1,5,8,12,16) Domestic markets for imported
drugs established themselves in many countries of
the region in the early 1990s, probably as a result of
a combination of various factors such as the open-
ing of borders, travel, convertibility of currencies,
trafficking practices and domestic changes affect-
ing demand. (5,12,16)
Specific trends in individual drugs
Cannabis
In most CEECs the use of cannabis products, mainly
marijuana, has been increasing since the beginning
of the 1990s, but its use varies substantially across
the region. It appears to be the most frequently
used drug among adolescents and young adults,
with Albania and Romania reporting the lowest lev-
els of use. Two patterns of use can be distinguished:
occasional and recreational use, and use as a sec-
ondary drug by problematic drug users.
The ESPAD survey shows that the lowest lifetime
prevalence rates are reported from Lithuania and
Hungary, medium rates from Estonia, Poland, the
Slovak Republic and Slovenia, and that the Czech
Republic ranges at the top (25 % for boys, 18 % for
girls) (see Table 1).
Surveys among older students show higher lifetime
prevalence rates for cannabis products: for exam-
ple, in 1994, 20 to 25 % of 15 to 18-year-olds in the
Czech Republic; 21 % for marijuana and 23 % for
hashish among Estonian 10th to 12th graders
(1997, telephone survey); and 15 % in a survey
among 14 to 18-year-olds in Bulgaria (1996). The
percentage of students that have experimented
with cannabis is in general higher in cities: for ex-
ample, 28 % of students at Warsaw University
(1992), 32 % of secondary school students in Ljubl-
jana (1992) (5,13) and nearly 40 % of 17-year-old stu-
dents in a national school survey in the Czech Re-
public (1996) had experimented with cannabis.
However, the interpretation of these figures is diffi-
cult, as some surveys have been conducted locally,
and there is often no information about how repre-
sentative the samples are.
Data from a Slovak Republic population survey con-
ducted in 1996 shows a lifetime prevalence for
cannabis of 2.6% (age range 18 to 60 years), but a
survey among the 15 to 64-year-old population of
the Czech Republic conducted in 1994 shows that
13.4 % of the population had used cannabis at
some time. This high prevalence rate was support-
ed by a similar study conducted in 1996, which also
showed a diminishing difference between Prague
and other parts of the country.
Cannabis cases are rarely recorded by the treat-
ment system. Hungary and the Czech Republic are
the exceptions: in Hungary 6.8 % of all treated in
1996 (8) identified cannabis as their primary drug,
while in the Czech Republic the figure was 16.3 % of
all first treatment demand in 1997. (2)
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Table 1: Lifetime cannabis use by schoolchildren (15-16 years old)
Cou
ntr
y
Sam
ple
siz
e Bo
ys Gir
ls
(%)
Czech Republic 2 962 25 18
Estonia 3 118 10   5
Hungary 2 571   5   4
Lithuania 3 196   2    1
Poland 8 940   2   5
Slovak Republic 2 376 12   6
Slovenia 3 306   4 12
(%)
*
Various levels of cannabis cultivation are reported
from all countries of the region, but production
mainly feeds the local markets. However, law en-
forcement sources in some countries also report
production for the neighbouring markets (e.g. Alba-
nia — Greece), or for western Europe. (12) Trafficking
through the region has been intensifying and big
single seizures were reported in 1996 (e.g. 11
tonnes in the Czech Republic and 5 tonnes in Bul-
garia) and in 1997 (2 tonnes in Hungary). (2,12)
Heroin
Since the early 1990s, many countries in the region
have experienced a considerable increase in heroin
consumption (Bulgaria, the former Yugoslav Repub-
lic of Macedonia, Hungary, the Czech Republic, the
Slovak Republic and Slovenia). Drug-use patterns
are slowly changing towards the use of imported
heroin, and injection is the most common route of
administration. Smoking or chasing is reported from
Albania and the former Yugoslav Republic of Mace-
donia and more recently from Bulgaria. In Latvia,
Lithuania and Poland injection of imported heroin
coexists beside the use of home-made opiates. In
Romania and Bosnia and Herzegovina the level of
heroin use appears to be relatively low. The socio-
demographic characteristics of those involved vary
between the countries. (1,2,3,5,7,8,10,12,13)
Illicit drug use is predominantly a city phenome-
non. Treatment data collected within several CEEC
cities show heroin to be the most frequently used
primary drug amongst problematic drug users (see
Table 2).
In Warsaw, a new pattern of amphetamines or
cannabis use has become visible among addicts in
treatment. This pattern arises in combination with
the use of home-made opiates, and yet has led to a
decrease in the percentage of clients identifying
opiates as their main problem drug. Drug users in
treatment in 1996 reported a lower age of first use
of their primary drug than in the previous two years
in Bratislava, Gdansk, Prague, Sofia and Szeged.
The percentage of injecting opiate users in the re-
gion is high, despite recent decreases in some
countries. In Poland 2 463 intravenous drug users
were known to be HIV positive by June 1995. (18)
Other countries reported much lower numbers, or
none (Hungary). (2) Comparable data do not exist
for the drug-using population across the region, as
levels of HIV testing vary substantially between
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Table 2: Percentage of users in CEEC cities who primarily use heroin 
Treatment demand — heroin/opiates
(M. Stauffacher, November 1997.  P-PG/Epid (97) 24/draft).
Cou
ntr
y
City
Tre
atm
ent
de
ma
nd %
(1996)
Bulgaria Sofia   449 95 up 63 down
Bulgaria Varna    70 86 up 73 stable
Czech Republic Prague   634 38 up 72 stable
Hungary Szeged   378 52 stable 50 up
Poland Gdansk   955 77 stable 77 stable
Poland Warsaw 1 023 57 down 59 down
Slovak Republic Bratislava   829 95 stable 86 up
Slovenia Ljubljana   139 69 stable 84 down
Primary drug
heroin
(1994-96)
IV injection
(1994-96)
Tre
nd % Tre
nd
CEECs. Fewer positive cases of HIV have been
recorded in Poland over the last few years, which
may be linked to the introduction of health educa-
tion programmes.
Information on the prevalence of hepatitis B and C
among injecting drug users is scarce, but some 
data have been collected among users in treatment
in Bulgaria, the Czech Republic, Estonia, Slovenia
and the former Yugoslav Republic of Macedonia.
Information about drug-related deaths is irregular
within the region. Some CEECs have reported an in-
crease (Bulgaria, Hungary, Latvia, the Slovak Repub-
lic), although a lack of reliable prevalence estimates,
combined with differences in reporting and defini-
tion, cloud the issue.
Heroin seizures by customs and police appear to
be rising within the region, although variations ex-
ist between countries. The figures are difficult to in-
terpret as they may simply reflect the increased re-
sources designated to law enforcement and border
control. Although there is a trend towards an in-
crease in prices throughout the region, prices are
lower than those found in western Europe.
Prescription drugs
The non-medical use of prescription drugs remains
an important and, in some countries, predominant
pattern, both in terms of consumption and indica-
tors such as hospital admissions. (16) In Hungary
clients reporting benzodiazepines to be their pri-
mary drug constituted 9.4 % of all treatment cases in
1996. (8) The ESPAD survey shows that lifetime use of
tranquillisers and sedatives without a doctor’s pre-
scription varies between 2 and 8 % for boys and be-
tween 2 and 25 % for girls, in the seven CEECs stud-
ied. Poly-drug use and combinations of medicines
and illicit drugs have become more common in re-
cent years in Bulgaria, Bosnia and Herzegovina, the
former Yugoslav Republic of Macedonia, Hungary,
the Slovak Republic and Slovenia.
Solvents
The ESPAD study shows solvents to be the second
most prevalent drug after marijuana among 16-
year-old schoolchildren (excluding alcohol and to-
bacco), with lifetime prevalence ranging from 5 %
to 10 % for girls and from 7 % to 18 % for boys in the
seven CEECs covered.
Clients with solvents as the primary drug are regis-
tered by the treatment systems of the Czech 
Republic, Hungary and the Slovak Republic, and are
also reported from Bosnia and Herzegovina. Treat-
ment demands for solvent abuse have levelled off
in the latter two countries, but have been rising in
Poland. Deaths related to solvent use have been
registered in some countries (e.g. 12 cases in 1995
and 8 in 1996 in Hungary).
Cocaine
Although cocaine seizures suggest an increasing
popularity of some countries such as Poland, the
Czech Republic, Hungary and Romania for traffick-
ing, the level of use is still low and is limited to par-
ticular segments of the population who are often
difficult to reach through conventional research
methods, or through existing monitoring and care
systems. (1,2,3,4,5,8,9,12,13,14,15,16,17)
The legal responses
A particular effort is being made by the candidate
countries to adapt their legislation to meet EU
standards, specifically in terms of money launder-
ing and chemical precursor control. Structures will
need to be reinforced or put into place to ensure
that legislation is effectively enforced. All coun-
tries have adopted new legislation in the drug
field (most laws dating from 1996 onwards), often
influenced by and derived from international
policies.
Table 3 is a synopsis of the current drug control sit-
uation in the CEECs. For the different categories of
drugs contained in the national legislation, the ma-
jority of the CEECs used the lists of the UN Conven-
tions and adapted them to their own legislative
framework. The new legislation on the control of
chemical precursors is mostly based on the EU reg-
ulations. In general, illicit drug consumption in itself
is not an offence, although drug dealers are sanc-
tioned. Drug production and trafficking are crimes
with penal sanctions in all countries. In a small
number of countries, treatment as an alternative to
penal procedures exists. (2,3,6,7)
All countries except Albania are signatories to the
three UN Conventions on narcotic drugs, psy-
chotropic substances and against illicit trafficking
(1961, 1971 and 1988) and have ratified them, ex-
cept Estonia which has not yet ratified the 1988 Con-
vention. The Strasbourg Convention (the Council of
Europe Convention on Laundering, Search, Seizure
and Confiscation of the Proceeds of Crime) of 1990
has been signed by Hungary, Poland, Slovenia, the
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Slovak Republic, Bulgaria, the Czech Republic and
Lithuania; the last three have already ratified the
Convention. (2,3,6,7,12)
Inter-ministerial bodies
All countries, except Bosnia and Herzegovina and
Romania, have established an inter-ministerial
body on drugs for planning and coordinating drug
control efforts between different ministries. Often,
sub-committees or working groups are created, in-
volving experts of the participating ministries, to
deal with specific issues. At a more technical level,
these groups have been charged with the prepara-
tion of new legislation, projects and reports, and of
national programmes on drugs. As a result, a com-
prehensive, multidisciplinary national programme
on drugs has been adopted in several of the
CEECs. Decentralisation of drug control efforts, in-
cluding consultation with NGOs, is in its infancy.
The map on page 68 presents an overview of the
current situation.
Demand reduction
Resources
In countries such as Poland, drug demand reduction
has been implemented for more than two decades,
while in others, such as Romania, systematic efforts
have only been made over the last two to three years.
Despite the efforts made in recent years, drug de-
mand reduction is still a low priority in most coun-
tries, or is no priority at all as is the case in both Alba-
nia and Bosnia and Herzegovina. This is reflected in
the allocated budget. In most countries, the balance
of the division of resources between law enforce-
ment (supply reduction) and the drug demand re-
duction sectors comes out largely in favour of the
former. Where formal drug demand reduction poli-
cies and strategies have been adopted and the legal
framework is modern and supportive (e.g. the Czech
Republic, Hungary, Poland, the Slovak Republic,
Slovenia), drug demand reduction is better posi-
tioned. Resources designated to demand reduction
vary greatly. Most structures are understaffed and
there is a need for more trained personnel.This prob-
lem has been addressed in recent years, with the es-
tablishment of a pool of well-trained experts, mainly
supported by bilateral and international assistance.
Treatment
Treatment in hospital settings, by psychiatrists and
other health professionals, still predominates. In-
patient treatment services, often limited to detoxifi-
cation, are available in all countries, with the total
number of beds varying between 10 (Bosnia and
Herzegovina) and 1 300 (Poland). Specialised out-
patient and non-residential services are less well
developed with the exceptions of the Czech Repub-
lic, Poland, Hungary, the Slovak Republic and Slove-
nia. Some countries (Hungary, Slovenia, the Slovak
Republic and the Czech Republic) have developed
regional treatment systems, but in most CEECs
treatment services are available predominantly in
the capital cities. Out-patient drug-free and long-
term residential treatment are the modalities with
the fastest development, with a number of new
services having been set up over the last few years
in almost all of the countries. Even as the current
state of drug demand reduction in most CEECs is
characterised by a dominance of the treatment sec-
tor, only a few countries can offer a range of treat-
ment and rehabilitation services. However, Poland
has developed a wide residential rehabilitation net-
work since the end of the 1970s. Early intervention,
alternatives to imprisonment, social reintegration,
aftercare, self-help groups and other components
of the care cycle are rarely offered or are unavail-
able. (5)
Prevention
In some countries like Poland, Hungary and to some
extent Bulgaria the preventative effort started ear-
lier than in the rest of the region. Prevention is a top
priority in most national strategies and pro-
grammes, and drug awareness and prevention pro-
grammes have been developed over the last few
years, including school-based drug education and
health promotion. Greater emphasis needs to be
placed on evaluation in order to increase effective-
ness. In some countries positive recent develop-
ments have been observed, such as the involve-
ment of the media in supporting awareness and
preventative efforts. The community, in particular
the family, is increasingly recognised as playing an
important role in prevention strategies, but efforts
to secure their effective involvement are at an early
stage.
Harm reduction
Within the last few years, outreach and harm reduc-
tion services have been added to the demand re-
duction sector. The availability of substitution
(methadone maintenance) programmes has in-
creased throughout the region. They constitute one
of the main treatment modalities in Slovenia and
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Lithuania, while in Bulgaria, the Czech Republic, Es-
tonia, the former Yugoslav Republic of Macedonia,
Latvia, and Poland substitution programmes are op-
erated on a pilot basis or as a single treatment serv-
ice. In Hungary, substitution programmes do not ex-
ist but methadone is prescribed by psychiatrists and
general practitioners on an individual basis. Low-
threshold services and syringe and needle exchange
schemes are increasingly available with more non-
governmental organisations focusing their activities
on this field. However, harm reduction options are
rarely available, even in major cities.
Non-governmental organisations
The need for active involvement of non-govern-
mental organisations in demand reduction is not
fully recognised and they often remain under-
utilised in most CEECs. NGOs are frequently inexpe-
rienced, relying on a single source of funding, often
from international organisations. For the majority of
CEECs, NGOs specialised in demand reduction are
uncommon. In those countries where they do exist,
their involvement is primarily in prevention. A dis-
advantage that has become apparent in the last
few years is the lack of community orientation. On-
ly the Czech Republic, Hungary, Poland, the Slovak
Republic and Slovenia regularly allocate funds from
their drug demand reduction budget to NGOs. Al-
though largely inexperienced, a small number of
NGOs do have relatively well-trained staff with de-
veloped skills and competence. Poland, for exam-
ple, has more than 100 NGOs active in demand re-
duction. The main needs in all the countries are for
a strengthening of capacity and performance, en-
larging the funding basis, and building cooperation
with governmental organisations.
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Main trends and recent developments
Heroin use is still on the increase in many countries
such as the Czech Republic, the Slovak Republic, Hun-
gary and the former Yugoslav Republic of Macedonia.
Use of illicit drugs is concentrated in big cities.
Changing patterns of use have been recently observed
in Poland, where opiate users are increasingly
combining with amphetamines, and in the Czech
Republic, where Pervitin retains its dominant position
for problematic drug users, but a shift towards heroin
can be observed.
Injecting remains the predominant route of
administration of opiates (and of Pervitin in the Czech
Republic), but in some countries smoking and chasing
have become more common in recent years; these
low-risk routes of administration seem to be chosen by
‘beginners’ in countries with higher availability of
opiates: Bulgaria and the former Yugoslav Republic of
Macedonia.
HIV prevalence in the region as a whole remains low
among the drug-using population.
Cocaine is increasingly available on domestic markets
but consumption seems low and limited to specific
groups.
Recreational use of cannabis is increasing.
The use of amphetamine-type stimulants seems to play
an important role in the northern part of the region
(Poland, the Czech Republic and the Baltic States).
The use of synthetic drugs, in the context of a ‘dance-
culture’ is a recent phenomenon throughout the
region.
The awareness about drug use and of the needs of
specific populations (women, prisoners and ethnic
minorities) is rising.
A positive general trend is that drug research
and needs assessment are attracting increasing
attention, while evaluation and qualitative stud-
ies have recently been introduced. Several coun-
tries are planning or have recently completed
studies of specific populations, often using qual-
itative methodologies. Many countries are striv-
ing to involve more professions and to adopt a
more multi disciplinary approach.
Synthetic drugs
It is difficult to assess the extent of consumption of
synthetic drugs. Traditional monitoring systems, as
far as they exist, are unlikely to generate an accu-
rate picture of recreational drug use. Almost all
countries report an increase in seizures and con-
sider synthetic drug use a worrying new trend, but
in many countries there is only anecdotal informa-
)
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tion, and few cases have been reported by the
health systems.
The ESPAD survey showed a lifetime prevalence of
Ecstasy use of 0.8 % among Polish and Hungarian
16-years-olds, and 1.8 % among Slovenian 16-year-
olds. In the same survey, big differences in knowl-
edge about synthetic drugs became apparent be-
tween countries. When asked whether they had
ever heard of LSD, 87 % of 16-year-old Hungarians
but only 6 % of Lithuanian students replied posi-
tively. Ecstasy was in general less known by this age
group: only between 17 % and 27 % of students in
the seven participating central and east European
countries had ever heard of this drug. (15)
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Table 3: Legislation: Current status and under development
Country Current status Legislation being developed
Albania • 1953, 1988: Existing legislation (narcotics).
• 1995: Penal Code updated (money laundering).
• 1994: National laws under preparation.
• 1995: Draft precursor law prepared.
Bosnia and 
Herzegovina
• Based on sections of Penal Code.
Bulgaria • 1974: Drug control based on 28 different texts.
• 1988: Public Health Act: Regulation of licit activities.
• 1995: Act on Medicines and Chemists in Human Medicine
(narcotic drugs and psychotropic substances).
• 1995: Inter-ministerial Committee regulation prohibiting
cultivation of cannabis and poppy.
• 1997: Precursors: Council of Ministers’ Governmental Decree
No 38.
• 1996: Special Act against Money Laundering;
Implementation rules still to be enacted.
• Special Law for control of Drugs and
Precursors  (will incorporate Decree No. 38).
Czech Republic • 1995: Amendments to Criminal Code (conspiracy and
organised crime with regard to trafficking).
• 1996: Money laundering legislation included in Act
prohibiting legalisation of gains from criminal activities.
• 1999: Draft bill on narcotic drugs,
psychotropic substances, precursors and
essential substances expected to come into
force.
Estonia • 1997: Narcotic Drugs and Psychotropic Substances Act.
• 1997: Governmental regulation regarding precursors.
• Act on Preventing Money Laundering.
Hungary • 1991: Law on Financial Institutions amended.
• 1993: Penal Code + penal procedure on drugs amended.
• 1991: Regulation of trade in precursors. 1996: replaced by
Governmental Order on Precursor Control.
• 1994: Order on drug treatment data collection (OSAP).
• 1994: Law on the Prevention and Hindering of Money
Laundering; related amendments to Penal Code.
• 1994: Law on the Police.
• 1996: Customs Law.
• 1997: Bill on the control of cultivation of poppy and
cannabis for industrial purposes.
Latvia • 1997: Criminal Code of 1974 amended.
• 1996: Law on Licit Control of Narcotic Drugs and
Psychotropic Substances and connected governmental
decrees.
• 1996: Precursors Law.
• 1997: Related Acts: Medical Law, Pharmacy Law,
Epidemiological Surveillance Law.
• 1997: Regulation defining ministries responsibilities in licit
drugs and international activities.
• 1998: Money Laundering Law.
• Criminal Code under a process of revision.
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Lithuania • 1997: Law on Narcological Supervision (regulation of
treatment of drugs and alcohol addicts; primary
prevention).
• 1997: Decree No 702 on approval of regulation of
substitutive; amended by Decree 68 in 1998: substitution
therapy limited to methadone substitution.
• 1998: Law on the Prevention of Money Laundering 
• 1997-8: Amendments to Penal Code: stricter penalties for
illicit drug trafficking.
• 1998: Law on Narcotic Drugs and Psychotropic Substances
Control.
• Draft law on precursors control  (precursors
decrees already exist).
• Treatment of drug addicts under examination
by Health Committee of the Lithuanian
Parliament.
Former Yugoslav
Republic 
of Macedonia
• Based on Law on Traffic and Production of Drugs, and on a
range of public order and health laws.
• Ministry of Health controls the legal trade in precursors
scheduled and classified by INCB.
• Draft law on the control of production and
trafficking of psychotropic substances and
precursors and for the prevention of drugs
and Psychotropic substances under
examination.
• Draft opium code.
• Draft money laundering law.
Poland • 1994: Law on Protection of Economic Transactions
(laundering of proceeds from drug trafficking punishable).
• 1997: Law on counteracting Drug Addiction (trafficking,
production and smuggling; precursors control; substitution
therapy; establishment of advisory governmental council;
prevention; monitoring).
• Executive acts of the new law are under
development.
• Draft bill on money laundering.
Romania • Precursors measures based on Decree 466/1979 (Toxic
Substances Regime).
• 1996: Amendment to Penal Code (consumption, possession,
dealing and trafficking penalised).
• 1997: Customs Regulation 141 prohibits narcotics,
psychotropic substances, and precursors from transit across
the border without authorisation.
• Law against illicit trafficking under
preparation, (reclassifies narcotic drugs into
high and low risk; drugs purchase operations;
witness protection; precursors; money
laundering).
• Draft money laundering law.
• Precursors legislation planned.
Slovak Republic • 1994: Amendments to Criminal Code regarding money
laundering, possession, production, trafficking.
• 1997: Regulation 181 (suspicious bank transactions).
• 1997: Law on Anti-Drug Funding came into force (anti-
drugs programmes and projects).
• Draft law on narcotic and hypnotic
substances.
• Draft law on precursors.
• Recodification of the Criminal Code of 1994
(stronger penalties for drug trafficking and
smuggling).
• Draft act on psychotropic substances.
• Data protection law to be updated.
Slovenia • 1978, 1985: Law on Production and Trade in Drugs.
• 1995: Penal Law 1995.
• 1994: Law on Money Laundering.
• Act on Drugs and Psychotropic Substances
(provides for Inter-ministerial Committee).
• Law on the Prevention of Illegal Drug Use and
Treatment of the Users of Illegal Drugs
(provides for Drug Committee and an
Information Unit for Drugs).
• Precursors Law expected.
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Table 4: National coordination: Ministries and coordination structures
Country subgroups Coordinating body; Ministries involved Structures and activities  
Albania National Committee for the Fight against Drugs
(1993) (1) — not operational
• Role of defining strategy • Restructured in
1996 and given decision-making powers.
Bosnia and
Herzegovina
No inter-ministerial body at present.
Bulgaria Inter-ministerial Council for the Fight against Drug Use
and Drug Trafficking (1993)
• Health (2) • Interior • Justice • Finance (Customs) • External
Affairs • Labour and Social Affairs • Education • Industry •
Commerce and Tourism • Youth and Sports Committee •
National Service on Drugs • National Centre for Drug Addiction
• National Service for Combating Organised Crime • National
PHARE Coordinator
• Serves directly under Council of Ministers •
Coordination role • Currently preparing a new
law on drugs control and precursors, which will
set out its structures and functions, and bring in
additional members. Also foreseen is a
multidisciplinary expert group to develop
programmes, project proposals, budgets and
reports.
Czech Republic National Drugs Commission (1993)
• Prime Minister • Health • Social Affairs • Education •
Interior • Justice • Defence
• 1995: Raised to a higher level to include prime
ministerial participation • Coordination role •
Contact person from each ministry
communicates with the Secretariat of the
Commission • Meetings twice annually • Regular
coordination meetings of inter-ministerial task
force groups, in the field of law enforcement and
prevention.
Estonia Ministers’ Committee for Drugs Policy (1996)
Social Affairs • Education • Finance • Foreign Affairs • Interior
• Justice • European Integration
• 1994: National Committee on Narcotic Drugs
established at the Ministry of Social Affairs
comprising experts from ministries, State
agencies and hospitals — Multidisciplinary
networks of experts then formed to prepare
national drug legislation, a national programme
for the prevention of  alcoholism and drug
addiction and principles of drug policy.
Hungary Inter-ministerial Drug Committee (1991) 
• Welfare • Interior • Agriculture • Justice • Industry •
Commerce and Tourism • Traffic • Telecommunications and
Water Management • Foreign Affairs • Education and Culture •
Defence • National Security Office • National Bank • National
Health Protection Institute • National Pharmaceutical Institute
• National Police Headquarters • National Customs Directorate
• Supreme Prosecutor’s Office • Highest Court.
Since March 1998 replaced by Drugs Coordination
Committee, chaired by the head of the Ministerial
Presidential Office and co-chaired by the Minister for Welfare
• Meets twice annually, and more often if
necessary • Role of developing coherent
strategy; coordination • Has established working
groups to elaborate recommendations, ensure
coordination among professionals and plan
legislation • Parliamentary ad hoc Committee for
the Reduction of the Drug Abuse Problem was
established (Jan. 1997-March 1998) to examine
the drug abuse situation, the anti-drug
measures of the government, and to enhance
the role of the IMDC.
Latvia Drug Control and Drug Abuse Combat Coordination
Commission (1996) • Interior • Education and Science •
Welfare • Finance (Customs) • Foreign Affairs • Defence •
Justice
• 1997: Amendments made to the statute
underlying the Committee strengthened its
structure and political support • Commission
consists of subcommittees whose work formed
the basis of national programme for the fight
against drugs and drug addiction (1997-98).
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Slovenia National Committee for the Implementation of the National
DDR Programme (1993)
• Health • Internal Affairs • Justice • Sports and Education •
representatives of media, NGOs, insurance • experts
• Meets once a month • Task: to carry out the
national programme • Government has set up
Special Bureau for Drugs at Ministry of Interior,
for coordination of repressive measures (not yet
operational) • Proposal for new committee,
comprising a State Secretary for Drugs, the
Inter-ministerial Council, a Coordination Unit,
and a Council of Experts; will be given some
executive power.
Lithuania Governmental Drug Control Commission (1995) •
Health • Interior • Education and Science • Foreign Affairs •
Agriculture • Finance • Customs Department • Justice •
Economy • Environment Protection • Social Affairs and Labour
• Narcotic Commission of State Medicine Control Agency
• 1995: Narcotic Commission for Licit Traffic
Control of Narcotic Drugs and Psychotropic
Substances established within the State
Medicine Control Agency (Ministry of Health) •
Drugs Control Unit against illicit trafficking of
drugs established in Ministry of the Interior.
Former 
Yugoslav Republic
of Macedonia
Inter-ministerial State Commission for the Fight against Illicit
Production and Trafficking in Drugs and for the Prevention of
Drug Abuse (1996)  
• Health • Education • Agriculture and Forestry • Social Welfare
• Justice • Foreign Affairs • Internal Affairs • Customs • a
pedagogical institute • National Institute for Social Welfare
• Since 1991 the Ministry of Health has also
housed a Commission on Narcotic Drugs and
Psychotropic Substances • Within the Ministry of
Internal Affairs, there is a Unit for Combating
Organised Crime and Drug Trafficking.
Poland Inter-ministerial Task Force for Coordination of Control of
Drugs and Psychotropic Substances (1994) — abolished
March 1998. • Health • Education • Justice • Home Affairs •
Agriculture • Customs Office • NGOs • Church • Researchers
• Task Force has an advisory role • Responsible
for the preparation of the draft national
programme and submits annual reports to
government • 1997 Law foresees the
establishment of an advisory governmental
council .
Romania An inter-ministerial body for drugs and drug addiction is
under development.
• National Council for Action against Organised
Crime and Corruption, coordinated by the
President, is active. • National multidisciplinary
networks are in their infancy but the fight
against the drugs phenomenon is included in
the strategy of the Romanian Government.
Slovak Republic Board of Ministers for Drug Addiction and Drug Control
(1995) • Health • Education • Transport 
• Post Office and Telecommunications • Finance • Economy •
Culture • Defence • Agriculture • Labour • Social Affairs and
Family • Justice • Interior • Foreign Affairs • the Prosecutor
General
• Regulated by statute • Meets at least  twice
annually • Has as an executive board, a supra-
ministerial body: the General Secretariat •
Chairman: Deputy Prime Minister; vice-chairmen
are Minister for Health and Minister for
Education • Submits twice annually a report to
the government and the Parliament on the
implementation and actualisation of the
national programme for the fight against drugs.
(1) Year of establishment.
(2) In bold — Ministry at which body is based.
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Over the last year coordinated national policies in-
volving various ministries (health, justice, home af-
fairs) have contributed to national drug strategies
and responses, including prevention programmes,
ministerial task forces, inter-ministerial coordination
bodies and parliamentary committees. There has
been a decentralisation of power from national to
local levels, with policies initiated by the State be-
ing developed by local authorities.
The range of anti-drug measures applied in EU
Member States is outlined. As all 15 Member States
regard drug-related problems as a top priority,
countries are keen to exchange relevant informa-
tion and experiences and to tackle the drug prob-
lem in a collaborative manner although national
policies differ.
How the 15 States control drug use, possession,
dealing and trafficking, and how drugs are classified
to define offences and set penalties, forms an im-
portant part of domestic drug laws.
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National strategies
In this chapter a comparative country
analysis of drug laws within the
European Union (EU) will summarise
the similarities and differences
which exist between Member States.
National and international drug laws,
established during the 1970s in
response to a rapid rise in drug
consumption, have been modified
several times since. The drug laws
of the Member States vary in
approach and measures used.
Chapter4
Belgium
A decree of 14 July 1997 reforms and reorganises the
structure of health promotion in Belgium (Wallonia).
Germany
Practical changes in the justice system will define
more operationally the legal distinction between
criminal offences of drug users and traffickers.
Greece
The legal provision is based on the distinction be-
tween addicts and non-addicts. New laws were
introduced for the protection of personal data
Law 2472/97, while definitions such as ‘especially
dangerous’ have been reintroduced for drug deal-
ers; penalties have increased for those dealing to
minors.
Action taken in 1997 by Member States
Spain
Royal Decree 79/1997, of 24 January 1997, modify-
ing the composition and structure of the Intermin-
isterial Group for the Execution of the National Plan
on Drugs (PNSD).
Royal Decree 364/1997, 14 March 1997, modifying
the structure and functions of various officially
recognised organisations under the Ministry of the
Interior on points relating to the fight against drug
trafficking.
Act 5/1997, of 24 March, on amendments to the text
of the Traffic, Circulation of Motor Vehicles and Road
Safety Act, modifies this Act increasing measures for
those driving a vehicle following the ingestion of al-
cohol, or under the effect of narcotics, psychotropics
or whatsoever other analogous substances.
Royal Decree 864/1997, of 6 June, by which is 
approved the Regulations of the Fund deriving
from goods confiscated due to drug trafficking and
other related offences.
Royal Decree 865/1997, of 6 June, by which is ap-
proved the Regulations developing Act 3/1996, of
10 January, on control measures for catalogued
chemical substances liable to being diverted for the
illicit manufacture of drugs.
Moreover, in 1997 laws on prevention, care and so-
cial incorporation were passed by various Au-
tonomous Communities (Cantabria, Andalusia, Mur-
cia, Valencia) and in the Autonomous Community
of Extremadura where a law on prevention and
control of the sale and advertising of alcoholic
drinks to the under-aged was adopted.
Ireland
A number of legislative changes were made in
1997:
• the Licensing (Combating Drug Abuse) Act;
• the Europol Act;
• the Criminal Justice Bill;
• the Bail Act;
• the Freedom of Information Act;
• the Non-Fatal Offences Against the Person Act;
• the Housing (Miscellaneous Provisions) Act;
• the Criminal Justice (Miscellaneous Provisions)
Act.
There is a proposal to establish special courts for
non-violent drug offenders, which will order reha-
bilitation, rather than imprisonment. Statutes were
enacted covering the control, use, supply and crim-
inal activities associated with drugs. This legislation
gives law enforcement agencies more powers to re-
spond to criminal activities.
Netherlands
(a) Measures to combat public nuisance include:
• Act on the Closing Down of Premises causing
Public Nuisance, 26 March 1997: this law, adding
Article 174a to the Municipality Act, allows may-
ors of municipalities to close down premises
when drug use or trafficking causes public nui-
sance.
(b) Increasing the scope of law enforcement and
improving investigation methods:
• setting up a synthetic drug unit, 1 January 1998.
• assessing the medical prescription of heroin,
• setting up a HARC team to improve investiga-
tional efforts in harbours and airports,
• a memorandum of understanding between the
Netherlands and France on customs coopera-
tion, 3 February 1997.
Austria
A law passed in 1997 came into force in January
1998, the main subjects of which are:
• reaffirmation of the basic principle ‘therapy in-
stead of punishment’;
• increasing the distinction between medical, pre-
ventive and therapeutic approaches from the
fight against organised crime and money laun-
dering;
• new regulations concerning cannabis for ‘first
consumers’.
Portugal
• The Portuguese Parliament approved a law
(7/97) broadening the network of services for
the treatment and rehabilitation of drug addicts,
guaranteeing access to prevention, treatment,
and rehabilitation.
• The Joint Dispatch established the criteria for
candidature of non-governmental organisations,
to help projects develop secondary and tertiary
prevention activities.
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• Joint Dispatch No 1-A/97 of 08-05 set out the
means of distributing money (raised by the social
game called ‘The Joker’) to services and activities
in prevention, treatment and rehabilitation.
Finland
The National Commission on Drug Policy presented
the plan of action 1997-2001:
• an amendment to the Coercive Criminal Investi-
gation Means Act 565/1997 empowered author-
ities on technical surveillance, on use of con-
trolled delivery of drugs, and compulsory DNA
testing;
• Order 28/1997 regulated medical detoxification
and substitute treatment for opiate addicts.
Sweden
The Act prohibiting Certain Doping Agents has
been reviewed along with the Motor Traffic Crime
Act, in an attempt to reduce driving while under the
influence of alcohol or drugs.
United Kingdom
• The Public Entertainment Licences Act empow-
ers authorities to close down clubs where ‘herbal
highs’ (drugs promoted as legal alternatives to
cannabis, Ecstasy or LSD) are supplied and con-
sumed.
• The Misuse of Drugs Regulations 1997 (supply to
addicts) revoked the legal requirement in the
Misuse of Drugs Regulation 1973, so doctors are
no longer required to provide the Home Office
with information on drug addicts.
• The first UK anti-drugs coordinator and deputy
co-ordinator were appointed.
• In December 1997, drug treatment and testing
orders introduced as part of the Crime and Dis-
order Bill to break the links between addiction
and offending, with offenders on non-custodial
sentences undergoing treatment, as well as reg-
ular drug testing (see Chapter 2).
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All EU Member States classify narcotic drugs and
psychotropic substances according to the model
set by the United Nations Conventions. This classi-
fication is twofold: according to the medical value
and abuse potential of the substance; and in terms
of controlling and regulating their licit trade. This
classification is not related to the penalties im-
posed for trafficking, possession or consumption.
Some Member States classify substances in terms
of medical use and health risks, and also by the
ways in which illicit activities are punished. These
countries distinguish between the nature of the
substance, varying the penalty accordingly. The
countries in which this happens are Ireland, Italy,
the Netherlands, Spain and the United Kingdom. In
the remaining 10 EU countries a drugs offence
may have the same outcome regardless of the
drug involved, although, in practice, most prosecut-
ing authorities will decide each case individually
and will take into account several circumstances
including the nature of the drug.
Special item: Cannabis
Cannabis is one of the most controversial policy is-
sues in EU countries. Although it is a classified nar-
cotic drug placed under control by the United Na-
tions and by all Member States, the measures
adopted to control it vary considerably.
While all Member States’ drug laws involve severe
measures against trafficking in cannabis, there are
significant differences for ‘personal use’ consumption
or possession,which themselves are defined and reg-
ulated in different ways from one country to another.
• Some countries or regions tolerate some forms
of cannabis possession and consumption.
• Some countries apply less severe penalties when
cannabis is involved in the offence.
• Even in countries where the formal legislation is
severe concerning penalisation for cannabis of-
fences (for instance in Member States which do
not differentiate between drugs), there are in-
Substances
!
creasingly pragmatic approaches to the imple-
mentation of drug legislation.
• As most legislations adopt either a punitive or
clinical perspective for dealing with drug use of-
fences, the concept of ‘recreational use’ is not
generally recognised and poses practical difficul-
ties for the implementation of criminal justice
policy.
The following table highlights Member States’ pol-
icy with regard to the use of cannabis.
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Table 1: Cannabis
Member States Law measures concerning cannabis
Austria • Withdrawal of reports in case of first consumption of cannabis.
• Penalties are defined also according to the quantity of drug involved; petty crimes (small quantity) fine and/or
up to six months’ imprisonment.
Belgium • Possession and cultivation for personal use less likely to be punished.
• To use in public, incite use, sell or traffic remain serious offences.
Denmark • No formal distinction between drugs.
• A first offence results in entry in Central Criminal Register.
• Subsequent offences result in fines or penalties.
• Recommendation of cautions for possession of small quantities.
France • No legal distinction between drugs, the use of which can result in a fine and/or up to one year imprisonment.
Medical treatment and social care for heavy cannabis users, acceptance of teratment being an alternative to
penalties.
• Warning for first offence of cannabis use, if use is occasional and the user socially integrated.
Germany • Possession of small quantities for personal use is a criminal offence, but will not be prosecuted/punished  as
long as there is no harm to third persons.
Greece • No distinction made between ‘soft’ and ‘hard’ drugs.
• It is considered that use can result in psychological and/or physical dependence, acts as a ‘gateway drug’ and a
risk to society.
Ireland • Distinction made between possession for personal use and possession with intent to supply.
• Fines for possession of cannabis for personal use for first or second offences.
Italy • Warning for first offence of possession for personal use.
• Subsequent offences having the purposes of personal use result in administrative sanctions (suspension of
driving licence, gun licence or passport).
Luxembourg No distinction between soft and hard drugs, but courts distinguish between:
• users who can receive a single warning (in case of very first time) or treatment (consumption  not usually
prosecuted), and
• dealers  who are pursued with repressive measures.
Netherlands • Possession and sale of up to 5g is generally not investigated.
• ‘AHOJ-G’ guidelines specify terms and conditions for sale, possession and use.
• Possession up to 30g is a minor offence, with a maximum sentence of one month’s imprisonment and/or fine.
Portugal • Each drug has an official daily dose limit.
• Possession is criminal offence. Small quantities may be regarded as a crime of use and therefore be punished
less severely with an “exemption from punishment”’ (which is nevertheless registered in the criminal record) if
proven that they are for personal use only and that the individual is an occasional user.
If quantity is above three times the average daily permitted it is punished more severely depending on the
fact that the substance is exclusively for personal use or for traffic.
Spain • Possession and use in public places is sanctioned by administrative measures.
• Distinction is made between drugs which cause serious health problems and those that do not, for cultivation
and dealing.
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Table 2: Illicit consumption of drugs
Law Notes on Member States
Illicit consumption
prohibited
• Greece, France, Luxembourg, Portugal, Finland and Sweden: prohibit the illicit use of narcotics with
penal laws, while stressing therapeutic and social approaches to drug use as an alternative to proceedings. In
the practical application of the law, under various circumstances and for individual cases the police and/or
prosecutors can issue warnings, suspend proceedings, or impose fines.
Illicit consumption
‘partially
prohibited’
• Belgium: Group drug use prohibited. Penal sanctions are often applied, especially when users are suspected of
selling.
• Ireland and the United Kingdom: Only formal prohibition is the consumption of prepared opium. Use of
other narcotics is indirectly prohibited by measures covering illicit possession and supply.
No reference made
in law concerning
illicit  consumption
• Denmark, Germany, the Netherlands and Austria: The criminal law does not refer to use of drugs.
However, possession of small quantities for personal use is a criminal offence and can be sanctioned by penal
code.
• Germany and Austria: Federal states apply different conditions in deciding whether or not to sanction the
‘possession of small quantities of drugs’ with intent to use.
• The Netherlands: A distinction exists between drugs with an unacceptable risk, and cannabis. Private
consumption is normally not prosecuted.
Decriminalisation
of any illicit drug
consumption
• Italy: Illicit activities such as import, acquisition or possession for personal use are regulated by administrative
sanctions. No sanction is made in the law to the use of illicit drugs.
• Spain: Use of narcotics in public is prohibited and regulated by administrative sanctions.
Finland • Use sentenced with a fine, or a maximum of 2 years’ imprisonment.
• In the application of penalties no distinction is made between drugs. However, Finnish law contains the
concept of ‘very dangerous drug’, which refers to a narcotic drug, which may cause death by overdose or serious
damage to health.
Sweden • Possession and use of cannabis are prohibited.
• Penalties are defined according to the quantities involved.
• Use of cannabis is sentenced with a fine. On a voluntary basis the fine could be exchanged for counselling.
United Kingdom • Possession of cannabis (a class B drug) carries a maximum prison sentence of 5 years and/or an unlimited fine.
• Supply of cannabis carries a maximum sentence of 14 years and/or an unlimited fine.
• Courts may also apply caution, probation or community service.
Laws on illicit drug use vary across Europe. In
nine of the 15 Member States, drug use is prohib-
ited and penal sanctions can be applied. In four
States, illicit drug consumption is not mentioned
in law as a specific offence, although it is con-
trolled by prohibiting the receipt and/or posses-
sion of drugs. Spain punishes public drug use by
administrative (1) rather than penal sanctions, and
Italy makes no reference to illicit drug consump-
tion but sanctions possession for personal use of
any drug.
Although the offence of illegal drug consumption is
defined differently in Member States, a common
principle is: ‘the defence of public health and protec-
tion of society from drug-related crimes’.
Illegal consumption
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Table 3: Illegal possession
Member States Notes on Member States
Belgium • For occasional and habitual use, the police file information on the user, but normally do not prosecute.
• No distinction made concerning quantity and substance type, but this may be modified to condemn marketing
and trafficking in cannabis.
• Penal code unaltered, but prosecutors will apply the lowest legal measures to possession of cannabis for
personal use.
Denmark • Offences may be classified as ‘minor’, ‘ordinary’ or ‘serious’. The final decision is left to the judicial authorities
depending on the circumstances.
Germany • Definitions such as ‘personal use’, ‘minor infraction’, ‘absence of public interest in the punishment’, and ‘minor
guilt’ are used to determine whether or not an individual offence will be prosecuted and punished.
Greece • Possession of drugs is a criminal offence.
• Addicts undergo compulsory treatment.
Spain • Possession for personal use results in administrative sanctions being applied.
France • Possession of drugs is a criminal offence, regardless of purpose.
Ireland • Possession for personal use does not automatically lead to prison sentence. Probation report issued and
offender encouraged to seek treatment.
• Possession with purposes of unlawful sale or supply results in penalties varying according to the type of
procedures:‘on indictment or summary’.
Italy • Possession for personal use subject to administrative sanctions.
Luxembourg • Possession of small amounts for personal use can result in a warning.
• Possession of drug will be prosecuted and punished.
Netherlands • Possession of cannabis up to 30g is a minor offence. Possession of other illegal drugs (hard drugs) is a criminal
offence. Guidelines for the investigation and prosecution of Opium Act offences assign low priority to the
possession of small quantities of drugs for personal use..
Austria • Possession of small quantities, for personal use, where the offender is willing to undergo treatment, result in
charges being provisionally set aside.
• Classification of quantity defines the offence and penalty.
Portugal • Possession is a criminal offence but it is punished according to the intention: use or traffic. Quantity is an
indication which may be used to distinguish between use and traffic  crimes or to distinguish between
different categories of gravity within these two crimes
The possession of illicit drugs without scientific or
medical reasons is forbidden and defined as a crim-
inal offence in all Member States. A major differ-
ence between Member States concerns the pur-
pose of possession. Some countries take into ac-
count the reason for possession, for example, those
possessing small quantities for personal use, while
others regard illicit possession of any amount as a
criminal offence. The EU countries which do not
take account of reasons for possession (using ver-
sus dealing) are Belgium, Denmark, Greece, France,
Ireland, Finland and the United Kingdom.
When applying the law, prosecuting authorities de-
cide the sentence according to the circumstances (1)
of the offence.
Illegal possession
Alternative measures to imprisonment 
or prosecution*
In the drugs field ‘alternative measures’ to prosecu-
tion or imprisonment are a concept defining those
measures which, depending on circumstances, al-
low individuals to be treated for their addictions or
to receive counselling, even when they have com-
mitted an offence in law.
All Member States foresee a comprehensive range
of ‘alternative measures’ that can be implemented at
different stages of the criminal justice system (police
inquiry, prosecution level and courts) in different
ways (therapeutic treatment, counselling, social
work, etc.) and on a voluntary or compulsory basis.
Despite these different options it is, however, im-
portant to note that even if not harmonised, laws
on alternative measures in the EU follow the basic
principle of a social and medical approach towards
drug addicted offenders.
Belgium: Prosecutors can propose that offenders
who admit addiction undergo treatment. Cases can
then be dropped and declared closed. Courts can or-
der probation and defer or suspend sentence, includ-
ing the obligation to carry out work of social value.
Treatment is commonly a condition of probation.
Denmark: Alternatives to prison include suspend-
ed sentences and conditional discharge. Prosecu-
tors may order treatment as an alternative to im-
prisonment.
Germany: Prosecution may be waived for offences
involving small quantities for personal use. Sen-
tences of less than two years’ imprisonment can be
suspended if an addicted offender is undergoing or
intends to undergo treatment.
Greece: Prosecution can be postponed if drug ad-
dicts agree to treatment and permanently sus-
pended if the programme is successfully complet-
ed. Treatment in a closed establishment can be or-
dered, time spent in treatment being deducted
from the sentence. Non-dependent users arrested
can be obliged to follow a counselling pro-
gramme.
Spain: Courts may encourage addicts to seek treat-
ment. Sentence may be conditionally suspended
for addicts sentenced to less than three years who
opt for treatment.
France: Prosecutors can order treatment as an al-
ternative to proceedings. Courts can decide to post-
pone sentencing and order therapeutic treatment
as a condition of probation.
Ireland: Sentence may be deferred if the offender
volunteers to undergo treatment. Offenders are of-
fered treatment while in custody.
Italy: Courts can offer alternative measures for ad-
dicts who volunteer for treatment. Sentences up to
four years are suspended for a probation period of
five years. If treatment is successful the case is closed.
Luxembourg: Magistrates may order detoxifica-
tion. If treatment is successful the offender will not
be prosecuted. Offenders volunteering for treat-
ment may have their sentence suspended for a pro-
bation period of two years.
Netherlands: Prosecutors may drop proceedings if
addicts volunteer for treatment. Courts can give a
provisional judgment if a drug user attends a treat-
ment centre or, rarely, order a drug addict to be
treated in a psychiatric institution.
Austria: if a drug user acquired, imported, export-
ed, offered or supplied drugs in small quantities
and voluntarily undergoes treatment, the prosecu-
tor may suspend proceedings for up to three
years, if a drug addict voluntarily undergoes treat-
ment. Courts can suspend the sentence and send
the person to treatment.
Portugal: Proceedings may be suspended if the of-
fender volunteers for and successfully concludes
treatment. This may be accompanied by a proba-
tion order.
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Finland • Possession of drugs is a criminal offence, regardless of purpose.
United Kingdom • No guidelines on possession for personal use.
• Quantity may be taken into account.
• A formal caution is followed by encouragement to seek treatment.
Sweden • The purpose of drug possession is not taken into account, although offences may be judged to be ‘minor’,
‘ordinary’ or ‘serious’.
* The information presented here is only a summary and is
not exhaustive. The EMCDDA is preparing a specific publica-
tion on the subject.
*
Finland: Prosecutors and courts can withdraw from
proceedings or waive punishment when the of-
fender voluntarily undergoes treatment.
Sweden: Courts may substitute treatment for im-
prisonment. Imprisoned drug users may serve the
last part of their sentence in a treatment pro-
gramme. The investigating magistrate may send the
case to social services.This practice is very often used
in the event of minor offences.
United Kingdom: In addition to a range of general
non-custodial alternatives (probation, community
service, or both), treatment may be made a condi-
tion for granting probation.
Illicit drugs trafficking
In recent years the European Union has drawn at-
tention to the illicit trafficking of drugs and invited
Member States to apply the most severe penalties
to drug trafficking offences*. All Member States are
agreed in regarding illicit drug trafficking as a very
serious criminal offence and will apply the most se-
vere penalties available.
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Table 4: Penalties for drug trafficking
Member States Sanctions
Austria Max. 5 years for basic offence;
1 to 10 years for drug traffickers (up to 15 years, large quantity) up to 20 years for gang leaders 
Belgium Addict-dealers – 3 months to 5 years;
Aggravating circumstances – 10 to 20 years.
Denmark Addict-dealers – max. 2 years;
Other (serious) offenders – max. 10 years.
Finland Addict-dealers – max. 2 years, or fine;
Aggravating circumstances – 1 to 10 years.
France Addict-dealers – max. 5 years;
Drug-traffickers – max. 30 years; Leader – life sentence.
Germany Basic offence – max. 5 years; severe cases – max. 15 years;
Trafficking – minimum 1 year. Special cases minimum 5 years
Money laundering – minimum 2 years.
Receiving proceeds of trafficking or possessing equipment for illicit production – minimum 3 years.
Greece 5  years to perpetuity.
Ireland Penalties range from a fine or imprisonment for 1 year to an unlimited fine or imprisonment for life.
Italy Basic offence (depending on drug) – 2 to 20 years and/or a fine.
Minor traffic – 6 months to 6 years and/or a fine.
Member of drug traffickers group  – min. 10 yrs; leader – min. 20 yrs.
Luxembourg 1-5 years to perpetuity (minor involved).
Netherlands National traffic – Unacceptable risk drugs - up to 8 years and/or a fine.
Other drugs – max. 2 years and/or a fine, max. 5 years if member of a criminal organisation.
International traffic – Unacceptable risk drugs – max. 12 yrs and/or fine.
Other drugs – max. 4 years and/or fine.
Penalties may be increased in cases where there are repeated violations of the Opium Act.
Portugal 1-25 years depending on drug, quantity involved and circumstances.
Spain Addict-dealers – substances causing less serious health hazard – 1 to 3 years; hazardous drugs – 3 to 9 years.
Aggravating circumstances – less hazardous substances – 3 to 4 years; hazardous drugs – 9 to 13 years.
Severe circumstances – less hazardous drugs – 4 to 6 years; hazardous drugs – 13 to 20 years.
* Joint Action 17 December 1996 on approximation of drugs
laws, Art. 4: ‘Member States shall ensure that under their legal
systems the penalties imposed for serious drug trafficking are
among the most severe penalties available for crime of compa-
rable gravity’.
)
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Sweden Minor offences – max. 6 months sentence or fine.
Basic offences – max. 3 years sentence.
Serious offences – 2 to 10 years imprisonment.
United Kingdom For less serious cases: Class A – 6 months and/or fine.
B – 6 months and/or fine.
C – 3 months and/or fine.
For serious cases: A – imprisonment up to life.
B – max. 14 years and/or fine.
C – max. 5 years and/or fine.
International cooperation between the Member
States has increased in several sectors, including
police forces, judicial authorities and customs, in an
attempt to combat drug-related criminality. Laws
also cover the following subjects.
Money laundering
One of the most important achievements is the
guidelines about money laundering contained in
EC Directive 91/308 that have been subsequently
transposed into national laws. With these laws, the
acquisition, use, conversion or transfer of property
derived from criminal activities related to psychoac-
tive substances, is defined as a criminal offence.
All EU Member States have adopted measures to
prevent, control and if necessary, repress activities
connected to money laundering. Each country has
developed legislation which covers the laundering
of proceeds linked to a wide variety of crimes, in-
cluding drug related crimes.
Some international agreements have established
guidelines for an international anti-money launder-
ing strategy (2).
Although EU Directive 91/308 applies primarily to
credit and financial institutions, Member States al-
ready apply anti-money laundering legislation to
activities beyond the financial sector or have draft
legislation pending on the subject.
Precursors
Control in those substances frequently used in the
illicit manufacture of narcotic or psychotropic sub-
stances, the so-called ‘precursors’, was introduced in
1988 by the UN Convention against illicit traffick-
ing. Since 1990 the European Community has ap-
proved a series of legal instruments (3) to put pre-
cursors under control in Europe. All 15 Member
States now have national regulations to control
their production and trade.
Controlled deliveries
Introduced by Article 11 of the 1998 UN Conven-
tion the controlled deliveries are collaborative ac-
tivities between Member States that also allow illic-
it consignments to pass through the territory of
one or more countries, under supervision, with a
view to identifying persons involved.
Extradition
The arrest and delivery of a fugitive wanted for a
crime committed in another country is usually under
the terms of an extradition treaty. Extradition is an
option if both countries involved perceive the crime
as warranting imprisonment, with the offender un-
dergoing penal procedures in the petitioner State.
In some countries the Penal Procedure Code permits
the searching of houses without a court warrant, as
long as a judge subsequently validates the procedure.
Law enforcement measures
1 Health of the subject, evidence of trafficking, quantity.
2 EU Directive on prevention of money laundering – 91/308/EEC,
UN Convention Against Illicit Traffic in Narcotic Drugs and Psy-
chotropic Substances1988, FACT recommendations, Convention
of the Council of Europe on Laundering,Search,Seizure and Con-
fiscation of the Proceeds from Crime 1990.
3 Precursors: Regulation No 3677/90 of 13.12.90 – Regula-
tion No 900/92 of 31.03.92 – Regulation No 3769/92 of
21.12.92 – Regulation No 2959/93 of 27.10.93 – Regulation
No 1485/96 of 26/7/96 – Regulation No 2093/97 of
24.10.97 – Directive No 92/109 of 14.12.92 – Directive No
93/46 of 22.06.93.
References
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Finland The relevant offence in the Finnish Penal Code covers the proceeds of all offences (the maximum sentence for
money laundering associated with narcotic offences is 18 months, 4 years in aggravated circumstances).
Sweden It is an offence to launder the proceeds of serious crime. Section 9 of the Swedish Penal Code states that it is an
offence to launder the proceeds of any serious criminal offence carrying a penalty of imprisonment of more than
6 months. Complicity in money laundering is also criminalised.
United Kingdom There is no general definition of the term ‘money laundering’ but in effect it is an offence to launder the proceeds
of serious crime including drug trafficking or any other ‘indictable offence’.
Luxembourg Current legislation covers only offences linked to drug-related money laundering. However, a draft law currently
before the Luxembourg Parliament would extend the range of predicate offences to any crime carrying a penalty
of more than 5 years’ imprisonment to offences involving organised crime and certain offences involving minors,
prostitution and corruption of young people.
Netherlands The Dutch law foresees a comprehensive range of measures to control money laundering which is a criminal
offence under Articles 416/417. The maximum penalty is 4 years’ imprisonment or a fine.
Austria The Austrian Penal Code criminalises the laundering of assets derived from serious crimes which, under Art. 165
of the Criminal Code, carry a prison sentence of 3 years.
Portugal Decree Law 15/93 made drug and precursor trafficking a criminal offence and criminalised money laundering.
Decree Law 313/93 transposed the money laundering EC Directive into Portuguese law.
Table 5: Money laundering
Money laundering (criminal activities covered by Member States in the anti-money laundering legislation)
Belgium The Penal Code (Art 505) covers the laundering of the proceeds of crime with imprisonment from 15 days to 5
years and /or fine. The specific anti-money laundering legislation (Law of 11/1/93) as amended) covers the
laundering of proceeds linked to crimes including drugs trafficking.
Denmark The Danish Money Laundering Act refers to assets originating from violation of the Danish Criminal Code. Money
laundering is not a separate offence under Danish law but is dealt with under two ‘receiving’ sections of the
criminal code: Section 191 (a) which makes it an offence to receive profit from a drug offence and Section 284
which creates an offence of accepting profits or helping others to enjoy profits from crime.
Germany Money laundering is a criminal offence pursuant to Section 261 of the Criminal Code (money laundering;
disguising of illegal assets). The EC directive on money laundering of June 1991 was incorporated into national
law by the Money Laundering Act of 1993. The Act on the Improvement of the Control of Organised Crime of May
1998 on the one hand particularly improved the taxation of the offenders’ assets and thus the absorption of
illegal profits by means of early disclosure of information to the tax offices and, on the other hand, it introduced
the supervision of the cross-border transfer of cash by the customs and the Federal Border Police.
Spain The Penal code Article 301 covers money laundering with penalties ranging from 6 months to 6 years. It refers to
all serious crime (any crime carrying a prison sentence of more than 3 years). The offence is considered to be
aggravated when it relates to a drugs trafficking offence. The Spanish Money Laundering Law of December 1993
has the objective of combating the laundering of the proceeds of organised crime, terrorism and drugs trafficking.
Royal Decree 864/1997 regulates the funds deriving from goods confiscated due to drug trafficking.
Greece The Greek Money Laundering Law covers trafficking in drugs.
Ireland The Criminal Justice Act 1994 criminalises the laundering of the proceeds of ‘drug trafficking or other criminal
activity’. The Proceeds of Crime Act 1996 complements the confiscations under the Criminal Justice Act 1994 and
the Criminal Assets Bureau Act 1996.
Italy Law 328/93 modified the Articles 648 bis and ter of the Criminal Code to criminalise the laundering of the
proceeds of all international criminal activities.
France The law of 13 May 1996 criminalises the laundering of the proceeds of all criminal activities. (The 1990 law
covered only the proceeds of drug trafficking).
The third European action plan to combat drugs
(adopted following the 1993 Treaty on European
Union coming into force) still provides the general
framework for anti-drug action in the European
Union. It emphasises coherence and coordination of
mutually reinforcing demand- and supply-reduction
policies both at EU level and in the 15 Member States,
as well as in their articulation at international level.
Similarly, the institutional and organisational con-
text remained almost unchanged in 1997. There
were no modifications to the legal and political
framework that could alter the roles of the four EU
institutions who are most actively involved in the
drugs phenomenon (European Parliament, Euro-
pean Council, Council of Ministers and European
Commission). Their roles have been outlined in pre-
vious annual reports and no further reference will
be made to them or to other bodies within the
Community framework.
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Action taken by the European Union
The EMCDDA’s first two annual
reports dealt thoroughly with the
history of the action taken by the
European Union on drugs and the
organisational, legal and political
framework of that action. In 1997, the
European Union’s legal and political
framework did not change, nor did
its organisational and institutional
context. 
Chapter5
General measures and political context
In 1997, the European Council Summits in Amster-
dam and Luxembourg followed the lead of previous
summits and addressed the drugs issue, maintain-
ing the policy impetus and confirming its top profile
among the Union’s political concerns. The issues of
new synthetic drugs, reliability of comparable infor-
mation on all drug issues, increased R & D provision,
training and interdisciplinary demand-reduction
programmes designed especially for the young, pre-
pared the way for the fourth EU plan for 2000-04.
Coordination
Coordinating anti-drug action continues to play a
key role in EU action in 1997. The Horizontal Drugs
Group (HDG), which held 12 monthly meetings dur-
ing the year (7 under the Dutch presidency and 5
under the presidency of Luxembourg), has contin-
ued its work. This group, an heir to the CELAD and
the Drug Experts Group, links the specialised
groups of the Council addressing drug issues and
thus the coherence of 15 national anti-drug poli-
cies, within both themselves and EU policy. In 1997,
Advances in 1997
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the HDG prepared two reports for the Summits of
Amsterdam and Luxembourg followed by joint
preparatory work for Ungass and other external 
issues.
Information
The EMCDDA and the EDU provide information on
drugs in the EU. The EMCDDA compiles and dis-
seminates non-confidential data on drug abuse to
support policy making. The EDU exchanges and
analyses data on organised drug trafficking and re-
lated criminal activities to support police opera-
tions. Both information bodies are involved in the
implementation of the early-warning mechanism
on new synthetic drugs (NSD), being joined for this
purpose by the EMEA.
The EMCDDA focuses on common indicators of
drug issues in the EC, developing appropriate
methods for the collection of comparable health
data to establish these indicators. As for the EDU, it
is developing, in cooperation with the European
Network of Forensic Laboratories, the drug purity
indicator system in order to obtain an EU-wide
overview of the average purity of the major types
of drugs, through analyses of samples by Member
States’ forensic laboratories that can be linked to
the already running EDU LOGO project database
system on the ballistic profiling of Ecstasy pills.
Training
During 1997, EU training and education pro-
grammes became more aware of drugs issues. As a
follow-up to the ‘Inventory of Community training
programmes’ the Commission organised a seminar
on ‘Training and drugs’ jointly held with the Luxem-
bourg presidency, to identify training needs for
trainers and addicts within Member States.The con-
clusions of the seminar will be valuable in design-
ing future programmes.
Research
Following the Florence seminar on drug-related re-
search initiatives in the EU, a synthesis report was
published and national reports compiled by the
Reitox focal points in a joint initiative of the Com-
mission and EMCDDA. A high level workshop was
organised in September at the initiative of the
Commission, with the support of the Dutch and
Luxembourg presidencies where clear priorities for
research in the field of synthetic drugs were identi-
fied mainly in the medical, pharmaco-toxicological,
psycho-sociological, epidemiological and monitor-
ing fields.
The Commission also proposed a fifth R & D frame-
work programme for 1998-2002, with a focus on
medical, socioeconomic and detection aspects. The
proposal sought the inclusion of drugs as a re-
search topic under the public-health and health-
services research area of ‘Theme 1: Quality of life
and management of living resources.’
Other
The Youth for Europe Programme III funds projects in
many different areas, for example: youth exchanges,
initiatives, training, research, and information. Re-
cently this programme has been emphasising its role
in preventing drug use in young people and the inte-
gration of drug users into society. Funding for drugs-
related projects is possible under the Leonardo da
Vinci vocational training programme. A small num-
ber of projects were financed, focusing in particular
on the design of interactive information and com-
munication tools for professionals in this field and a
number of initiatives were undertaken to promote
the integration of drug abusers and the develop-
ment of social skills in particular in deprived areas.
Under the initiative URBAN, the EU has supported a
number of drug related projects proposed by na-
tional or local authorities. The Commission has also
encouraged the exchange of knowledge and expe-
rience of drugs and security issues in the context of
the URBAN initiative, highlighting drug abuse as a
rising problem affecting Europe’s towns and cities.
The report presented by Mrs Hedy d’Ancona
(NL/PSE),chairperson of the Committee on Civil Liber-
ties and Public Affairs of the European Parliament on
the ‘Harmonisation of drug legislation in the Member
States’adopted by this committee in November 1997
is also worthy of mentioning in this context.
Demand reduction
The EU’s most relevant demand reduction action in
1997 was the implementation of the Community ac-
tion programme on the prevention of drug depen-
dence, within the objectives of public health for
1996-2000. This aimed to encourage coordination
and cooperation between Member States and to
support action preventing drug dependence and
associated risks. In 1997, 33 projects were supported
with a priority given to activities developed by Euro-
pean networks of professionals and to promoting
transnational cooperation. Public health Commu-
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nity action programmes,adopted in 1996 and devel-
oped in 1997, included health promotion, informa-
tion, education and training, the prevention of AIDS
and other communicable diseases, and health mon-
itoring. Representatives of the EFTA countries that
are members of the EEA attended the’Drug Depen-
dence’ Committee as observers, to facilitate their full
participation in the programme once the participa-
tion procedures have been completed.
Social policy was more consistently reinforced by the
EU in 1997. This was primarily achieved through the
allocation of a substantial part of the Employment-
Integra initiative for rehabilitation of drug addicts.
The Commission presented a proposal to the Coun-
cil promoting road safety in the EU by reducing the
incidence of driving under the influence of alcohol,
medicines or illicit drugs.
Supply reduction
Precursors and money laundering
The Community monitors the intra-Community and
the external trade of precursor chemicals frequent-
ly used for the illicit manufacture of narcotic drugs
and psychotropic substances.This is done at legisla-
tive and policy level in the Council and at the com-
mittee of drugs precursors under Article 10 of Reg-
ulation 3677/90 laying down measures to be taken
to discourage the diversion of certain substances to
the illicit manufacture of narcotic drugs and psy-
chotropic substances.
Anti-money laundering measures continue to be
seen as crucial. Under the action plan to combat or-
ganised crime approved by the Amsterdam Sum-
mit, any Member States not having achieved ratifi-
cation/implementation of the Vienna and Stras-
bourg Conventions will have to report to the Coun-
cil in writing on the reasons for this.
Cooperation in the field of justice and home
affairs
Greater cooperation was implemented between
police, customs and judicial authorities, and cus-
toms cooperation at external borders. Priority was
given to the eight joint actions and six resolutions
adopted in 1996 which focused on supply reduc-
tion. Its measures covered:
• customs control at external borders
• customs/business cooperation
• trafficking on European routes
• police and customs cooperation
• domestic cultivation and production of illicit
drugs
• chemical profiling of drugs seized
• a drugs purity indicator system
• combating drug tourism
• establishment of directory of skills
• OISIN (cooperation between law enforcement
authorities of Member States)
• Grotius (cooperation between practitioners of
the judicial system)
• Falcone (cooperation on combating organised
crime).
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Joint action on new synthetic drugs
In June 1997, the Council of the EU adopted a joint action aiming at the creation of an early warning system on new
synthetic drugs and the assessment of their risks in
order to permit the application of the measures of
control on psychotropic substances applicable in the
Member States, equally to new synthetic drugs. The
EMCDDA and the EDU have been mandated to collect
the required information and to participate in the
committee tasked to assess the possible risks caused
by the use of and traffic in new synthetic drugs. This
new outfit is expected to characterise the period
ahead with a view to 
support the EU objective to tackle the spreading 
drug problem, so that the entirely new aspect of NSD
can be progressively curbed. The initiative relates to
new synthetic drugs which are not currently listed in
the Schedules to the UN Convention on Psychotropic
Substances (Vienna 1971) and which pose a threat to
public health. This joint action meets the need to
provide the EU with a more flexible and rapid
mechanism for tackling synthetic drugs. However, it
does not prevent any Member State from maintaining
or introducing on its territory any national control
measure it deems appropriate once a new 
synthetic drug has been identified by a Member 
State.
)
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Table 1: EU actions and events in 1997 relating to drugs
January-March April -June
European
Parliament (EP)
• Resolution on the communication of the
Commission to the Council and to the EP on ‘The EU
and Latin America: the present situation and
prospects for closer partnership 1996-2000’.
• Resolution on the functioning and future of the
Schengen Agreement.
• Decision on the connor position adapted by the
Council with a wiew to the adaption of a Council
regulation on North-South cooperation in the
campaign against drugs and drug addiction.
European Council
(EC)
• Decision concerning the conclusion of the
cooperation agreement between the EC and Mexico
on cooperation regarding the control of precursors
and chemical substances frequently used in the illicit
manufacture of narcotic drugs or psychotropic
substances.
• Convention against corruption involving officials of
the EC or Member States.
• Joint action with regard to cooperation on law and
order and security.
• Decision concerning the conclusion of an agreement
between the European Community and the United
States on precursors and chemical substances
frequently used in the illicit manufacture of narcotic
drugs or psychotropic substances.
• Joint action concerning information exchange, risk
assessment and control of new synthetic drugs (see
previous page).
• Resolution concerning a handbook for joint customs
surveillance operations.
Co-decision • Decision No 1400/97/EC  adopting a programme of
Community action monitoring  public health.
• Common position with a view to adopting a
directive amending Directive 76/769/EEC on the
approximation of the laws, regulations and
administrative provisions of the Member States
relating to restrictions on the marketing and use of
certain dangerous substances and preparations.
Commission • Fifth R & D framework programme for 1998-2002.
• Communication to EP and EC on the action plan for
transit in Europe  — a new policy COM/97/0188.l
• Report on activities of EMCDDA (1994-96) to the EP
and the Council of the EU, for information to the
Economic and Social Committee and Committee of
the Regions in accordance with Article 18 of Council
Regulation (EEC) No 302/93.
• Communication to EC and EP on the control of new
synthetic drugs.
Other • First European Conference on Evaluation of
Prevention organised by the EMCDDA
• Joint assembly of the convention concluded
between the African, Caribbean and Pacific States
and the EC (ACP-EU) resolutions adopted on orphan
drugs (ACP-EC /2098/97/fin)
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July-September October-December
• Resolution on the action plan to combat organised crime.
• Report on the ‘Harmonisation of drug legislation in the Member States’ adopted
by the Committee on Civil Liberties and Public Affairs.
Conclusions on health aspects of the drug problem • Common position on negotiations in the Council of Europe and OECD relating to
corruption.
• Proposal for a Council regulation amending Regulation (EEC) No 302/93 of 8
February 1993 establishing an EMCDDA.
• Regulation (EC) No 2046/97 on North-South cooperation against drugs and
addiction.
• Resolution on priorities for cooperation in JHA for the period until 1.1.98 from
the date of activation of the Treaty of Amsterdam.
• Convention on mutual assistance and cooperation between customs
administrations.
• Joint action establishing a mechanism for evaluating and implementing
international undertakings against organised crime.
• Regulation (EC) No 2093/97 amending Regulation (EEC) No 3769/92
implementing and amending Council Regulation (EEC) No 3677/92 laying down
measures to be taken to discourage the diversion of certain substances to the
illicit manufacture of  narcotic drugs and psychotropic substances.
• Seminar on training and drugs jointly held with the Luxembourg Presidency.
Third annual EU situation report on drug production
and drug trafficking.
(EDU).
• Financial report of the EMCDDA together with Centre’s replies.
• Second Annual Report on the State of the Drugs Problem  in the EU produced by
the EMCDDA.
• Seminar on the evaluation of prevention, treatment and drug policy jointly
organised by the EMCDDA and COST A6.
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Table 2: Cooperation with non-EU countries
Fra
me
wo
rk
Act
ion
NIS Tacis programme. Visits to former Greater cooperation in justice and home affairs
Soviet Union (Feb-June)
North-South Cooperation with Council regulation allowing the Combat drug production, trafficking and abuse.
cooperation Third World Countries Community to cooperate in the
on drugs field of drugs with
developing countries.  
USA EU-US summit at Agreement signed on Implementing Caribbean drug initiative:
The Hague controlling chemical drug combating international drug trafficking in
precursors. central and eastern Europe and the former
Soviet Union.
Conference Intensify efforts to combat illicit drug
production,trafficking and use.
Asia Heads of State or Conference Greater effectiveness at combating drug
Government Summit trafficking and money laundering.
Africa Regional drugs control Conference To enhance the 'conditional development'
action plan for approach to the region.
southern Africa
Europe Pan-European International Greater effectiveness at combating drug
Conference of the Financial and technical trafficking and money laundering.
Pompidou Group. support
Latin America EU/Rio Group Ministerial Meeting of both partners Implementation of the commitments
Meeting (Noordwijk) on drugs (Brussels)  of the Noordwijk meeting
ACP countries European Development Allocation of a cooperation Substantial adoption of national plans on drugs
Fund budget and promotion of demand reduction activities
Tar
get
International action
Coordination
The increasing importance of a common interna-
tional strategy on drugs reinforced the need for a
more coherent EU international policy. Cooperating
under the common foreign and security policy,
Member States are increasingly pooling their diplo-
matic efforts; using the weight of the Union to rein-
force their positions in international forums and ex-
ternal political dialogue.
Together with efforts enhanced by the Lomé Con-
vention, the main initiatives supported by the EU fo-
cused on central and eastern Europe, the Andean re-
gion, the Caribbean, central Asia/NIS, south-east and
south-west Asia, south and west Africa. The follow-
ing areas were addressed: demand reduction; adop-
tion of national master plans; alternative develop-
ment; institution-building; and precursor control.
Accession countries
Ten central and east European countries (CEECs) are
currently preparing for accession to the EU. The
multi-country PHARE programme for the fight
against drugs is monitoring the efforts of each can-
didate country in drug control.
The PHARE programme was established to help the
CEECs integrate into the Union during the pre-ac-
cession period. Programmes include the multi-
country programme for the fight against drugs, the
horizontal programme on justice and home affairs,
and the multi-country programme for transit facili-
tation and customs modernisation.
The multi-country programme for the fight against
drugs helps the CEECs develop a comprehensive
policy, and promotes cooperation intra-regionally,
with the EU and with Member States. More specifi-
cally, it features a project on precursor control
*
which aims at setting up Community-compatible
precursor control legislation across the PHARE
countries and its administrative implementation by
the competent administrations. Steps have also
been taken as regards the participation of the asso-
ciated CEECs in the Community’s public health 
action programmes, including drug dependence.
Cooperation with non-EU countries
As for cooperation with non-EU countries please re-
fer to the Table 2.
Cooperation with international forums
In 1997, the EU actively participated in the prepara-
tions and outcome of the Ungass. At internal level,
the Commission issued a communication to the
Council and the European Parliament attempting to
establish a common platform for statements of the
EU and its Member States.The EU also participated in
the meetings of the UNDCP Major Donors Group
and in meetings of the Committee on Narcotic
Drugs.
Another forum followed closely by the European
Union is the Financial Action Task Force (FATF),
which analyses the implications of money launder-
ing for the international financial system (see Chap-
ter 6 on international action).
Action taken by the European Union 91
The European Union gives support to the fight
against drugs by funding anti-drug activities within
the EU or supporting the activities of its interna-
tional partners. The allocation of funding reflects
the political priorities of the EU.
Internal funding
In 1997 the EU supported nine budget lines, to-
talling ECU 33.3 million, for internal use only, three
on drug specific lines and six on programmes not
exclusively devoted to drugs.
Specific drug related budget lines
Prevention of drug dependence
The programme of Community action on the preven-
tion of drug dependence (1996-2000) funds actions
on public health aspects of drug issues. It hosts the
Community action programme on the prevention of
drug dependence in a public health framework
(1996-2000), adopted by the EP and the Council in
December 1996. It was first implemented in 1997
with an annual budget of approximately ECU 4.9
million. From the 157 proposals submitted, 19 proj-
ects were selected for funding. Priority was given to
projects involving cross-border networks of profes-
sionals: 63 % of the budget was spent by networks
involving at least nine Member States. It addressed:
• development of cooperation between cities,
• promotion and evaluation of best practices with
regard to specific target groups,
• training for professionals in contact with target
groups of young people,
• responses to new synthetic drugs.
Global aspects of the fight against drugs
This budget funds anti-drug actions contributing to
the EU action plan to combat drugs (1995-99). This
covers drug demand reduction, supply reduction,
international cooperation, and coordination of mul-
tidisciplinary issues, such as research and training.
Since demand reduction and international cooper-
ation are covered by other budgets, the focus is
mainly on the funding of actions on supply reduc-
tion and horizontal issues.
Supply reduction accounts for 67 % of this budget
line:
• projects which further implement existing Com-
munity legislation on precursors (30 %)
• to fund anti-money laundering practices (4 %)
• reinforcement of the EC-Reitox legal database
and the production of publications (12 %)
• training in demand reduction (12 %)
• the organisation of two seminars on synthetic
drugs (9 %).
EMCDDA
In 1997 the EMCDDA had an operational budget of
about ECU 3.2 million (51 % of its overall funding). It
supported studies, surveys, consultations, training
and production of specialised publications to facili-
tate data analysis and exchange of information.
Anti-drug programmes funded by the EU in 1997
*
Non-specific drug related budget lines
Youth for Europe
This programme funded 15 drug-related projects in
1997, costing ECU 132 000. A variety of actions were
covered, including youth exchanges, training and
research, promoting prevention, and advancing the
need for reintegrating addicts into society.
Leonardo da Vinci
Four projects were funded by this programme (to-
talling about ECU 600 000) including vocational
training in the field of drugs.
Employment-Integra programme
The E-I programme supported about 230 projects,
targeting the problems of substance abusers. The
average contribution to each project was about
ECU 240 000 (total = ECU 55.2 million). Though
funded by the 1997 budget, implementation will
take place up to 1999. To avoid disproportionate
figures that fail to correspond to real implementa-
tion, it has been estimated that an average of ECU
18.4 million per year will be spent under this head-
ing until 1999.
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Table 3: EU budget lines supporting action on drugs in 1997
Bu
dg
et
ite
ms
Lin
e
Internal
Specific drug related items
Programme of Community action on the
prevention of drug dependence (1996-2000) B3-4302 4 900 000
Measures to combat drugs B3-440 1 160 000
EMCDDA B3-441 6 300 000
Non-specific drug-related items
Youth for Europe B3-1010     132 000
Leonardo da Vinci B3-1021     600 000 
Biomed B6-7142   1 000 000
Employment-Integra B2-1422 18 400 000
Cooperation in the field of justice and
home affairs (Grotius+OISIN) B5-800   822 000
IDA B5-7210       50 000
     Total internal 33 364 000
External
Specific drug-related items
North-South cooperation on drugs
and drug addiction B7-6210   8 900 000
PHARE multi-country programme for
the fight against drugs B7-5000   5 000 000
Non-specific drug-related budget items
Development cooperation constituted by
Lomé Convention (ACP) EDF   6 200 000
     Total external 20 100 000
     Total spending 53 464 000
ECU
Biomed
This research programme funded projects for ECU 1
million on neuro-physiological aspects of drug ad-
diction. An increase of funding for areas including
biomedical and socioeconomic research, and re-
search on drug consumption (including NSD), will
start following implementation of the fifth frame-
work programme on R & D (1998-2002).
Cooperation in the field of justice and home affairs
Two multiannual programmes intend to foster co-
operation between law enforcement bodies and
practitioners of the Member States (GROTIUS and
OISIN) were allocated altogether ECU 822 000 for
anti-drug actions.
IDA/Reitox project
A total of ECU 50 000 was allocated to this pro-
gramme to establish a public open access informa-
tion resource linking the EMCDDA, the focal points,
the Commission and six international organisa-
tions.
External actions
Specific drug related budget lines
North-South cooperation
This allows funding of direct actions in developing
countries (demand and supply reduction). Four re-
gions (Latin America, Asia, the Caribbean and Africa
and the Mediterranean region including the
Maghreb and Mashreq) are covered. In comparison
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Chart1: Analysis of internal spending %
Health
(15%)
Information
(19%)
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(2%)Social rehabilitation
(55%)
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 and research
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Cooperation in the field
of justice and home affairs
(3%)
Summary of internal spending: In 1997 the Eu-
ropean Community spent ECU 33.3 million on
drug-related activities within the Union. It was
divided amongst the following projects:
• social and professional reintegration of drug
addicts (55 %)
• information and harmonisation of data, main-
ly through the EMCDDA (19 %)
• public health projects (15 %)
• increasing cooperation in the field of justice
and home affairs (3 %)
• vocational training, youth education and re-
search (6 %)
• precursor and money laundering control
(2 %).
A decisive increase of the total budget allocated
to anti-drug actions within the EU took place in
1997. The total internal investment in 1996 to-
talled ECU 15.2 million; in 1997 this went up to
ECU 33.3 million. This increase is due to the in-
clusion of social reintegration figures (ECU 18.4
million) in the calculations. In comparison with
1996, the other anti-drug budget lines were
slightly reduced: health aspects of drug abuse
(ECU 6.5 million in 1996; only ECU 4.9 million in
1997) and the IDA/Reitox programme (ECU
750 000 in 1996; ECU 50 000 in 1997).
)!
with 1996 (when 75 % of the budget was spent on
the Asian and Latin-American region against 56 %
in 1997), there is a budgetary move towards the
Caribbean and Maghreb and the Mashreq region,
which received 44 % of the total budget.The follow-
ing received priority:
• drug demand reduction
• strengthening of judicial and law enforcement
system
• chemical precursor control.
PHARE multi-country programme for the fight
against drugs
The main objective of this programme is to pre-
pare the associated countries to be in line with
the EU action plan to combat drugs (1995-99)
and the Member States’ drugs policies. The PHARE
budget was about ECU 5 million. This money was
spent on:
• establishment of multi-country information sys-
tem
• creation of money laundering legislation
• EU compatible precursor control legislation
• drug demand reduction strategy
• staff training.
Non-specific drug related budget lines
European Development Fund (EDF)
In 1997 the EDF allocated a budget of ECU 6.2 million
for drug-related projects: 92 % being spent in the
African region, mainly in Guinea-Bissau, Zambia and
Botswana; the remaining 8 % in the Caribbean region
(Trinidad and Tobago and the Dominican Republic).
Overall analysis
In 1997, more than ECU 53 million was spent on
drug related actions: 62 % for actions within the EU;
38 % for actions outside the EU.
Within the EU, more than half of the budget (55 %)
was spent on rehabilitation actions (mainly fund-
ed by Employment-Integra), 19 % was allocated to
the EMCDDA to collect information on drugs and
15 % to reduce demand for drugs (mainly funded
by the Community prevention programme).
Outside the EU, due to the support of the EDF and
PHARE programme, the African and the CEEC re-
gion received more than 60 % of the ‘external’ bud-
get. The majority was spent on actions reducing de-
mand (more on prevention and treatment than re-
habilitation). In 1997 capacity building became the
second most funded field.
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Chart 2: External drug-related Community 
expenditure according to the region
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Summary of external expenditure: In 1997 the
European Community spent a total budget of
ECU 20.1 million on drug-related projects out-
side the EU. The breakdown is shown in Chart 2.
The external expenditure was allocated in such a
way that 53 % went to drug demand reduction
activities; 15 % to capacity building and the re-
maining budget on actions in the fields of mon-
ey laundering, precursors, alternative develop-
ment, research, information, etc. (see Chart 3).
!
The vast majority (81 %) of the drug related EDF bud-
get was spent on demand reduction projects.
In 1996, the total drug-related budget was ECU 61
million of which ECU 46 million was spent on ex-
ternal actions, and ECU 15 million within the EU. In
1997 there was an overall decrease. However, there
is a huge modification in budget allocation be-
tween 1996 and 1997. The majority of the budget
in 1997 (62 %) was allocated internally, for use
within the EU. This change in ratio can probably be
explained by two main factors: firstly, in 1996, ECU
30 million (about half of the total budget) was al-
located to Bolivia for a crop substitution pro-
gramme in the framework of cooperation with
Latin-American countries. In 1997, there were no
new drug-related allocations for this budget item.
Although this budget will be spent over a period
of five years, it has not been included again in the
1997 budget. The 1996 allocation of ECU 30 million
to one specific project has given a disproportional
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Contribution au rapport annuel 1998 de l’OEDT sur l’état du
phénomène de la drogue dans l’Union Européenne, Commis-
sion européenne, Secrétariat Général, Groupe Interservices
‘Drogues’, Brussels, March 1998.
‘The European Union in action against drugs’, European Com-
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97-632-EN-C. ISBN 92-828-0426-7.
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weighting to external expenditure; secondly, more
internal budget items have been included in this
year’s report (e.g. Integra, research, training, etc.).
This is partly due to the consolidation of the EC-
Reitox Focal Points’ work, partly due to new policy
developments within the Commission.
The work of these bodies has both a direct and an
indirect impact on the situation within the EU. As a
result, European national administrations and EU
institutions can no longer function outside the
framework of the work undertaken by these inter-
national organisations.
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International action
Efforts to combat the drugs problem
at national level in the EU are
enhanced and supported by
international organisations operating
globally, regionally or sub-regionally.
These organisations play different
roles, including the overall
coordination of regional policies; the
control of narcotic drugs, information
and statistics; or operational
coordination.
Chapter6
United Nations
Since 1946, the United Nations has played a major
role in international drug control. Since that time,
several UN programmes have been established to
deal with this phenomenon.
Commission on Narcotic Drugs
This was established in 1946 by the Economic and
Social Council. The Commission is the central pol-
icy-making body of the UN system that deals with
drug-related matters. It analyses drug abuse and
develops proposals to strengthen international
drug control. Its functions include monitoring new
trends, preparing international conventions, updat-
ing the drug-control system, and overseeing the in-
ternational obligations of Member States.
The Commission, in collaboration with the World
Health Organisation (WHO), may place a new sub-
stance on one of the schedules that control the
availability of narcotic or psychotropic substances
and drug precursors (in 1986, for instance, it placed
MDMA (‘Ecstasy’) under formal control). It may
transfer a substance from one schedule to another
or remove substances from control.
In response to the need for closer cooperation and
coordination in drug law enforcement matters at the
regional level, the Commission established five re-
gional subsidiary bodies of heads of national drug
law enforcement agencies (Honlea) between 1974
and 1990 which regularly meet, exchange informa-
tion and elaborate common strategies.
International organisations
*
International Narcotics Control Board (INCB)
This is an independent and quasi-judicial body set
up to monitor the implementation of international
drug-control conventions. It was established by the
1961 Single Convention on Narcotic Drugs and be-
came operational in 1968. With regard to the licit
manufacture of and trade in drugs, the Board seeks
to ensure that adequate supplies are available for
medical and scientific uses and that leakage lead-
ing to illicit traffic does not occur. The Board identi-
fies weaknesses in national and international drug-
control systems and helps correct them. In cases
where the INCB finds that governments are not
meeting their treaty obligations, it urges them to
adopt remedial measures. It may bring violations to
the attention of the parties involved, the Commis-
sion and the Economic and Social Council.
Under the UN 1988 Convention,the INCB monitors in-
ternational trade in 22 substances with a view to pre-
venting their diversion for use in the illicit manufac-
ture of narcotics. It is also responsible for assessing
new chemicals found to be used in the illicit manu-
facture of drugs, for possible international control.
United Nations International Drug Control
Programme (UNDCP)
In 1991, the three UN drugs units — the Division of
Narcotic Drugs (DND), the United Nations Fund for
Drug Abuse Control (Unfdac) and the INCB Secre-
tariat — merged into a single drug-control pro-
gramme responsible for coordinating all UN drug-
control activities. UNDCP with its network of field of-
fices provides legal assistance and trains govern-
ment officials to set up adequate drug-control struc-
tures and to elaborate national, regional and sub-re-
gional strategies and programmes. UNDCP also col-
lects, analyses and disseminates data, information
and experience on drug control and provides tech-
nical assistance in the fields of demand reduction,
alternative development, law enforcement, forensic
laboratories, precursor control, prevention of money
laundering and institution building.
World Health Organisation (WHO)
The WHO, based in Geneva, is required by interna-
tional treaties to play an active role in promoting
public health and better life conditions, and in re-
ducing abuse of all psychoactive substances. It pro-
vides training in collecting accurate and relevant in-
formation on drug use and its health consequences.
The WHO is also actively involved in scheduling
drugs under the 1961 and 1971 Conventions.
Through regional offices and national contacts, the
WHO’s programme on substance abuse collects,
analyses and disseminates data on prevention, de-
mand reduction and the negative effects of drug con-
sumption (including tobacco and alcohol).The head-
quarters in Geneva houses a global database on to-
bacco that will soon also include data on alcohol. Epi-
demiological networks and existing sources provide
the WHO with information about illicit drugs. The
WHO develops and tests epidemiological method-
ologies and indicators in cooperation with UNDCP.
The Regional Office for Europe (WHO-Europe),
based in Copenhagen, assesses regional trends in
drug abuse, the risks of licit consumption and eval-
uates prevention policies. In 1991, health data from
41 countries were included in the first European
summary on drugs, tobacco and alcohol (ESDA). The
Office has also published a directory of European
research centres on alcohol, tobacco and drugs.
WHO-Europe and the EMCDDA are increasing co-
operation on epidemiology and methodology. This
will increase the quality and quantity of informa-
tion on drug abuse. The WHO-Europe acts as an ob-
server in the EMCDDA’s Management Board meet-
ings.
Other United Nations bodies
The following specialised UN agencies play a signif-
icant role in drug control:
• the International Labour Organisation (ILO)
deals with drug-related problems in the work-
place;
• the Centre for International Crime Prevention
(CICP) is concerned with aspects of the drug
phenomenon linked to criminality, money laun-
dering and the judicial system; together with the
UNDCP, the CICP forms part of the United Na-
tions Office for Drug Control and Crime Pre-
vention (ODCCP);
• the United Nation Children’s Fund (Unicef)
focuses its drug-prevention activities on vulnera-
ble groups of children and young people;
• the United Nations Educational, Scientific and
Cultural Organisation (Unesco) underlines pre-
vention policy in schools;
• the United Nations Industrial Development
Organisation (UNIDO) cooperates with govern-
ments to set up agro-industries in areas where 
illicit crops are grown;
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• the United Nations Development Programme
(UNDP) incorporates drug-control elements in
its development programmes;
• the United Nations Food and Agriculture 
Organisation (FAO) assists projects which raise
the income levels of farmers and reduce incen-
tives to cultivate illicit crops;
• the United Nations Joint Programme on
HIV/AIDS (UNAIDS) focuses on the link be-
tween injecting drug use and the spread of the
HIV virus;
• the United Nations Interregional Crime and
Justice Research Centre (Unicri) operates in
the field of documentary research into criminal
behaviour and drug abuse;
• the United Nations Population Fund (UNFPA)
addresses drug abuse within its educational 
programmes;
Other international organisations
Of the international organisations involved in drug
control, Interpol and the World Customs Organisa-
tion (WCO) play an active role in Europe.
Interpol
The International Criminal Police Organisation
(ICPO or Interpol), based in Lyon, France, com-
prises a general assembly, a general secretariat,
national central offices and advisers. Interpol pro-
motes cooperation between law enforcement ser-
vices on international drug-related crime such as il-
licit drug production, manufacture and trafficking.
Interpol is not a police force and does not have
supranational authority. Interpol focuses on in-
creasing cooperation between national police ser-
vices. It uses a sophisticated telecommunications
network to optimise communication.
In the 1970s, Interpol established a drugs subdivision,
with an operation group and an intelligence group.
Since then, the functions of the sub-directorate have
become twofold in the area of drug-related activity
with both functions extending to all the 177 member
countries. These functions are the liaison and spe-
cialised functions. The first covers coordination, ex-
change of information and drug information assis-
tance. The second addresses collection and analysis
of data, preparation of analytical/strategic intelli-
gence reports, analysis of drug trafficking trends and
the preparation of drug statistical reports.
A data bank of identified drug traffickers, information
on investigations, and tactical and strategic intelli-
gence has been established to provide national ser-
vices with information on illicit drug-related activities.
In addition, Interpol now also provides information on
international organised crime and money laundering.
The Fonds Provenant d’Activités Criminelles (FOPAC)
targets money laundering, the confiscation of assets
and related financial investigation techniques.
Interpol’s first contact with the EMCDDA was in
1995 and information exchange between the or-
ganisations will be strengthened. With the WCO
and UNDCP, Interpol has established programmes
for training police and customs officers.
World Customs Organisation (WCO)
The WCO attempts to increase the effectiveness of
customs enforcement activities.
A legal framework for these activities, provided by
the 1977 Nairobi Convention, still forms the basis
for exchanging intelligence and mutual technical
support. The WCO is also developing a comprehen-
sive programme of memoranda of understanding
(MoU) with other agencies and commercial organi-
sations to enhance its ability to support members’
law enforcement capabilities. Recent signatories in-
clude the UNDCP, the International Chamber of
Commerce, and Commercial Crime Services. Negoti-
ations with Interpol are also under way.
The EU Member States, as member administrations
of the WCO, play an active role in the law enforce-
ment programmes developed by the Council’s
working parties and committees.
In 1992, the WCO developed a regional reporting
system for drug seizures and has 10 regional intelli-
gence liaison offices (RILOs) reporting to a central
information system in Brussels.
Regional organisations
Pompidou Group
The Cooperation Group to Combat Drug Abuse and
Illicit Trafficking in Drugs — the Pompidou Group
— is an intergovernmental structure within the
Council of Europe. It aims to ‘promote and support
the establishment of national policies and pro-
grammes, and the strengthening of international
cooperation allowing a multidisciplinary approach
to the problem of drug abuse and illicit trafficking,
in a pan-European context’.
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The Group includes the 15 EU Member States, the
European Commission, Bulgaria, Croatia, Cyprus, the
Czech Republic, Hungary, Liechtenstein, Malta, Nor-
way, Poland, San Marino, the Slovak Republic, Slove-
nia, Switzerland and Turkey. In 1991 the group ex-
tended technical cooperation to Albania, Belarus,
Estonia, Latvia, Lithuania, Romania, Russia and
Ukraine. Non-European countries may also be invit-
ed to participate in the group’s activities.
The Pompidou Group functions on three levels:
ministerial; senior civil servants (or ‘permanent cor-
respondents’); and technical experts and officials.
The permanent correspondents make public the
majority of studies carried out on its behalf; but in-
formation is not made public on airport drug
seizures with details of how drugs are transported
(data collected by the Cooperation Group of Drug
Control Services at European airports).
Dublin Group
Created, on the initiative of CELAD, as an informal
body to coordinate international drug-control pol-
icy, the Dublin Group includes the EU Member
States, Australia, Canada, Japan, Norway and the
USA. The European Commission and the UNDCP are
also represented. The group exchanges information
on drug actions and measures taken in member
countries. The Dublin Group consists of central po-
litical, regional and local working groups.
The Mini Dublin Group is composed of the heads
of local missions, diplomats with expert knowledge
and liaison officers from law enforcement agencies.
It assesses a country’s drug-related political, social
and economic state and identifies the need for as-
sistance. This information is reported to the Region-
al Dublin Group.
The Regional Dublin Group, composed of ministe-
rial experts, meets twice a year to summarise the re-
ports supplied by the Mini Dublin Group. The group
submits a regional report to the Central Dublin
Group consisting of an overview, recommendations
and draft resolutions to be adopted. Once the 
Central Dublin Group adopts a decision, it is im-
plemented by the Regional Dublin Group.
The Central Dublin Group consists of all Member
States and meets annually in Brussels. Its primary
task is coordination and decision-making, and it dis-
cusses the recommendations of the Regional
Dublin Group and adopts measures/actions.
Inter-American Drug Abuse Control
Commission (CICAD)
This Commission, with 31 member States, was es-
tablished by the Organisation of American States
(OAS) to ‘promote and facilitate multilateral cooper-
ation among the member countries in the control
of drug trafficking, production and use’.
CICAD has 34 drug information centres throughout
the western hemisphere (IADIS) and publishes an
annual statistical summary. Each year, CICAD adopts
an action plan which includes cooperation with EU
Member States and institutions. CICAD focuses on
demand reduction, supply reduction, assistance to
member states and information exchange.
The Financial Action Task Force (FATF)
The FATF was created by the G7 to analyse the impli-
cations of money laundering in the financial system
and propose measures to control it. In 1990, the task
force made 40 recommendations to its 28 member
countries and international organisations. EU Direc-
tive 91/308/EEC on money laundering has put into
practice many of the FATF’s recommendations.
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International cooperation
Legal framework
Approximately 74 % of countries worldwide have
signed UN international drug control treaties. All 15
EU Member States are now parties to the three UN
Conventions. Cooperation and coordination among
international organisations are essential if drug
problems are to be tackled without duplication of
effort or resources.
Main events relevant to the EU in 1997
• Much of 1997 was spent preparing a UN General
Assembly Special Session (Ungass) on illicit
drugs (held from 8 to 10 June 1998) to adopt a
political declaration, a declaration on the guid-
Advances in 1997
*
ing principles of drug demand reduction, an ac-
tion plan against illicit manufacture, trafficking
and abuse of amphetamine-type stimulants and
their precursors, an action plan on international
cooperation on the eradication of illicit drug
crops and on alternative development, as well as
a set of measures to control precursors, to pro-
mote judicial cooperation and to counter money
laundering.
• Two special meetings took place (in Sydney in
August and in Vienna in October) to discuss the
demand-reduction resource book series devel-
oped by UNDCP to complement the Ungass de-
mand-reduction declaration.
• The UNDCP produced its first ‘World drug report’
— an all-embracing publication covering a
broad range of issues, from cultivation, produc-
tion, trafficking and consumption trends, theo-
ries of drug use, health consequences, organi-
sational structures of the illicit drug industry,
money laundering, to drug policies, including a
review of the legalisation debate and strategies
to counter the drug threat.
• In April, the UNDCP and the United Nations De-
velopment Programme signed a working agree-
ment on division of tasks between the two.
• The WHO programme on substance abuse, con-
sists of prevention, advocacy and promotion
(PAP), treatment and care (TAC), and regulatory
control.
• A WHO report, ‘Smoking, Drinking and Drug-
taking in the European Region’, was published 
in April.
• The Interpol network communicated about two
million messages relating to criminal activities in
177 countries in 1997, 55 % of which were relat-
ed to drug offences. The 66th session of the In-
terpol General Assembly in New Delhi, India, in
October 1997 passed 18 resolutions, including
resolutions on anti-money laundering.
• In 1997, the WCO Central Information System
(CIS) published its ‘Customs and drugs report
1996’ and began the 1997 version. The number
of detections increased by more than 10 % from
1996.
• The Dublin Group’s 1997 work focused on con-
trolling chemical precursors.
Illegal cultivation, production and
trafficking of narcotic drugs
Summary of international reports on drug
supply to the EU
According to data collected and treated by the
UNDCP, the INCB, Interpol, the WCO and the Europol
Drugs Unit (EDU), drug supply continues to increase.
Despite national and international improvements in
law enforcement cooperation, traffickers are aug-
menting supplies to consumer markets, especially of
synthetic drugs. An increase in quantities of drugs
seized, without a corresponding increase in price or
decrease in availability, is evidence of this increase.
According to Interpol, about 800 tonnes of cocaine
and 450 tonnes of heroin are produced annually
worldwide. UNDCP data for 1995 and 1996 suggest
availability of heroin on the market — after seizures
— of some 380 tonnes. Much of this ends up in the
EU (38 tonnes of cocaine and 4.4 tonnes of heroin
were seized in the European Union in 1997, accord-
ing to the EDU). As it is impossible to quantify pre-
cisely drugs supplied and consumed, drug seizures
represent an important indirect indicator.
Some of the data mentioned here refer to all of 
Europe and not exclusively to the European Union
as all the international organisations mentioned
above, apart from the EDU, work at global level.
Both police and customs data indicate that there
was a significant increase in cocaine and ampheta-
mine seizures in 1997, a slight increase in cannabis
resin (hashish) seizures, and a slight decrease in
heroin and cannabis leaf (marijuana) seizures in the
European region.
Trafficking routes remain largely unchanged. The
Balkan route from South-West Asia is used primari-
ly to supply Europe with heroin. The maritime route
across the North Atlantic from Central America re-
mains the most popular method for transporting
cocaine to Europe. There has been an increase in
production and trade in synthetic drugs in Europe,
especially eastern Europe, including the export of
synthetic drugs to other regions.
Cannabis
Cannabis remained the principal drug of abuse in
Europe and cultivation and trafficking of high po-
tency cannabis is increasing.
The UNDCP reports that, in the EU, seizures of
cannabis resin increased. Morocco is a major suppli-
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er of cannabis resin to the Member States. More
than 315 tonnes (much of it of Moroccan origin)
were seized in Spain. The UK and France recorded
23 % and 19 % of total cannabis resin seizures in Eu-
rope respectively in accordance with WCO data.
Cannabis resin was also smuggled into Europe from
Pakistan. A seizure of 6.4 tonnes in Greece demon-
strates that South-West Asia is an important resin
provider. Large-scale smuggling takes place in 
lorries, vans and campers, and by sea in trawlers
and yachts.
The WCO reports that as for herbal cannabis (leaf )
most seizures were made in the UK (23 %), Belgium
(22 %), and Spain (13 %). The Netherlands, the tradi-
tional entry point for cannabis smuggled into Eu-
rope, recorded 12 % of herbal cannabis seizures.
Two large seizures, originating in Ghana, were made
in Rotterdam and Hamburg (2.8 and 2.5 tonnes re-
spectively). This may indicate an increase of West
African drug trafficking groups in Europe. Colom-
bia, South Africa, Nigeria and Thailand are also 
suppliers of herbal cannabis to the EU. Albania is
developing into a major source of herbal cannabis
for Greece and Italy.
Heroin
Heroin entering the EU comes mainly (about 80 %)
from South-West Asia (the ‘golden crescent’ of
Afghanistan, Iran and Pakistan), through Turkey to
Germany. According to the INCB, the Balkan route is
most frequently used by traffickers — significant
seizures taking place in 1997 in Turkey, Germany,
Bulgaria and Yugoslavia. The increasing importance
of Central Asia for markets in Europe, as reported by
the UNDCP, must also be noted. Sea transport has
been used but the overland system presents the
most consistent threat.
However, the largest amounts seized were in the UK
and Germany. As a consequence of the turmoil in
the former Yugoslavia, Romania has become an 
important transit route for trafficking, its territory
being used to store illicit drugs in transit. However,
increasingly, the ‘traditional’ route through the 
former Yugoslavia is once again being used.
According to the EDU,Turkish organised crime syndi-
cates, often using local Turkish communities as cover
for their activities, remain an active force in heroin
trafficking and have been identified as operating in
12 Member States. Ethnic Albanian-Yugoslav groups
are also prominent in heroin trafficking.
Cocaine
Bolivia, Colombia and Peru are the main producers of
cocaine destined for the EU, with Argentina,
Venezuela,Brazil,Ecuador and Suriname as major tran-
sit countries. The EDU reports that the transit role of
central and east European countries is increasing.
Colombia remains, however, the main producer of co-
caine destined for the Member States. Transported
mainly by sea (75 %), cocaine spreads quickly through
EU countries with a maritime border — Spain,
Portugal, the Netherlands, Germany, Belgium and
the UK. The WCO reports that cocaine seizures in-
creased by about 30 % in Europe in 1997. Most of this
was seized in Spain (over 45% of total seizures in the
region), the Netherlands (about 17%) and Portugal
and Belgium (both over 10 %).Several Member States
have noted a trend towards the trafficking of smaller
quantities rather than multi-tonne shipments. Ac-
cording to the EDU, despite the increase in seizures,
no lasting effects have been detected in price.
Synthetic drugs
Synthetic drugs are difficult to seize, as trafficking
and smuggling routes are simpler than for other
drugs, as they are produced within the EU or in the
CEECs and so are close to their consumer markets.
Profit margins ensure continued production. Ac-
cording to the EDU, the cost of producing one 
Ecstasy pill is less than ECU 0.3, compared with a re-
tail price of ECU 7 to 18 (a 2 300 to 4 600% profit).
The European Union is one of the world’s major pro-
duction regions of amphetamine- and Ecstasy-type
stimulants, with illicit laboratories operating in most
Member States. Intra-EU trafficking predominantly
takes place overland in cars, lorries and trains. In
1997, eastern Europe emerged as a major supplier of
amphetamine-type stimulants. The Czech Republic,
Poland, Bulgaria and the Baltic States are major
source countries and the production in central and
eastern Europe is partly destined for the northern
Member States. Synthetic drugs used within the EU
are also produced in Asia and China.Simultaneously,
and according to the UNDCP, Ecstasy manufactured
in Europe is increasingly being abused in several
Asian countries. In 1997, the importance of eastern
Europe as a supplier of amphetamine-type stimu-
lants continued to grow.
The WCO and the INCB report that laboratories for
the illicit manufacture of amphetamines and/or
MDMA or other ‘Ecstasy-type’ hallucinogenic am-
phetamine derivatives were dismantled in several
European countries.
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Amphetamines
Both the EDU and WCO report an increase of am-
phetamine seizures from 1996 to 1997. The EDU
claims that, of the 1.9 tonnes seized in the Euro-
pean Union, 46 % were seized in the UK, 11 % in
Germany and 10 % in France. The WCO estimates
that Poland supplies 40 % of the Scandinavian mar-
ket and 20 % of German seizures were from Poland.
Other amphetamine producers are Lithuania,
Latvia, Hungary, the Czech Republic (for the
methamphetamine ‘Pervitin’) and Ukraine.
Ecstasy (MDMA)
The WCO reports that the total amount seized in
1997 in Europe was 578.1 kg (925 623 tablets), a
slight increase in weight compared with 1996 (498
kg), but a slight decrease in terms of dose
(1 009 205 tablets). According to Interpol and the
WCO, the Netherlands is believed to be the main
source in the region. Europe seems to be at the
centre of world Ecstasy activity as 70 % of global
seizures occurred there. It is also now an export-
ing region, particularly to South-East Asia (5 out of
the 12 largest Ecstasy seizures were destined for
Asia).
LSD
There was a considerable decrease in seizures in
1997 (the EDU reports a fall in doses of 22 % com-
pared with 1996 in the European Union).
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United Nations
International Drug control
programme (UNDCP)
International Narcotics
Control Board
(INCB)
World Health
Organisation
(WHO)
Financial Action
Task Force
(FATF)
Council of Europe
‘Pompidou Group’
CICAD
Dublin Group
Interpol
(ICPO)
World Customs
Organisation
(WCO)
Commission on
Narcotic Drugs
(CND)
UN Commission on
Crime Prevention and
Criminal Justice
European Union
ROLE: UN crime
prevention policy.
EU status: observer.
ROLE: coordination of all UN
drug control activities.
EU status: observer.
EMCDDA-UNDCP: exchange
of data, contribution to
the annual report.
ROLE: evaluation of licit needs
of drugs, international
cooperation.
EMCDDA-INCB: exchange
of data, contribution to
the annual report.
ROLE: health promotion.
EU status: observer.
EMCDDA-WHO: exchange
of data, contribution to
the annual report.
ROLE: money
laundering prevention.
EU status: member.
ROLE: international cooperation
in a pan-European context.
EU status: permanent
correspondent.
EMCDDA-Pompidou Group:
exchange of data, contribution
to the annual report.
ROLE: cooperation
within American states.
EU status: participation
where of mutual
benefit.
ROLE: informal
policy- making body.
EU status: observer.
ROLE: international police
cooperation.
EU status: observer.
EMCDDA-ICPO: exchange
of data, contribution to
the annual report.
ROLE: international
customs cooperation.
EU status: observer.
EMCDDA-WCO: exchange
of data, contribution to
the annual report.
ROLE: drug general
policies, control of
international treaties.
EU status: observer
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The field of public spending on drugs
Examining public spending on various drug poli-
cies is a way of attempting to identify the most
effective policy. Even if this is not possible, the
mirror of public spending should shed greater
light on the relationship between spending and
outcome.
Identifying spending linked to drug policies in pub-
lic administration budgets poses problems of defin-
ition. What are the domains of drug policies? The
question is not only theoretical — it has concrete
applications in three areas: enforcement, treatment,
and prevention.
Enforcement
Any person violating national drug legislation will
encounter an action by the State. The spending tied
to the enforcement of the law on drugs is clearly
and easily defined. The problem lies with crimes
committed by drug users: is crime a direct conse-
quence of drug addiction?
Treatment
A significant number of HIV infections are drug-
related. Should the cost of AIDS patient care be in-
cluded as part of public drug spending, if they are
infected through their drug use? If AIDS is a direct
consequence of drug use, the mechanisms and
spending are no longer geared to drug addicts but
to individuals with AIDS.
Prevention
As primary prevention covers the whole popula-
tion, it is tempting to just consider the nature of the
preventive actions and not to include actions that
explicitly address addiction, such as publicity cam-
paigns against drug use. However, this reductionist
idea of prevention is disputable. Conversely, an in-
clusive concept would include everything that pro-
motes health as preventing risk behaviour, without
specifying the prevention of addiction.
A preliminary collection of statistics
The EMCDDA collects and analyses data gathered
by Reitox in order to allow an international compar-
ison of public spending on drugs.The elements that
follow are incomplete and efforts must continue.
In general, public spending on drugs takes two
forms.
Firstly, spending directly allotted to a drug mission,
where the title leaves no doubt about the destina-
tion of the money and so accounting for this
spending poses no problems. A problem arises be-
cause the drug problem remains a significant con-
cern, and so certain administrations are tempted to
apply for drug funding, only to use the funds for
other projects. A careful calculation would demand
that budgets specifically allocated for drugs be sub-
tracted from the sums labelled as such to thwart
such management control and to oppose the gen-
eral tendency of reducing public spending.
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Analysis of public spending on drugs
Drug use and drug trafficking impose
costs on the community. Although the
governments of the EU allocate
significant resources to combating
drug use, little attempt is made to
assess and compare the
effectiveness of methods employed
by different countries.
Chapter7
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Secondly, a proportion of the activity of ministries
and public administrations (police, courts, customs,
health) is dedicated to combating drugs and addic-
tion. Given that public administrations present their
budgets by spending lines and not by functions,
the difficulty lies in interpreting distribution to cal-
culate the funds actually allocated to drugs. It is
thus necessary to consider all relevant budgets, and
estimate the part of each that corresponds to the
drug activity of the service.
The results presented below constitute only an in-
termediary step.Table 1, which regroups eight coun-
tries (seven countries of the EU and Switzerland) is
constructed for five countries of the EU studied here
(Belgium, Ireland, Spain, Portugal and Denmark) on
the basis of a questionnaire given to the correspon-
dents of Reitox. It is complemented by data from the
study on France (which remains the most complete
and on which the Reitox questionnaire is based) and
by the results of a Swiss study.
Table 1 retraces public spending lines and calcu-
lates elements that, following the method used in
the French study, permit calculations of the drug
budget of each country.
The information in Table 1 is linked to the informa-
tion furnished by the national correspondents of
Reitox, which are themselves constrained by avail-
ability of source information. Table 1 is incomplete
as a large amount of information is not the object
of systematic study in each of the countries exam-
ined. In the same manner, note that the information
presented in Table 1 is not ‘adjusted’ on the same
year of reference which has no significant effect on
the results if one accepts that spending on drugs is
quite stable from one year to the next.
The data provided by Reitox correspondents vary
from one country to another. The most salient ex-
ample is that of arrests for ‘drug offences’ in the first
section of Table 1 (see Chapter 2). Certain countries
include the number of people the police record as
having infringed drug laws, whilst other countries
count the number of infringements. The perceived
degree of seriousness for crimes also varies from
one country to another. Such problems of defini-
tion emphasise the urgency of developing a com-
parative method.
Belgium
The police budget is divided into expenses for 
personnel (BEF 60 681 851 270), operations 
(BEF 5 878 325 143) and investments (BEF 3 758 154
231).The police workforce consists of 18 745 commu-
nity officers, 15 929 gendarmes, and 1 440 police judi-
cial officers. Police arrests for drugs (1996 statistics)
show a distinction between arrests for drug posses-
sion (13 812), for importing,exporting,manufacturing
and trafficking (8 362) and a category labelled ‘di-
verse’(1 588).The total judicial budget (1998 statistics)
includes expenses for personnel, buildings, and
equipment. Finally, for the line ‘social, health and pre-
vention’ a total has been given (BEF 280 000 000),
without a breakdown between ‘social and health’and
‘prevention’. It should be noted that BEF 3 350 million
(from the budget for ‘mental health’), for the care of
drug addicts, should be added to this sum.
Denmark
The police force (10 034 individuals) is the sole se-
curity force. All statistics date from 1997, apart from
the number of customs guards, which dates from
1998.
France
Budget lines for all police forces, the total number
of police officers, and the total number of spe-
cialised drugs officers come only from the national
police, and do not include the State police force
(gendarmerie).
Ireland
The  police budget is derived from 1997 statistics.
The specialised forces for combating drugs com-
prised 50 individuals grouped in a special ‘Garda
National Drugs Unit’ and 246 national police offi-
cers. The customs budget comprises both the ‘cus-
toms budget’ and taxes. There are 85 customs offi-
cers specialised in drugs. However, ‘pensions and
salaries’ are excluded from this budget.
The operational budget for penal institutions (1997
statistics) includes the operating costs of central
stores and the training centre. The number of indi-
viduals incarcerated for drug offences dates from
1994, while the total number of prisoners dates
from 1997. Finally, the number concerning actions
at international level represents the Irish contribu-
tion to the UNDCP for 1997.
The line ‘budget of institutions specialising in treat-
ing drug addiction’, IEP 7 788 000 (i.e. ECU 10.09 mil-
lion ) includes IEP 6 788 000 which was allocated to
the Department of Health and Children for drug
treatment services in regional health board areas.
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Table 1: Public spending and ‘drug-budget’
(1) In million ECU. ECU conversion based on average 1997 exchange rate for each national currency.
(2) Kopp and Palle, MILDT report (1996).
(3) ‘Tackling drugs together strategy for England 1995-98’, HMSO, May 1995.
(4) J. Estermann, ‘Consommation et trafic de drogues: les coûts de la répression (estimation pour la Suisse 1991)’.
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1. Law-enforcement costs
    1.1. Police
Budget of all national police forces(1) 1 724.71 667.37 3 780.15 620.61 n.a. 3 166.43 865.77 12 516.37
Police manpower 36 114.00 12 965.00 132 626.00 10 968.00 2 300.00 121 376.00 n.a. 210 472.00
Police manpower specialising in the fight against drugs n.a n.a. 2 194.00 296.00 200.00 1 643.00 n.a. n.a.
Interpellations for drug offences 23 762.00 13 992.00 79 271.00 n.a. 9 333.00 79 445.00 42 000.00 998.00
Total number of interpellations n.a. 531 115.00 790 000.00 n.a. 321 643.00 1 984 755.00 n.a. 26 062.00
    1.2. Customs
Customs budget(1) n.a. n.a. 585.32 65.05 n.a. n.a. n.a. 1 282.28
Number of customs officers n.a. 250.00 20 000.00 85.00 n.a. n.a. n.a. 24 778.00
Number of customs offences involving drugs n.a. 217.00 25 195.00 483.00 76.00 n.a. n.a. 2 257.00
Total number of customs offences n.a. n.a. 100 000.00 2 354.00 n.a. n.a. n.a. 3 259.00
    1.3. Justice
Budget of the criminal justice system(1) 463.83 1 062.28 3 094.73 894.44 n.a. 707.12 n.a. 2 024.92
Number of prosecutions for drug offences n.a. n.a. n.a. 4 156.00 4 433.00 34 772.00 41 000.00 53 545.00
Total number of prosecutions (excluding minor offences) n.a. n.a. n.a. 30 768.00 420 217.00 n.a. n.a. 2 134 425.00
    1.4. Custodial institutions
Operational budget of all custodial institutions(1) n.a. 178.99 866.11 163.21 n.a. 479.69 285.44 2 591.59
Number of persons imprisoned for drug offences n.a. 1 282.00 11 816.00 225.00 3 653.00 9 925.00 n.a. 6 400.00
Total number of persons imprisoned n.a. 3 533.00 51 325.00 11 620.00 14 634.00 43 147.00 n.a. 57 598.00
2. Health and social services
Budget of institutions specialising in treating drug
addiction(1) 69.38 n.a. n.a. 10.09 3.77 94.61 n.a. 273.27
        State(1) 69.38 n.a. n.a. 8.79 n.a. 16.12 n.a. n.a.
        Regions(1) n.a. n.a. n.a. 1.30 n.a. 78.49 n.a. n.a.
Budget of non-specialised institutions or cost
indicators(1) n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Statistics identifying which patients out of
all admissions were  treated for drug addiction n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
3. Prevention
Budgetary lines allocated to drug prevention(1) n.a. n.a. n.a. 0.46 12.14 36.77 n.a. 252.25
        State(1) n.a. n.a. n.a. n.a. n.a. 16.12 n.a. n.a.
        Regions(1) n.a. n.a. n.a. n.a. n.a. 20.66 n.a. n.a.
        Local(1) n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Budget of institutions specialising in drug prevention(1) n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Budget of non-specialised institutions(1) n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Activities that ascribe part of their costs to the fight
against drugs n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
4. Research
Amount spent on research(1) n.a. n.a. 6.35 1.30 n.a. 7.35 n.a. n.a.
        State(1) n.a. n.a. 6.35 n.a. n.a. 3.22 n.a. n.a.
        Regions(1) n.a. n.a. n.a. n.a. n.a. 4.13 n.a. n.a.
5. Action at international level
Amount spent on international action(1) n.a. n.a. 10.58 0.19 0.01 4.26 n.a. 273.27
        UNDCP(1) n.a. n.a. n.a. 0.19 0.01 0.39 n.a. n.a.
        National plan on drugs(1) n.a. n.a. n.a. n.a. n.a. 3.87 n.a. n.a.
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IEP 5 475 000 of this was allocated to the Eastern
Health Board. It is important to note that the Eastern
Health Board is the only health board with specific
specialised drug treatment facilities. Moreover, the
Eastern Health Board budget incorporates HIV/AIDS
with drug treatment. Other health board treatment
activities include alcohol and drugs. On another
side, IEP1 000 000 was allocated to local area drug
task forces arising from the ministerial task force re-
ports on measures to reduce the demand for drugs.
IEP 355 231 was allocated for prevention to the
Health Promotion Unit at the Department of Health
and Children for drug prevention activities, and IEP
1 000 000 was allocated for research under the ‘Sci-
ence and technology against drugs’ initiative.
Portugal
All data refer to 1997. The number given for the po-
lice force is for the judicial police force only, while
the total number of police officers should be count-
ed as the judicial police (Policia Judiciara), the civil
security officers (Policia de Seguranca Publica) and
the national guard (Guardia Nacional Republicana).
Unfortunately, there was no data available at the
time for the last two categories. Only officers of the
judicial police are considered drug specialists. The
line ‘criminal justice system budget’ is the budget
for criminal costs. The line ‘operational budget 
for all judicial institutions’ is the budget of the gen-
eral management of penal services. Finally, the 
line ‘budget of institutions specialised in the treat-
ment of drug users’ includes the budgets of 
public (PTE 148 587 000) and private institutions
(PTE 614 348 000).
Spain
The police force comprises the National Police
Corps and the Guardia Civil.The role of the Customs
Surveillance Service, which carries out its work in
the fight against drugs at sea and at the borders,
should also be highlighted.
Switzerland
The number for arrests corresponds to the number
of proceedings initiated by the police in 1996, rather
than the actual number of arrests.The number of ju-
dicial proceedings for drug abuse (41 000) repre-
sents the number of convictions for 1993. The Swiss
study also presents CHF 500 million as the total cost
of repressive activities by the law and the police in
1991. Unfortunately, it is not possible to divide this
between the two institutions. Finally, the police bud-
get (1991 statistics) accounts for the costs of region-
al police forces and does not include traffic police.
United Kingdom
The total police budget for the UK (1998/99) is di-
vided into GBP 7.15 billion for England and Wales,
GBP 650.9 million for Scotland and GBP 535 million
for Northern Ireland. There are 179 480 persons 
in the total police manpower in England and 
Wales (126 862 ‘officers’ and 52 618 ‘civilians’);
19 235 for Scotland (14 788 ‘regular police officers’
and 4 477 ‘support staff’); in Northern Ireland 
11 757 (8 429 ‘officers’ and 3 328 ‘civilians’).
The number of 998 arrested persons for drug of-
fences and the total number of arrested persons 
(26 062) do not give a clear picture of the situation in
the UK because they cover only Northern Ireland. Da-
ta for England,Wales and Scotland are not available.
The justice budget for England and Wales is GBP 590
million for all justice courts (criminal and non crimi-
nal courts), GBP 300 million for the Prosecution Ser-
vice and GBP 225.7 million for legal aid. In Scotland,
GBP 28.8 million goes to justice courts, GBP 46.3 mil-
lion for prosecutions (the Crown Office and the
Procurator Fiscal Service), GBP 89.7 million for Legal
Aid. In Northern Ireland, GBP 31.5 million is dedicated
to justice courts, GBP 8 million to prosecutions and
GBP 28.6 million for legal aid. There are 3 259 cus-
toms offences implying persons and companies.
There are 49 897 persons prosecuted in court for
drug offences in Wales and England, 2 900 in Scot-
land, and 748 in Northern Ireland. There were
1 923 000 persons prosecuted in England and Wales,
175 457 in Scotland and 35 968 in Northern Ireland.
The budget for custodial institutions is GBP 1.401
billion for England and Wales, GBP 183 million for
Scotland and GBP 142 million for Northern Ireland.
In 1997 5 269 persons were imprisoned for drug of-
fences in England and Wales,1 011 in Scotland and 120
in Northern Ireland among the 43 055 prisoners in
England and Wales, 13 150 in Scotland and 1 393 in
Northern Ireland.The budget of all the agencies dedi-
cated to drug treatment represents 13 % of a total
amount of GBP 1.4 billion.12 % of this sum goes to pre-
vention and 13 % to actions at the international level.
Outline of a method of calculating 
a ‘drug budget’
It is possible, using Table 1, to calculate the drug
budget of each country; that is national public
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spending on drugs by adding the funds directly re-
lated to public activity on drugs, to the drug budget
of major administrations (police, law, customs,
health).
The spending directly allotted to combating drug
use (in Table 1) can be used as the basis for calcu-
lating approximate values for the public expendi-
ture of major administrations.
For police forces, we generally take the number of
officers involved and the budget. It is then possible
to calculate the hourly cost of a police officer. Sub-
sequently, we can calculate the number of hours
spent by the police officers on drug-related affairs
to obtain the total spending of the police in terms
of drugs.
Take as an example the French police force. Public
security officers spend 70 % of their time on penal
matters and the remaining 30 % on general mat-
ters. The penal matters can be divided into two
equal parts: repressive activities and preventive 
activities.
Approximately 12 % of violations concern drug
laws. The amount of the police budget allocated to
repressing drug trafficking and drug use can thus
be estimated at 4 % of the total. One study indicates
that 3 % of police officials’ drug work involves pre-
vention. The addition of funds allocated to spe-
cialised drug forces gives a total estimate for French
police funding devoted to drug matters of ECU 
186.74 million. Although these calculations are ap-
proximate, sources of error are similar from one
country to another.
To use the relationship between drug law violations
and all judicial infractions as a criterion for breaking
down the work time of police officers rests on the
hypothesis that the police treat drug issues and
other crimes in an identical manner. In reality, al-
though the frequency varies from country to coun-
try, the arrest of a person involved in drugs does
not involve a hearing. This type of intervention is
not accounted for.
Similar calculations provide an approximate total
for judicial spending on drug matters. Knowing the
hourly median cost of a magistrate, one can esti-
mate the number of hours devoted to drugs. In to-
tal hours worked, one can distinguish those allotted
to penal affairs; then those that concern violations
of drug laws. Besides magistrates, one must also
consider court clerks, and attribute to total drug
spending part of the general expenses of the min-
istry, of judicial aid, expenses and controls.
The calculation of prison spending poses more
complex problems, due to the high levels of expen-
diture involved. In theory, it should simply be a case
of multiplying the annual cost of incarcerating one
individual by the number of individuals incarcerat-
ed for violating drug laws, which would provide an
estimate of total spending by the prison adminis-
tration on drugs. Such a calculation, however, is bi-
ased as a number of prisoners are in prison for
crimes other than drug law infractions. These
crimes (robbery, prostitution, etc.) may be commit-
ted to procure drugs or under the influence of
drugs. This raises the question of whether a part of
the cost of detaining non-drug offenders should be
linked to the drug budget. Existing studies general-
ly decline to do this but the question remains open.
Some results
The work of gathering and analysing the statistics
for public drug spending is not finished. It is impos-
sible to analyse definitively the allocation of State
spending to a ‘drug budget’, following the method
outlined above, without the cooperation of statisti-
cians from the various EU countries. The lack of
standardisation in criminal and public health statis-
tics makes comparison and statistical re-analysis
problematic, particularly without a thorough
knowledge of the terrain described. The need for a
European study on the comparison of ‘drug bud-
gets’ is evident.
Such a comparison would allow clear measurement
of the size of each country’s effort against drugs in
which public spending on drugs is assessed as a
function of a GDP percentage or State budget. As
an indication, it is interesting to present such a
comparison for five countries.
The results, with the exception of those for France,
have not been furnished by 1998 EMCDDA and 
Reitox data, but come from a range of diverse, earl-
ier sources. These studies, using a related (though
less detailed) method, permit comparison between
France, the Netherlands and the UK, as well as
Switzerland and the USA which, although they do
not belong to the EU, are useful for comparison (see
Table 2).
According to these statistics, the drug budget ex-
pressed as a percentage of GDP (gross domestic
product), is very similar in the three European coun-
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tries (1 %), and substantially higher in the USA
(1.6 %). Expressed as a percentage of public spend-
ing, the proportion dedicated to drugs by the
American public administrations (0.87 % each) is
much higher than that of France (0.29 %), the
Netherlands (0.32 %) and the United Kingdom
(0.34 %).
The apportionment of the drug budget between
repression and prevention/treatment differs be-
tween Europe and the USA. In Europe, the parts of
the budget allotted to repression (between 70 %
and 80 %) and prevention/treatment (20 %) are
quite stable despite marked political differences.
However, the budget for repression (93 %) is clearly
greater in the United States than in Europe. It is still
possible that prevention/treatment spending (7 %)
is underestimated due to the decentralisation of
health care in the USA.
However, a distribution of budgets to repression
versus prevention/treatment is inevitably cursory.
The prevention part is often underestimated since
it is difficult to take into account the cost of gener-
al public prevention campaigns that reduce addic-
tion, but are not explicitly anti-drug.
The repression part is probably overestimated since
the greater degree of centralisation of enforcement
administrations allows accurate accounting of ex-
penses. Inversely, the decentralised character of
treatment leads to underestimates. Generally, the
greater the degree of centralisation, the easier it be-
comes to attribute budget money to a particular
action, which is practically impossible when the ac-
tion is decentralised among several agencies.
To distinguish repression and prevention/treat-
ment in the presentation of drug budgets suggests
that it would be possible to reattribute a part of the
spending in favour of repression at the expense of
care or prevention. However, a sizeable part of pub-
lic spending cannot be reassigned. It is, for example,
often impossible, in the short and medium term, to
reduce national police spending at the expense of
health (and the reverse holds true, as well), since
such a reallocation would mean eliminating lines in
one area to create them in another, which is admin-
istratively complex.
Experience has shown that when an effort is made
in one part of the budget, it requires greater fi-
nance, but not tapping into another budget line.
Annual report on the state of the drugs problem in the European Union110
Table 2: Drug budget and public spending
(1) All figures are in billion ECU. ECU conversion based on average 1997 exchange rate for each national currency.
(2) Figures for 1996.
(3) Millions (figures for 1995).
Fra
nce
All State expenditure (1), (2) 0 233.522 % 080.520 0 233.829 1 273.954
GDP (2) 1 190.005 297.038 1 113.739 6 915.414
State expenditure as % of GDP 0 019.62 % 027.11 % 0 020.99 % 0 018.42 %
Anti-drug expenditure (1) 0 000.683 0 00.260 0 000.790 0 011.140
   Enforcement 0 000.54 0 00.180 0 000.542 0 010.380
0((80 %) ((70 %) 0((68 %) 0((93 %)
   Treatment, prevention 0 000.14 0 00.080 0 000.248 0 000.760
0((20 %) ((30 %) 0((32 %) 00((7 %)
As % of GDP 0 000.06 % 0 00.09 % 0 000.07 % 0 000.16 %
As % of State expenditure 0 000.29 % 0 00.32 % 0 000.34 % 0 000.87 %
Population (3) 0 058.15 0 15.45 0 058.26 0 263.17
Ne
the
rlan
ds
UK US
A
Reinforcing a budget line supposes, in general, a
rise in the global budget. In a context of meagre
budgetary resources, it is very difficult to reattribute
budgets among different agencies.
The redeployment of funds should be negotiated
within the agency in question. Since budgetary ex-
penses are more or less fixed, an increase in one
drug programme is to the detriment of another
programme. The idea that a political authority will
modify the allocation of resources between sectors,
depending on well-defined priorities, seems con-
trary to reality.
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Term Definition
Accession countries Central and east European countries (CEECs) currently preparing for ac-
cession to the EU (Hungary, Poland, Estonia, the Czech Republic, the 
Slovak Republic and Cyprus)
ACP African, Caribbean and Pacific countries
Autonomous communities Regional governments (Spain)
Biomed research programme Biomedical/health research programme (DG XII of the European Com-
mission)
CAN Swedish Council for Information on Alcohol and other Drugs
CEECs Central and east European countries
CELAD Ad hoc political group of national drug coordinators set up in 1989 to
assist the Council of the European Union. The group drew up the first
two European action plans to combat drugs, adopted in 1990 and 1992
Chemical precursor Substance used in the conversion of licit substances into illicit drugs
CND Commission on Narcotic Drugs: a United Nations committee estab-
lished in 1946 and responsible for controlling implementation of inter-
national treaties in the drug field
COST A6 A programme run by the European Commission’s Directorate-General
XII (Science, Research and Development) to stimulate research into the
impact of various drug policies and measures on the extent, nature and
consequences of drug abuse
Council of Europe Set up in 1949, the Council of Europe, based in Strasbourg, France, is an
intergovernmental political organisation of some 40 European pluralist
democracies. Although often confused with the European Union, the
Council is a distinct organisation primarily concerned with strengthen-
ing political, social, legal and cultural cooperation and promoting hu-
man values throughout Europe
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Glossary
DATs Drug action teams (UK)
Demand reduction Activities aimed at preventing drug use, assisting and treating drug
users, reducing the harmful consequences of such use and promoting
positive health
Depenalisation The sanctions to be applied in case of an offence are administrative. The
Criminal Code is not applied so that instead of a sentence of imprison-
ment the offender will be find or restricted in some rights (e.g. suspen-
sion of driving licence, suspension of passport)
DIMS Drugs information monitoring system (NL)
D.O.B. Dihydroxybenzoic acid
Formula — C7H6O4 (amphetamine)
Domestically produced drugs Home-made illicit drugs (frequently produced by consumers). ‘Domes-
tic’ in law enforcement and street language, particularly in the United
States, means produced within the Member State rather than imported
Drug Experts Group A group of national experts on drugs, meeting within the Council of the
European Union, now known as the Horizontal Drugs Group
Drug tourism Phenomenon of people going from one country to another to buy
and/or use drugs
DSM IV Diagnostic statistical manual, fourth edition
Dublin Group An informal body formed to coordinate international drug policy. It in-
cludes EU Member States, Australia, Canada, Japan, Norway and the
United States
EC European Commission
EC focal point Interface of the European Commission with the EMCDDA Reitox net-
work, currently the C/5 unit within the Secretariat-General
EDF European Development Fund
EDU Europol Drugs Unit
EMEA European Agency for the Evaluation of Medicinal Products, a London-
based EU agency
Employment-Integra EU programme for social and professional reintegration
ESPAD European school survey report on alcohol and other drug use among
15- to 16-year-olds
EU action plan to combat drugs European Community programme outlining the main policy orienta-
tions in the field of drugs at EU level
Europasi European addiction severity index
Eurostat Statistical Office of the European Communities
Falcone EU programme to reinforce cooperation to combat organised crime (in-
cluding drug-related aspects)
FATF Financial Action Task Force: created by the G7 industrialised nations to
analyse the implications of money laundering for the international fi-
nancial system
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Fifth framework programme An overall EU framework programme which defines priorities of the EU
research, development and technology programmes for a five-year pe-
riod (1998-2002)
Front-line agencies Bodies and agencies that deal directly with substance misusers
G7 Group of Seven industrialised nations
GP General practitioner
Grotius EU programme designed to develop training, exchange and work pro-
grammes for the criminal justice system, strengthening cooperation be-
tween the respective practitioners
High-Level Group Group created by the Dublin Summit of December 1996 to draw up a
comprehensive action plan containing specific recommendations to
fight organised crime
High-threshold services Services with high entry barriers requiring a high level of commitment
on the part of the client
Horizontal Drugs Group (HDG) A group of national experts on drugs, meeting within the Council of the
European Union, formerly known as the Drug Experts Group
IDA Interchange of data between administrations (EU programme to de-
velop computerised information exchange)
IMC In-patient Motivation Centre (NL)
INCB International Narcotics Control Board established in 1961 to analyse
and evaluate the legitimate demand for narcotic drugs, psychotropic
substances and drug precursors
JHA Justice and home affairs
LAAM Levo-alpha acetyl methadol — a longer-acting alternative to
methadone
Legalisation Legal measure aimed at controlling a substance and its related market.
With legalisation, the production process belongs to the authority, the
State, that through laws and regulations may control production, culti-
vation, sale and consumption
Leonardo da Vinci EU vocational training programme
Liberalisation This is a term used to indicate the political approach of a drug policy or
strategy; when it refers to a substance (e.g. liberalisation of soft drugs),
this means that the drug will be available on the market and regulated
by the economic law of supply and demand (often the term is improp-
erly used meaning legalisation or depenalisation)
Linha VIDA Telephone helpline in Portugal for the prevention of drug addiction
Lomé Convention Convention between the EC and African, Caribbean and Pacific coun-
tries to support development efforts
Low-threshold services Treatment facilities with easy access and reduced time delays (frequent-
ly part of harm-reduction strategies)
MCPPAD Multi-country PHARE programme for the fight against drugs
MCPTFCM Multi-country programme for transit facilitation and customs moderni-
sation
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Money laundering The conversion or transfer of money, assets and property derived from
criminal activities to apparently legitimate status by disguising their ori-
gin through a variety of financial manoeuvres
MS Member States of the European Union
National focal points (NFPs) National expert monitoring centres forming the EMCDDA Reitox network
NGOs Non-governmental organisations
NIS New independent States
North-South cooperation EU programme which funds actions in developing countries in the field 
on drugs and drug addiction of drug demand and drug supply reduction
NSD New synthetic drugs; laboratory-made substances that are similar to
controlled drugs, for example Ecstasy or amphetamines, but which are
not controlled under the 1972 UN Convention on Psychotropic Sub-
stances
NTORS National treatment outcome research study (UK)
OECD Organisation for Economic Cooperation and Development
OISIN EU programme to enhance cooperation between law enforcement 
authorities
PCAPDD Programme of Community action on the prevention of drug depen-
dence
PHARE drugs programme EU programme established to help the CEECs integrate into the EU and
to monitor the efforts of each candidate country in drug control
Poly-drug use Concurrent or consecutive use of more than one illicit substance, alco-
hol and/or non-medical use of pharmaceuticals
Pompidou Group An intergovernmental structure within the Council of Europe which
aims to ‘promote and support the establishment of national policies
and programmes and the strengthening of international cooperation
allowing a multidisciplinary approach to the problem of drug abuse
and illicit trafficking in a pan-European context’
Precursor control Measures to avoid diversion of precursor chemicals used in the pre-
paration of illicit drugs
R & D Research and development
RDT Research, development and technology
Reitox European information network on drugs and drug addiction (Réseau 
européen d’information sur les drogues et les toxicomanies)
SCODA Standing Conference on Drug Abuse (UK)
Social reintegration figures Rates for the successful rehabilitation of problem substance users — i.e.
the extent of employment and home ownership following treatment
Strasbourg Convention 1990 Council of Europe Convention on the laundering, search, seizure
and confiscation of the proceeds from crime
Supply reduction Strategies aimed at reducing availability of illicit drugs by targeting pro-
ducers, importers and traffickers
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TACIS programme EU cooperation programme with the new independent States of the
former Soviet Union
Third countries Non-EU countries
Trafficking Transportation and bulk trading in illicit drugs, usually at international
level, for the purpose of distribution or sale
UNDCP United Nations Drug-Control Programme. In 1991 the three UN drug
units — the Division of Narcotic Drugs (DND), the United Nations Foun-
dation for Drug Abuse Control (Unfdac) and the INCB Secretariat —
merged into a single drug-control programme responsible for coordi-
nating all UN drug-control activities
Ungass United Nations General Assembly Special Session (on drugs, New York,
June 1998)
Vienna Convention United Nations Convention against illicit traffic in narcotic drugs and
psychotropic substances (1988)
WCO World Customs Organisation
WHO World Health Organisation (based in Geneva)
WHO-Europe World Health Organisation regional office for Europe (based in Copen-
hagen)
Youth for Europe EU programme for the promotion of general youth activities
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